<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">39457048</PMID><DateCompleted><Year>2024</Year><Month>10</Month><Day>26</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>28</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1422-0067</ISSN><JournalIssue CitedMedium="Internet"><Volume>25</Volume><Issue>20</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>19</Day></PubDate></JournalIssue><Title>International journal of molecular sciences</Title><ISOAbbreviation>Int J Mol Sci</ISOAbbreviation></Journal><ArticleTitle>Immunity and Coagulation in COVID-19.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">11267</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/ijms252011267</ELocationID><Abstract><AbstractText>Discovered in late 2019, the SARS-CoV-2 coronavirus has caused the largest pandemic of the 21st century, claiming more than seven million lives. In most cases, the COVID-19 disease caused by the SARS-CoV-2 virus is relatively mild and affects only the upper respiratory tract; it most often manifests itself with fever, chills, cough, and sore throat, but also has less-common mild symptoms. In most cases, patients do not require hospitalization, and fully recover. However, in some cases, infection with the SARS-CoV-2 virus leads to the development of a severe form of COVID-19, which is characterized by the development of life-threatening complications affecting not only the lungs, but also other organs and systems. In particular, various forms of thrombotic complications are common among patients with a severe form of COVID-19. The mechanisms for the development of thrombotic complications in COVID-19 remain unclear. Accumulated data indicate that the pathogenesis of severe COVID-19 is based on disruptions in the functioning of various innate immune systems. The key role in the primary response to a viral infection is assigned to two systems. These are the pattern recognition receptors, primarily members of the toll-like receptor (TLR) family, and the complement system. Both systems are the first to engage in the fight against the virus and launch a whole range of mechanisms aimed at its rapid elimination. Normally, their joint activity leads to the destruction of the pathogen and recovery. However, disruptions in the functioning of these innate immune systems in COVID-19 can cause the development of an excessive inflammatory response that is dangerous for the body. In turn, excessive inflammation entails activation of and damage to the vascular endothelium, as well as the development of the hypercoagulable state observed in patients seriously ill with COVID-19. Activation of the endothelium and hypercoagulation lead to the development of thrombosis and, as a result, damage to organs and tissues. Immune-mediated thrombotic complications are termed "immunothrombosis". In this review, we discuss in detail the features of immunothrombosis associated with SARS-CoV-2 infection and its potential underlying mechanisms.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Avdonin</LastName><ForeName>Piotr P</ForeName><Initials>PP</Initials><AffiliationInfo><Affiliation>Koltzov Institute of Developmental Biology RAS, ul. Vavilova, 26, 119334 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blinova</LastName><ForeName>Maria S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Koltzov Institute of Developmental Biology RAS, ul. Vavilova, 26, 119334 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Serkova</LastName><ForeName>Anastasia A</ForeName><Initials>AA</Initials><AffiliationInfo><Affiliation>Koltzov Institute of Developmental Biology RAS, ul. Vavilova, 26, 119334 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Komleva</LastName><ForeName>Lidia A</ForeName><Initials>LA</Initials><AffiliationInfo><Affiliation>Koltzov Institute of Developmental Biology RAS, ul. Vavilova, 26, 119334 Moscow, Russia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Avdonin</LastName><ForeName>Pavel V</ForeName><Initials>PV</Initials><Identifier Source="ORCID">0000-0002-4138-1589</Identifier><AffiliationInfo><Affiliation>Koltzov Institute of Developmental Biology RAS, ul. Vavilova, 26, 119334 Moscow, Russia.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>22-15-00409</GrantID><Agency>Russian Science Foundation</Agency><Country /></Grant><Grant><GrantID>0088-2024-0009</GrantID><Agency>Government program of basic research</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016454">Review</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>19</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Int J Mol Sci</MedlineTA><NlmUniqueID>101092791</NlmUniqueID><ISSNLinking>1422-0067</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="Y">SARS-CoV-2</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001777" MajorTopicYN="Y">Blood Coagulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013927" MajorTopicYN="Y">Thrombosis</DescriptorName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000209" MajorTopicYN="N">etiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007113" MajorTopicYN="N">Immunity, Innate</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">coagulation</Keyword><Keyword MajorTopicYN="N">complement</Keyword><Keyword MajorTopicYN="N">immunothrombosis</Keyword><Keyword MajorTopicYN="N">inflammation</Keyword><Keyword MajorTopicYN="N">thrombotic microangiopathies</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>8</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>19</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>26</Day><Hour>1</Hour><Minute>6</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>10</Month><Day>19</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39457048</ArticleId><ArticleId IdType="pmc">PMC11508857</ArticleId><ArticleId IdType="doi">10.3390/ijms252011267</ArticleId><ArticleId IdType="pii">ijms252011267</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Fernandez-Dominguez I.J., Manzo-Merino J., Taja-Chayeb L., Duenas-Gonzalez A., Perez-Cardenas E., Trejo-Becerril C. The role of extracellular DNA (exdna) in cellular processes. Cancer Biol. Ther. 2021;22:267–278. doi: 10.1080/15384047.2021.1890319.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/15384047.2021.1890319</ArticleId><ArticleId IdType="pmc">PMC8183512</ArticleId><ArticleId IdType="pubmed">33858306</ArticleId></ArticleIdList></Reference><Reference><Citation>van Eijk L.E., Binkhorst M., Bourgonje A.R., Offringa A.K., Mulder D.J., Bos E.M., Kolundzic N., Abdulle A.E., van der Voort P.H., Olde Rikkert M.G., et al. COVID-19: Immunopathology, pathophysiological mechanisms, and treatment options. J. Pathol. 2021;254:307–331. doi: 10.1002/path.5642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.5642</ArticleId><ArticleId IdType="pmc">PMC8013908</ArticleId><ArticleId IdType="pubmed">33586189</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang X., Yu Y., Xu J., Shu H., Xia J., Liu H., Wu Y., Zhang L., Yu Z., Fang M., et al. Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: A single-centered, retrospective, observational study. Lancet Respir. Med. 2020;8:475–481. doi: 10.1016/S2213-2600(20)30079-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30079-5</ArticleId><ArticleId IdType="pmc">PMC7102538</ArticleId><ArticleId IdType="pubmed">32105632</ArticleId></ArticleIdList></Reference><Reference><Citation>Haroon S., Nirantharakumar K., Hughes S.E., Subramanian A., Aiyegbusi O.L., Davies E.H., Myles P., Williams T., Turner G., Chandan J.S., et al. Therapies for long COVID in non-hospitalised individuals: From symptoms, patient-reported outcomes and immunology to targeted therapies (the tlc study) BMJ Open. 2022;12:e060413. doi: 10.1136/bmjopen-2021-060413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2021-060413</ArticleId><ArticleId IdType="pmc">PMC9044550</ArticleId><ArticleId IdType="pubmed">35473737</ArticleId></ArticleIdList></Reference><Reference><Citation>Cui S., Chen S., Li X., Liu S., Wang F. Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J. Thromb. Haemost. JTH. 2020;18:1421–1424. doi: 10.1111/jth.14830.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14830</ArticleId><ArticleId IdType="pmc">PMC7262324</ArticleId><ArticleId IdType="pubmed">32271988</ArticleId></ArticleIdList></Reference><Reference><Citation>Goshua G., Pine A.B., Meizlish M.L., Chang C.H., Zhang H., Bahel P., Baluha A., Bar N., Bona R.D., Burns A.J., et al. Endotheliopathy in COVID-19-associated coagulopathy: Evidence from a single-centre, cross-sectional study. Lancet Haematol. 2020;7:e575–e582. doi: 10.1016/S2352-3026(20)30216-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(20)30216-7</ArticleId><ArticleId IdType="pmc">PMC7326446</ArticleId><ArticleId IdType="pubmed">32619411</ArticleId></ArticleIdList></Reference><Reference><Citation>Trimaille A., Bonnet G. COVID-19 and venous thromboembolism. Ann. Cardiol. D’angeiologie. 2020;69:370–375. doi: 10.1016/j.ancard.2020.09.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ancard.2020.09.027</ArticleId><ArticleId IdType="pmc">PMC7522640</ArticleId><ArticleId IdType="pubmed">33081917</ArticleId></ArticleIdList></Reference><Reference><Citation>Nicolai L., Leunig A., Brambs S., Kaiser R., Weinberger T., Weigand M., Muenchhoff M., Hellmuth J.C., Ledderose S., Schulz H., et al. Immunothrombotic dysregulation in COVID-19 pneumonia is associated with respiratory failure and coagulopathy. Circulation. 2020;142:1176–1189. doi: 10.1161/CIRCULATIONAHA.120.048488.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.048488</ArticleId><ArticleId IdType="pmc">PMC7497892</ArticleId><ArticleId IdType="pubmed">32755393</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C., Shen L., Le K.J., Pan M.M., Kong L.C., Gu Z.C., Xu H., Zhang Z., Ge W.H., Lin H.W. Incidence of venous thromboembolism in hospitalized coronavirus disease 2019 patients: A systematic review and meta-analysis. Front. Cardiovasc. Med. 2020;7:151. doi: 10.3389/fcvm.2020.00151.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcvm.2020.00151</ArticleId><ArticleId IdType="pmc">PMC7423832</ArticleId><ArticleId IdType="pubmed">32850990</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang L., Feng X., Zhang D., Jiang C., Mei H., Wang J., Zhang C., Li H., Xia X., Kong S., et al. Deep vein thrombosis in hospitalized patients with COVID-19 in Wuhan, China: Prevalence, risk factors, and outcome. Circulation. 2020;142:114–128. doi: 10.1161/CIRCULATIONAHA.120.046702.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.046702</ArticleId><ArticleId IdType="pubmed">32421381</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway E.M., Mackman N., Warren R.Q., Wolberg A.S., Mosnier L.O., Campbell R.A., Gralinski L.E., Rondina M.T., van de Veerdonk F.L., Hoffmeister K.M., et al. Understanding COVID-19-associated coagulopathy. Nat. Rev. Immunol. 2022;22:639–649. doi: 10.1038/s41577-022-00762-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-022-00762-9</ArticleId><ArticleId IdType="pmc">PMC9362465</ArticleId><ArticleId IdType="pubmed">35931818</ArticleId></ArticleIdList></Reference><Reference><Citation>Bouck E.G., Denorme F., Holle L.A., Middelton E.A., Blair A.M., de Laat B., Schiffman J.D., Yost C.C., Rondina M.T., Wolberg A.S., et al. COVID-19 and sepsis are associated with different abnormalities in plasma procoagulant and fibrinolytic activity. Arterioscler. Thromb. Vasc. Biol. 2021;41:401–414. doi: 10.1161/ATVBAHA.120.315338.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.120.315338</ArticleId><ArticleId IdType="pmc">PMC7942774</ArticleId><ArticleId IdType="pubmed">33196292</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell R.A., Hisada Y., Denorme F., Grover S.P., Bouck E.G., Middleton E.A., Wolberg A.S., Rondina M.T., Mackman N. Comparison of the coagulopathies associated with COVID-19 and sepsis. Res. Pract. Thromb. Haemost. 2021;5:e12525. doi: 10.1002/rth2.12525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rth2.12525</ArticleId><ArticleId IdType="pmc">PMC8131194</ArticleId><ArticleId IdType="pubmed">34027292</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonaventura A., Vecchie A., Dagna L., Martinod K., Dixon D.L., Van Tassell B.W., Dentali F., Montecucco F., Massberg S., Levi M., et al. Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19. Nat. Rev. Immunol. 2021;21:319–329. doi: 10.1038/s41577-021-00536-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00536-9</ArticleId><ArticleId IdType="pmc">PMC8023349</ArticleId><ArticleId IdType="pubmed">33824483</ArticleId></ArticleIdList></Reference><Reference><Citation>Connors J.M., Levy J.H. COVID-19 and its implications for thrombosis and anticoagulation. Blood. 2020;135:2033–2040. doi: 10.1182/blood.2020006000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020006000</ArticleId><ArticleId IdType="pmc">PMC7273827</ArticleId><ArticleId IdType="pubmed">32339221</ArticleId></ArticleIdList></Reference><Reference><Citation>Engelmann B., Massberg S. Thrombosis as an intravascular effector of innate immunity. Nat. Rev. Immunol. 2013;13:34–45. doi: 10.1038/nri3345.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3345</ArticleId><ArticleId IdType="pubmed">23222502</ArticleId></ArticleIdList></Reference><Reference><Citation>Middleton E.A., He X.Y., Denorme F., Campbell R.A., Ng D., Salvatore S.P., Mostyka M., Baxter-Stoltzfus A., Borczuk A.C., Loda M., et al. Neutrophil extracellular traps contribute to immunothrombosis in COVID-19 acute respiratory distress syndrome. Blood. 2020;136:1169–1179. doi: 10.1182/blood.2020007008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020007008</ArticleId><ArticleId IdType="pmc">PMC7472714</ArticleId><ArticleId IdType="pubmed">32597954</ArticleId></ArticleIdList></Reference><Reference><Citation>Skendros P., Mitsios A., Chrysanthopoulou A., Mastellos D.C., Metallidis S., Rafailidis P., Ntinopoulou M., Sertaridou E., Tsironidou V., Tsigalou C., et al. Complement and tissue factor-enriched neutrophil extracellular traps are key drivers in COVID-19 immunothrombosis. J. Clin. Investig. 2020;130:6151–6157. doi: 10.1172/JCI141374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI141374</ArticleId><ArticleId IdType="pmc">PMC7598040</ArticleId><ArticleId IdType="pubmed">32759504</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcos-Jubilar M., Lecumberri R., Paramo J.A. Immunothrombosis: Molecular aspects and new therapeutic perspectives. J. Clin. Med. 2023;12:1399. doi: 10.3390/jcm12041399.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm12041399</ArticleId><ArticleId IdType="pmc">PMC9958829</ArticleId><ArticleId IdType="pubmed">36835934</ArticleId></ArticleIdList></Reference><Reference><Citation>Frantzeskaki F., Armaganidis A., Orfanos S.E. Immunothrombosis in acute respiratory distress syndrome: Cross talks between inflammation and coagulation. Respir. Int. Rev. Thorac. Dis. 2017;93:212–225. doi: 10.1159/000453002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000453002</ArticleId><ArticleId IdType="pubmed">27997925</ArticleId></ArticleIdList></Reference><Reference><Citation>Bauer A.T., Gorzelanny C., Gebhardt C., Pantel K., Schneider S.W. Interplay between coagulation and inflammation in cancer: Limitations and therapeutic opportunities. Cancer Treat. Rev. 2022;102:102322. doi: 10.1016/j.ctrv.2021.102322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ctrv.2021.102322</ArticleId><ArticleId IdType="pubmed">34922151</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T., Levi M., Levy J.H. Intracellular communication and immunothrombosis in sepsis. J. Thromb. Haemost. JTH. 2022;20:2475–2484. doi: 10.1111/jth.15852.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15852</ArticleId><ArticleId IdType="pmc">PMC9804233</ArticleId><ArticleId IdType="pubmed">35979601</ArticleId></ArticleIdList></Reference><Reference><Citation>Mantovani S., Oliviero B., Varchetta S., Renieri A., Mondelli M.U. TLRS: Innate immune sentries against SARS-CoV-2 infection. Int. J. Mol. Sci. 2023;24:8065. doi: 10.3390/ijms24098065.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24098065</ArticleId><ArticleId IdType="pmc">PMC10178469</ArticleId><ArticleId IdType="pubmed">37175768</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim E.H.T., van Amstel R.B.E., de Boer V.V., van Vught L.A., de Bruin S., Brouwer M.C., Vlaar A.P.J., van de Beek D. Complement activation in COVID-19 and targeted therapeutic options: A scoping review. Blood Rev. 2023;57:100995. doi: 10.1016/j.blre.2022.100995.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2022.100995</ArticleId><ArticleId IdType="pmc">PMC9338830</ArticleId><ArticleId IdType="pubmed">35934552</ArticleId></ArticleIdList></Reference><Reference><Citation>Xiao M.T., Ellsworth C.R., Qin X. Emerging role of complement in COVID-19 and other respiratory virus diseases. Cell. Mol. Life Sci. CMLS. 2024;81:94. doi: 10.1007/s00018-024-05157-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-024-05157-8</ArticleId><ArticleId IdType="pmc">PMC10874912</ArticleId><ArticleId IdType="pubmed">38368584</ArticleId></ArticleIdList></Reference><Reference><Citation>Zelek W.M., Harrison R.A. Complement and COVID-19: Three years on, what we know, what we don’t know, and what we ought to know. Immunobiology. 2023;228:152393. doi: 10.1016/j.imbio.2023.152393.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2023.152393</ArticleId><ArticleId IdType="pmc">PMC10174470</ArticleId><ArticleId IdType="pubmed">37187043</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva M.J.A., Ribeiro L.R., Gouveia M.I.M., Marcelino B.D.R., Santos C.S.D., Lima K.V.B., Lima L. Hyperinflammatory response in COVID-19: A systematic review. Viruses. 2023;15:553. doi: 10.3390/v15020553.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15020553</ArticleId><ArticleId IdType="pmc">PMC9962879</ArticleId><ArticleId IdType="pubmed">36851766</ArticleId></ArticleIdList></Reference><Reference><Citation>Markiewski M.M., Lambris J.D. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am. J. Pathol. 2007;171:715–727. doi: 10.2353/ajpath.2007.070166.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2007.070166</ArticleId><ArticleId IdType="pmc">PMC1959484</ArticleId><ArticleId IdType="pubmed">17640961</ArticleId></ArticleIdList></Reference><Reference><Citation>Duan T., Du Y., Xing C., Wang H.Y., Wang R.F. Toll-like receptor signaling and its role in cell-mediated immunity. Front. Immunol. 2022;13:812774. doi: 10.3389/fimmu.2022.812774.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.812774</ArticleId><ArticleId IdType="pmc">PMC8927970</ArticleId><ArticleId IdType="pubmed">35309296</ArticleId></ArticleIdList></Reference><Reference><Citation>Sabroe I., Parker L.C., Dower S.K., Whyte M.K. The role of TLR activation in inflammation. J. Pathol. 2008;214:126–135. doi: 10.1002/path.2264.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/path.2264</ArticleId><ArticleId IdType="pubmed">18161748</ArticleId></ArticleIdList></Reference><Reference><Citation>Wilhelm G., Mertowska P., Mertowski S., Przysucha A., Struzyna J., Grywalska E., Torres K. The crossroads of the coagulation system and the immune system: Interactions and connections. Int. J. Mol. Sci. 2023;24:12563. doi: 10.3390/ijms241612563.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241612563</ArticleId><ArticleId IdType="pmc">PMC10454528</ArticleId><ArticleId IdType="pubmed">37628744</ArticleId></ArticleIdList></Reference><Reference><Citation>Smole U., Kratzer B., Pickl W.F. Soluble pattern recognition molecules: Guardians and regulators of homeostasis at airway mucosal surfaces. Eur. J. Immunol. 2020;50:624–642. doi: 10.1002/eji.201847811.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201847811</ArticleId><ArticleId IdType="pmc">PMC7216992</ArticleId><ArticleId IdType="pubmed">32246830</ArticleId></ArticleIdList></Reference><Reference><Citation>Birra D., Benucci M., Landolfi L., Merchionda A., Loi G., Amato P., Licata G., Quartuccio L., Triggiani M., Moscato P. COVID-19: A clue from innate immunity. Immunol. Res. 2020;68:161–168. doi: 10.1007/s12026-020-09137-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-020-09137-5</ArticleId><ArticleId IdType="pmc">PMC7286633</ArticleId><ArticleId IdType="pubmed">32524333</ArticleId></ArticleIdList></Reference><Reference><Citation>Debnath M., Banerjee M., Berk M. Genetic gateways to COVID-19 infection: Implications for risk, severity, and outcomes. FASEB J. 2020;34:8787–8795. doi: 10.1096/fj.202001115R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.202001115R</ArticleId><ArticleId IdType="pmc">PMC7300732</ArticleId><ArticleId IdType="pubmed">32525600</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedayat M., Netea M.G., Rezaei N. Targeting of toll-like receptors: A decade of progress in combating infectious diseases. Lancet Infect. Dis. 2011;11:702–712. doi: 10.1016/S1473-3099(11)70099-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(11)70099-8</ArticleId><ArticleId IdType="pubmed">21719349</ArticleId></ArticleIdList></Reference><Reference><Citation>Li D., Wu M. Pattern recognition receptors in health and diseases. Signal Transduct. Target. Ther. 2021;6:291. doi: 10.1038/s41392-021-00687-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00687-0</ArticleId><ArticleId IdType="pmc">PMC8333067</ArticleId><ArticleId IdType="pubmed">34344870</ArticleId></ArticleIdList></Reference><Reference><Citation>Jeong E., Lee J.Y. Intrinsic and extrinsic regulation of innate immune receptors. Yonsei Med. J. 2011;52:379–392. doi: 10.3349/ymj.2011.52.3.379.</Citation><ArticleIdList><ArticleId IdType="doi">10.3349/ymj.2011.52.3.379</ArticleId><ArticleId IdType="pmc">PMC3101043</ArticleId><ArticleId IdType="pubmed">21488180</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L., Wang L., Chen S. Endogenous toll-like receptor ligands and their biological significance. J. Cell. Mol. Med. 2010;14:2592–2603. doi: 10.1111/j.1582-4934.2010.01127.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2010.01127.x</ArticleId><ArticleId IdType="pmc">PMC4373479</ArticleId><ArticleId IdType="pubmed">20629986</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawai T., Akira S. Toll-like receptors and their crosstalk with other innate receptors in infection and immunity. Immunity. 2011;34:637–650. doi: 10.1016/j.immuni.2011.05.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2011.05.006</ArticleId><ArticleId IdType="pubmed">21616434</ArticleId></ArticleIdList></Reference><Reference><Citation>Aboudounya M.M., Heads R.J. COVID-19 and toll-like receptor 4 (TLR4): SARS-CoV-2 may bind and activate TLR4 to increase ace2 expression, facilitating entry and causing hyperinflammation. Mediat. Inflamm. 2021;2021:8874339. doi: 10.1155/2021/8874339.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/8874339</ArticleId><ArticleId IdType="pmc">PMC7811571</ArticleId><ArticleId IdType="pubmed">33505220</ArticleId></ArticleIdList></Reference><Reference><Citation>Roh J.S., Sohn D.H. Damage-associated molecular patterns in inflammatory diseases. Immune Netw. 2018;18:e27. doi: 10.4110/in.2018.18.e27.</Citation><ArticleIdList><ArticleId IdType="doi">10.4110/in.2018.18.e27</ArticleId><ArticleId IdType="pmc">PMC6117512</ArticleId><ArticleId IdType="pubmed">30181915</ArticleId></ArticleIdList></Reference><Reference><Citation>Sameer A.S., Nissar S. Toll-like receptors (TLRS): Structure, functions, signaling, and role of their polymorphisms in colorectal cancer susceptibility. BioMed Res. Int. 2021;2021:1157023. doi: 10.1155/2021/1157023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/1157023</ArticleId><ArticleId IdType="pmc">PMC8452412</ArticleId><ArticleId IdType="pubmed">34552981</ArticleId></ArticleIdList></Reference><Reference><Citation>Fitzgerald K.A., Kagan J.C. Toll-like receptors and the control of immunity. Cell. 2020;180:1044–1066. doi: 10.1016/j.cell.2020.02.041.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2020.02.041</ArticleId><ArticleId IdType="pmc">PMC9358771</ArticleId><ArticleId IdType="pubmed">32164908</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawasaki T., Kawai T. Toll-like receptor signaling pathways. Front. Immunol. 2014;5:461. doi: 10.3389/fimmu.2014.00461.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00461</ArticleId><ArticleId IdType="pmc">PMC4174766</ArticleId><ArticleId IdType="pubmed">25309543</ArticleId></ArticleIdList></Reference><Reference><Citation>Bortolotti D., Gentili V., Rizzo S., Schiuma G., Beltrami S., Strazzabosco G., Fernandez M., Caccuri F., Caruso A., Rizzo R. TLR3 and TLR7 RNA sensor activation during SARS-CoV-2 infection. Microorganisms. 2021;9:820. doi: 10.3390/microorganisms9091820.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9091820</ArticleId><ArticleId IdType="pmc">PMC8465566</ArticleId><ArticleId IdType="pubmed">34576716</ArticleId></ArticleIdList></Reference><Reference><Citation>Sariol A., Perlman S. SARS-CoV-2 takes its toll. Nat. Immunol. 2021;22:801–802. doi: 10.1038/s41590-021-00962-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-00962-w</ArticleId><ArticleId IdType="pmc">PMC8238877</ArticleId><ArticleId IdType="pubmed">34103714</ArticleId></ArticleIdList></Reference><Reference><Citation>Yokota S., Okabayashi T., Fujii N. The battle between virus and host: Modulation of toll-like receptor signaling pathways by virus infection. Mediat. Inflamm. 2010;2010:184328. doi: 10.1155/2010/184328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2010/184328</ArticleId><ArticleId IdType="pmc">PMC2903949</ArticleId><ArticleId IdType="pubmed">20672047</ArticleId></ArticleIdList></Reference><Reference><Citation>Ebermeyer T., Cognasse F., Berthelot P., Mismetti P., Garraud O., Hamzeh-Cognasse H. Platelet innate immune receptors and TLRS: A double-edged sword. Int. J. Mol. Sci. 2021;22:7894. doi: 10.3390/ijms22157894.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22157894</ArticleId><ArticleId IdType="pmc">PMC8347377</ArticleId><ArticleId IdType="pubmed">34360659</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang Y., Liu J., Zhang D., Xu Z., Ji J., Wen C. Cytokine storm in COVID-19: The current evidence and treatment strategies. Front. Immunol. 2020;11:1708. doi: 10.3389/fimmu.2020.01708.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01708</ArticleId><ArticleId IdType="pmc">PMC7365923</ArticleId><ArticleId IdType="pubmed">32754163</ArticleId></ArticleIdList></Reference><Reference><Citation>Manik M., Singh R.K. Role of toll-like receptors in modulation of cytokine storm signaling in SARS-CoV-2-induced COVID-19. J. Med. Virol. 2022;94:869–877. doi: 10.1002/jmv.27405.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.27405</ArticleId><ArticleId IdType="pmc">PMC8662021</ArticleId><ArticleId IdType="pubmed">34672376</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu Z.M., Yang M.H., Yu K., Lian Z.X., Deng S.L. Toll-like receptor (TLRS) agonists and antagonists for COVID-19 treatments. Front. Pharmacol. 2022;13:989664. doi: 10.3389/fphar.2022.989664.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2022.989664</ArticleId><ArticleId IdType="pmc">PMC9518217</ArticleId><ArticleId IdType="pubmed">36188605</ArticleId></ArticleIdList></Reference><Reference><Citation>Bell J.K., Mullen G.E., Leifer C.A., Mazzoni A., Davies D.R., Segal D.M. Leucine-rich repeats and pathogen recognition in toll-like receptors. Trends Immunol. 2003;24:528–533. doi: 10.1016/S1471-4906(03)00242-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1471-4906(03)00242-4</ArticleId><ArticleId IdType="pubmed">14552836</ArticleId></ArticleIdList></Reference><Reference><Citation>Behzadi P., Garcia-Perdomo H.A., Karpinski T.M. Toll-like receptors: General molecular and structural biology. J. Immunol. Res. 2021;2021:9914854. doi: 10.1155/2021/9914854.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2021/9914854</ArticleId><ArticleId IdType="pmc">PMC8181103</ArticleId><ArticleId IdType="pubmed">34195298</ArticleId></ArticleIdList></Reference><Reference><Citation>West A.P., Koblansky A.A., Ghosh S. Recognition and signaling by toll-like receptors. Annu. Rev. Cell Dev. Biol. 2006;22:409–437. doi: 10.1146/annurev.cellbio.21.122303.115827.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.cellbio.21.122303.115827</ArticleId><ArticleId IdType="pubmed">16822173</ArticleId></ArticleIdList></Reference><Reference><Citation>Gay N.J., Gangloff M. Structure and function of toll receptors and their ligands. Annu. Rev. Biochem. 2007;76:141–165. doi: 10.1146/annurev.biochem.76.060305.151318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.biochem.76.060305.151318</ArticleId><ArticleId IdType="pubmed">17362201</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Z.L. Important aspects of toll-like receptors, ligands and their signaling pathways. Inflamm. Res. 2010;59:791–808. doi: 10.1007/s00011-010-0208-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00011-010-0208-2</ArticleId><ArticleId IdType="pubmed">20593217</ArticleId></ArticleIdList></Reference><Reference><Citation>Takeda K., Akira S. Toll-like receptors. Curr. Protoc. Immunol. 2015;109:12–14. doi: 10.1002/0471142735.im1412s109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/0471142735.im1412s109</ArticleId><ArticleId IdType="pubmed">25845562</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssens S., Beyaert R. Role of toll-like receptors in pathogen recognition. Clin. Microbiol. Rev. 2003;16:637–646. doi: 10.1128/CMR.16.4.637-646.2003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/CMR.16.4.637-646.2003</ArticleId><ArticleId IdType="pmc">PMC207104</ArticleId><ArticleId IdType="pubmed">14557290</ArticleId></ArticleIdList></Reference><Reference><Citation>Piccinini A.M., Midwood K.S. Dampening inflammation by modulating TLR signalling. Mediat. Inflamm. 2010;2010:672395. doi: 10.1155/2010/672395.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2010/672395</ArticleId><ArticleId IdType="pmc">PMC2913853</ArticleId><ArticleId IdType="pubmed">20706656</ArticleId></ArticleIdList></Reference><Reference><Citation>Kono H., Rock K.L. How dying cells alert the immune system to danger. Nat. Rev. Immunol. 2008;8:279–289. doi: 10.1038/nri2215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2215</ArticleId><ArticleId IdType="pmc">PMC2763408</ArticleId><ArticleId IdType="pubmed">18340345</ArticleId></ArticleIdList></Reference><Reference><Citation>Gushiken F.C., Han H., Li J., Rumbaut R.E., Afshar-Kharghan V. Abnormal platelet function in c3-deficient mice. J. Thromb. Haemost. JTH. 2009;7:865–870. doi: 10.1111/j.1538-7836.2009.03334.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2009.03334.x</ArticleId><ArticleId IdType="pmc">PMC2867673</ArticleId><ArticleId IdType="pubmed">19291167</ArticleId></ArticleIdList></Reference><Reference><Citation>Hurst J., Prinz N., Lorenz M., Bauer S., Chapman J., Lackner K.J., von Landenberg P. TLR7 and TLR8 ligands and antiphospholipid antibodies show synergistic effects on the induction of il-1beta and caspase-1 in monocytes and dendritic cells. Immunobiology. 2009;214:683–691. doi: 10.1016/j.imbio.2008.12.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2008.12.003</ArticleId><ArticleId IdType="pubmed">19249118</ArticleId></ArticleIdList></Reference><Reference><Citation>Doring Y., Hurst J., Lorenz M., Prinz N., Clemens N., Drechsler M.D., Bauer S., Chapman J., Shoenfeld Y., Blank M., et al. Human antiphospholipid antibodies induce tnfalpha in monocytes via toll-like receptor 8. Immunobiology. 2010;215:230–241. doi: 10.1016/j.imbio.2009.03.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2009.03.002</ArticleId><ArticleId IdType="pubmed">19457574</ArticleId></ArticleIdList></Reference><Reference><Citation>Mielcarska M.B., Bossowska-Nowicka M., Toka F.N. Cell surface expression of endosomal toll-like receptors—A necessity or a superfluous duplication? Front. Immunol. 2020;11:620972. doi: 10.3389/fimmu.2020.620972.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.620972</ArticleId><ArticleId IdType="pmc">PMC7882679</ArticleId><ArticleId IdType="pubmed">33597952</ArticleId></ArticleIdList></Reference><Reference><Citation>Pohar J., Pirher N., Bencina M., Mancek-Keber M., Jerala R. The role of UNC93B1 protein in surface localization of TLR3 receptor and in cell priming to nucleic acid agonists. J. Biol. Chem. 2013;288:442–454. doi: 10.1074/jbc.M112.413922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M112.413922</ArticleId><ArticleId IdType="pmc">PMC3537042</ArticleId><ArticleId IdType="pubmed">23166319</ArticleId></ArticleIdList></Reference><Reference><Citation>Brzezinska-Blaszczyk E., Wierzbicki M. mast cell toll-like receptors (TLRS) Postep. Hig. Med. Dosw. 2010;64:11–21.</Citation><ArticleIdList><ArticleId IdType="pubmed">20093719</ArticleId></ArticleIdList></Reference><Reference><Citation>Flo T.H., Halaas O., Torp S., Ryan L., Lien E., Dybdahl B., Sundan A., Espevik T. Differential expression of toll-like receptor 2 in human cells. J. Leukoc. Biol. 2001;69:474–481. doi: 10.1189/jlb.69.3.474.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.69.3.474</ArticleId><ArticleId IdType="pubmed">11261796</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu L., Feng Z. The role of toll-like receptor signaling in the progression of heart failure. Mediat. Inflamm. 2018;2018:9874109. doi: 10.1155/2018/9874109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/9874109</ArticleId><ArticleId IdType="pmc">PMC5822798</ArticleId><ArticleId IdType="pubmed">29576748</ArticleId></ArticleIdList></Reference><Reference><Citation>Oliveira-Nascimento L., Massari P., Wetzler L.M. The role of TLR2 in infection and immunity. Front. Immunol. 2012;3:79. doi: 10.3389/fimmu.2012.00079.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2012.00079</ArticleId><ArticleId IdType="pmc">PMC3342043</ArticleId><ArticleId IdType="pubmed">22566960</ArticleId></ArticleIdList></Reference><Reference><Citation>Colleselli K., Stierschneider A., Wiesner C. An update on toll-like receptor 2, its function and dimerization in pro- and anti-inflammatory processes. Int. J. Mol. Sci. 2023;24:12464. doi: 10.3390/ijms241512464.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms241512464</ArticleId><ArticleId IdType="pmc">PMC10419760</ArticleId><ArticleId IdType="pubmed">37569837</ArticleId></ArticleIdList></Reference><Reference><Citation>Vaure C., Liu Y. A comparative review of toll-like receptor 4 expression and functionality in different animal species. Front. Immunol. 2014;5:316. doi: 10.3389/fimmu.2014.00316.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2014.00316</ArticleId><ArticleId IdType="pmc">PMC4090903</ArticleId><ArticleId IdType="pubmed">25071777</ArticleId></ArticleIdList></Reference><Reference><Citation>Park B.S., Lee J.O. Recognition of lipopolysaccharide pattern by TLR4 complexes. Exp. Mol. Med. 2013;45:e66. doi: 10.1038/emm.2013.97.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emm.2013.97</ArticleId><ArticleId IdType="pmc">PMC3880462</ArticleId><ArticleId IdType="pubmed">24310172</ArticleId></ArticleIdList></Reference><Reference><Citation>Cao Y., Zhang E., Yang J., Yang Y., Yu J., Xiao Y., Li W., Zhou D., Li Y., Zhao B., et al. Frontline science: Nasal epithelial gm-csf contributes to TLR5-mediated modulation of airway dendritic cells and subsequent iga response. J. Leukoc. Biol. 2017;102:575–587. doi: 10.1189/jlb.3HI0816-368RR.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.3HI0816-368RR</ArticleId><ArticleId IdType="pubmed">28522600</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang R., Ahmed J., Wang G., Hassan I., Strulovici-Barel Y., Salit J., Mezey J.G., Crystal R.G. Airway epithelial expression of TLR5 is downregulated in healthy smokers and smokers with chronic obstructive pulmonary disease. J. Immunol. 2012;189:2217–2225. doi: 10.4049/jimmunol.1101895.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1101895</ArticleId><ArticleId IdType="pmc">PMC3579667</ArticleId><ArticleId IdType="pubmed">22855713</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang J., Yan H. TLR5: Beyond the recognition of flagellin. Cell. Mol. Immunol. 2017;14:1017–1019. doi: 10.1038/cmi.2017.122.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/cmi.2017.122</ArticleId><ArticleId IdType="pmc">PMC5719140</ArticleId><ArticleId IdType="pubmed">29151579</ArticleId></ArticleIdList></Reference><Reference><Citation>Kulka M., Alexopoulou L., Flavell R.A., Metcalfe D.D. Activation of mast cells by double-stranded RNA: Evidence for activation through toll-like receptor 3. J. Allergy Clin. Immunol. 2004;114:174–182. doi: 10.1016/j.jaci.2004.03.049.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2004.03.049</ArticleId><ArticleId IdType="pubmed">15241362</ArticleId></ArticleIdList></Reference><Reference><Citation>Town T., Jeng D., Alexopoulou L., Tan J., Flavell R.A. Microglia recognize double-stranded rna via TLR3. J. Immunol. 2006;176:3804–3812. doi: 10.4049/jimmunol.176.6.3804.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.176.6.3804</ArticleId><ArticleId IdType="pubmed">16517751</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang F., Ooka K., Sun X., Shah R., Bhattacharyya S., Wei J., Varga J. A synthetic TLR3 ligand mitigates profibrotic fibroblast responses by inducing autocrine ifn signaling. J. Immunol. 2013;191:2956–2966. doi: 10.4049/jimmunol.1300376.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1300376</ArticleId><ArticleId IdType="pmc">PMC3924580</ArticleId><ArticleId IdType="pubmed">23956427</ArticleId></ArticleIdList></Reference><Reference><Citation>Bugge M., Bergstrom B., Eide O.K., Solli H., Kjonstad I.F., Stenvik J., Espevik T., Nilsen N.J. Surface toll-like receptor 3 expression in metastatic intestinal epithelial cells induces inflammatory cytokine production and promotes invasiveness. J. Biol. Chem. 2017;292:15408–15425. doi: 10.1074/jbc.M117.784090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M117.784090</ArticleId><ArticleId IdType="pmc">PMC5602399</ArticleId><ArticleId IdType="pubmed">28717003</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Song Y., Du W., Gong L., Chang H., Zou Z. Tumor-associated macrophages: An accomplice in solid tumor progression. J. Biomed. Sci. 2019;26:78. doi: 10.1186/s12929-019-0568-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12929-019-0568-z</ArticleId><ArticleId IdType="pmc">PMC6800990</ArticleId><ArticleId IdType="pubmed">31629410</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto M., Funami K., Tanabe M., Oshiumi H., Shingai M., Seto Y., Yamamoto A., Seya T. Subcellular localization of toll-like receptor 3 in human dendritic cells. J. Immunol. 2003;171:3154–3162. doi: 10.4049/jimmunol.171.6.3154.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.171.6.3154</ArticleId><ArticleId IdType="pubmed">12960343</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsumoto M., Oshiumi H., Seya T. Antiviral responses induced by the TLR3 pathway. Rev. Med. Virol. 2011;21:67–77. doi: 10.1002/rmv.680.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.680</ArticleId><ArticleId IdType="pubmed">21312311</ArticleId></ArticleIdList></Reference><Reference><Citation>Agier J., Zelechowska P., Kozlowska E., Brzezinska-Blaszczyk E. Expression of surface and intracellular toll-like receptors by mature mast cells. Cent.-Eur. J. Immunol. 2016;41:333–338. doi: 10.5114/ceji.2016.65131.</Citation><ArticleIdList><ArticleId IdType="doi">10.5114/ceji.2016.65131</ArticleId><ArticleId IdType="pmc">PMC5382879</ArticleId><ArticleId IdType="pubmed">28450795</ArticleId></ArticleIdList></Reference><Reference><Citation>Turton H.A., Thompson A.A.R., Farkas L. Rna signaling in pulmonary arterial hypertension-a double-stranded sword. Int. J. Mol. Sci. 2020;21:3124. doi: 10.3390/ijms21093124.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21093124</ArticleId><ArticleId IdType="pmc">PMC7247700</ArticleId><ArticleId IdType="pubmed">32354189</ArticleId></ArticleIdList></Reference><Reference><Citation>Zainol M.I.B., Kawasaki T., Monwan W., Murase M., Sueyoshi T., Kawai T. Innate immune responses through toll-like receptor 3 require human-antigen-r-mediated atp6v0d2 mRNA stabilization. Sci. Rep. 2019;9:20406. doi: 10.1038/s41598-019-56914-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-019-56914-w</ArticleId><ArticleId IdType="pmc">PMC6938500</ArticleId><ArticleId IdType="pubmed">31892731</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Y., Liu L., Davies D.R., Segal D.M. Dimerization of toll-like receptor 3 (TLR3) is required for ligand binding. J. Biol. Chem. 2010;285:36836–36841. doi: 10.1074/jbc.M110.167973.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.167973</ArticleId><ArticleId IdType="pmc">PMC2978612</ArticleId><ArticleId IdType="pubmed">20861016</ArticleId></ArticleIdList></Reference><Reference><Citation>Alexopoulou L., Desnues B., Demaria O. toll-like receptor 8: The awkward TLR. Med. Sci. M/S. 2012;28:96–102. doi: 10.1051/medsci/2012281023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1051/medsci/2012281023</ArticleId><ArticleId IdType="pubmed">22289837</ArticleId></ArticleIdList></Reference><Reference><Citation>Hornung V., Rothenfusser S., Britsch S., Krug A., Jahrsdorfer B., Giese T., Endres S., Hartmann G. Quantitative expression of toll-like receptor 1-10 mRNA in cellular subsets of human peripheral blood mononuclear cells and sensitivity to cpg oligodeoxynucleotides. J. Immunol. 2002;168:4531–4537. doi: 10.4049/jimmunol.168.9.4531.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.168.9.4531</ArticleId><ArticleId IdType="pubmed">11970999</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo H., Liu S., Wang Y., Phillips-Howard P.A., Ju S., Yang Y., Wang D. Age differences in clinical features and outcomes in patients with COVID-19, Jiangsu, China: A retrospective, multicentre cohort study. BMJ Open. 2020;10:e039887. doi: 10.1136/bmjopen-2020-039887.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2020-039887</ArticleId><ArticleId IdType="pmc">PMC7536631</ArticleId><ArticleId IdType="pubmed">33020106</ArticleId></ArticleIdList></Reference><Reference><Citation>Gantier M.P., Tong S., Behlke M.A., Xu D., Phipps S., Foster P.S., Williams B.R. TLR7 is involved in sequence-specific sensing of single-stranded rnas in human macrophages. J. Immunol. 2008;180:2117–2124. doi: 10.4049/jimmunol.180.4.2117.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.180.4.2117</ArticleId><ArticleId IdType="pubmed">18250417</ArticleId></ArticleIdList></Reference><Reference><Citation>Jung H.E., Lee H.K. Current understanding of the innate control of toll-like receptors in response to SARS-CoV-2 infection. Viruses. 2021;13:2132. doi: 10.3390/v13112132.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13112132</ArticleId><ArticleId IdType="pmc">PMC8622567</ArticleId><ArticleId IdType="pubmed">34834939</ArticleId></ArticleIdList></Reference><Reference><Citation>Ohto U., Ishida H., Shibata T., Sato R., Miyake K., Shimizu T. Toll-like receptor 9 contains two DNA binding sites that function cooperatively to promote receptor dimerization and activation. Immunity. 2018;48:649–658 e644. doi: 10.1016/j.immuni.2018.03.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2018.03.013</ArticleId><ArticleId IdType="pubmed">29625894</ArticleId></ArticleIdList></Reference><Reference><Citation>Leadbetter E.A., Rifkin I.R., Hohlbaum A.M., Beaudette B.C., Shlomchik M.J., Marshak-Rothstein A. Chromatin-igg complexes activate b cells by dual engagement of igm and toll-like receptors. Nature. 2002;416:603–607. doi: 10.1038/416603a.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/416603a</ArticleId><ArticleId IdType="pubmed">11948342</ArticleId></ArticleIdList></Reference><Reference><Citation>Lester S.N., Li K. Toll-like receptors in antiviral innate immunity. J. Mol. Biol. 2014;426:1246–1264. doi: 10.1016/j.jmb.2013.11.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmb.2013.11.024</ArticleId><ArticleId IdType="pmc">PMC3943763</ArticleId><ArticleId IdType="pubmed">24316048</ArticleId></ArticleIdList></Reference><Reference><Citation>Tang N., Li D., Wang X., Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J. Thromb. Haemost. JTH. 2020;18:844–847. doi: 10.1111/jth.14768.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14768</ArticleId><ArticleId IdType="pmc">PMC7166509</ArticleId><ArticleId IdType="pubmed">32073213</ArticleId></ArticleIdList></Reference><Reference><Citation>Khan S., Shafiei M.S., Longoria C., Schoggins J., Savani R.C., Zaki H. SARS-CoV-2 spike protein induces inflammation via TLR2-dependent activation of the nf-kappab pathway. bioRxiv Prepr. Serv. Biol. 2021;10:e68563. doi: 10.1101/2021.03.16.435700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2021.03.16.435700</ArticleId><ArticleId IdType="pmc">PMC8709575</ArticleId><ArticleId IdType="pubmed">34866574</ArticleId></ArticleIdList></Reference><Reference><Citation>Xia S., Zhu Y., Liu M., Lan Q., Xu W., Wu Y., Ying T., Liu S., Shi Z., Jiang S., et al. Fusion mechanism of 2019-nCOV and fusion inhibitors targeting HR1 domain in spike protein. Cell. Mol. Immunol. 2020;17:765–767. doi: 10.1038/s41423-020-0374-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-020-0374-2</ArticleId><ArticleId IdType="pmc">PMC7075278</ArticleId><ArticleId IdType="pubmed">32047258</ArticleId></ArticleIdList></Reference><Reference><Citation>Landolina N., Ricci B., Veneziani I., Alicata C., Mariotti F.R., Pelosi A., Quatrini L., Mortari E.P., Carsetti R., Vacca P., et al. TLR2/4 are novel activating receptors for SARS-CoV-2 spike protein on nk cells. Frontiers in immunology. 2024;15:1368946. doi: 10.3389/fimmu.2024.1368946.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2024.1368946</ArticleId><ArticleId IdType="pmc">PMC11176535</ArticleId><ArticleId IdType="pubmed">38881905</ArticleId></ArticleIdList></Reference><Reference><Citation>Palestra F., Poto R., Ciardi R., Opromolla G., Secondo A., Tedeschi V., Ferrara A.L., Di Crescenzo R.M., Galdiero M.R., Cristinziano L., et al. SARS-CoV-2 spike protein activates human lung macrophages. Int. J. Mol. Sci. 2023;24:3036. doi: 10.3390/ijms24033036.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24033036</ArticleId><ArticleId IdType="pmc">PMC9917796</ArticleId><ArticleId IdType="pubmed">36769357</ArticleId></ArticleIdList></Reference><Reference><Citation>Qian Y., Lei T., Patel P.S., Lee C.H., Monaghan-Nichols P., Xin H.B., Qiu J., Fu M. Direct activation of endothelial cells by SARS-CoV-2 nucleocapsid protein is blocked by simvastatin. J. Virol. 2021;95:e0139621. doi: 10.1128/JVI.01396-21.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/JVI.01396-21</ArticleId><ArticleId IdType="pmc">PMC8577385</ArticleId><ArticleId IdType="pubmed">34549987</ArticleId></ArticleIdList></Reference><Reference><Citation>Zheng M., Karki R., Williams E.P., Yang D., Fitzpatrick E., Vogel P., Jonsson C.B., Kanneganti T.D. TLR2 senses the SARS-CoV-2 envelope protein to produce inflammatory cytokines. Nat. Immunol. 2021;22:829–838. doi: 10.1038/s41590-021-00937-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41590-021-00937-x</ArticleId><ArticleId IdType="pmc">PMC8882317</ArticleId><ArticleId IdType="pubmed">33963333</ArticleId></ArticleIdList></Reference><Reference><Citation>Mohanty M.C., Varose S.Y., Sawant U.P., Fernandes M.M. Expression of innate immune response genes in upper airway samples of SARS-CoV-2 infected patients: A preliminary study. Indian J. Med. Res. 2021;153:677–683. doi: 10.4103/ijmr.IJMR_131_21.</Citation><ArticleIdList><ArticleId IdType="doi">10.4103/ijmr.IJMR_131_21</ArticleId><ArticleId IdType="pmc">PMC8555587</ArticleId><ArticleId IdType="pubmed">34528526</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang C.A., Huang Y.L., Chiang B.L. Innate immune response analysis in COVID-19 and kawasaki disease reveals mis-c predictors. J. Formos. Med. Assoc. Taiwan Yi Zhi. 2022;121:623–632. doi: 10.1016/j.jfma.2021.06.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jfma.2021.06.009</ArticleId><ArticleId IdType="pmc">PMC8214167</ArticleId><ArticleId IdType="pubmed">34193364</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y., Kuang M., Li J., Zhu L., Jia Z., Guo X., Hu Y., Kong J., Yin H., Wang X., et al. SARS-CoV-2 spike protein interacts with and activates TLR41. Cell Res. 2021;31:818–820. doi: 10.1038/s41422-021-00495-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41422-021-00495-9</ArticleId><ArticleId IdType="pmc">PMC7975240</ArticleId><ArticleId IdType="pubmed">33742149</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhury A., Mukherjee S. In silico studies on the comparative characterization of the interactions of SARS-CoV-2 spike glycoprotein with ACE-2 receptor homologs and human TLRS. J. Med. Virol. 2020;92:2105–2113. doi: 10.1002/jmv.25987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.25987</ArticleId><ArticleId IdType="pmc">PMC7267663</ArticleId><ArticleId IdType="pubmed">32383269</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirato K., Kizaki T. SARS-CoV-2 spike protein s1 subunit induces pro-inflammatory responses via toll-like receptor 4 signaling in murine and human macrophages. Heliyon. 2021;7:e06187. doi: 10.1016/j.heliyon.2021.e06187.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.heliyon.2021.e06187</ArticleId><ArticleId IdType="pmc">PMC7887388</ArticleId><ArticleId IdType="pubmed">33644468</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank M.G., Nguyen K.H., Ball J.B., Hopkins S., Kelley T., Baratta M.V., Fleshner M., Maier S.F. SARS-CoV-2 spike s1 subunit induces neuroinflammatory, microglial and behavioral sickness responses: Evidence of pamp-like properties. Brain Behav. Immun. 2022;100:267–277. doi: 10.1016/j.bbi.2021.12.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2021.12.007</ArticleId><ArticleId IdType="pmc">PMC8667429</ArticleId><ArticleId IdType="pubmed">34915155</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Q., Xiang R., Huo S., Zhou Y., Jiang S., Wang Q., Yu F. Molecular mechanism of interaction between SARS-CoV-2 and host cells and interventional therapy. Signal Transduct. Target. Ther. 2021;6:233. doi: 10.1038/s41392-021-00653-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-021-00653-w</ArticleId><ArticleId IdType="pmc">PMC8193598</ArticleId><ArticleId IdType="pubmed">34117216</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Navajas J.M., Lee J., David M., Raz E. Immunomodulatory functions of type i interferons. Nat. Rev. Immunol. 2012;12:125–135. doi: 10.1038/nri3133.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri3133</ArticleId><ArticleId IdType="pmc">PMC3727154</ArticleId><ArticleId IdType="pubmed">22222875</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato H., Takeuchi O., Mikamo-Satoh E., Hirai R., Kawai T., Matsushita K., Hiiragi A., Dermody T.S., Fujita T., Akira S. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-i and melanoma differentiation-associated gene 5. J. Exp. Med. 2008;205:1601–1610. doi: 10.1084/jem.20080091.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20080091</ArticleId><ArticleId IdType="pmc">PMC2442638</ArticleId><ArticleId IdType="pubmed">18591409</ArticleId></ArticleIdList></Reference><Reference><Citation>Brisse M., Ly H. Comparative structure and function analysis of the rig-i-like receptors: Rig-i and mda5. Front. Immunol. 2019;10:1586. doi: 10.3389/fimmu.2019.01586.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01586</ArticleId><ArticleId IdType="pmc">PMC6652118</ArticleId><ArticleId IdType="pubmed">31379819</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuel C.E. Interferon at the crossroads of SARS-CoV-2 infection and COVID-19 disease. J. Biol. Chem. 2023;299:104960. doi: 10.1016/j.jbc.2023.104960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jbc.2023.104960</ArticleId><ArticleId IdType="pmc">PMC10290182</ArticleId><ArticleId IdType="pubmed">37364688</ArticleId></ArticleIdList></Reference><Reference><Citation>Totura A.L., Whitmore A., Agnihothram S., Schafer A., Katze M.G., Heise M.T., Baric R.S. Toll-like receptor 3 signaling via trif contributes to a protective innate immune response to severe acute respiratory syndrome coronavirus infection. mBio. 2015;6:e00638–e00715. doi: 10.1128/mBio.00638-15.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/mBio.00638-15</ArticleId><ArticleId IdType="pmc">PMC4447251</ArticleId><ArticleId IdType="pubmed">26015500</ArticleId></ArticleIdList></Reference><Reference><Citation>Fallerini C., Daga S., Mantovani S., Benetti E., Picchiotti N., Francisci D., Paciosi F., Schiaroli E., Baldassarri M., Fava F., et al. Association of toll-like receptor 7 variants with life-threatening COVID-19 disease in males: Findings from a nested case-control study. Elife. 2021;10:e67569. doi: 10.7554/eLife.67569.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.67569</ArticleId><ArticleId IdType="pmc">PMC7987337</ArticleId><ArticleId IdType="pubmed">33650967</ArticleId></ArticleIdList></Reference><Reference><Citation>Paschou S.A., Psaltopoulou T., Halvatsiotis P., Raptis A., Vlachopoulos C.V., Dimopoulos M.A. Gender differences in COVID-19. Maturitas. 2022;161:72–73. doi: 10.1016/j.maturitas.2022.03.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.maturitas.2022.03.004</ArticleId><ArticleId IdType="pmc">PMC8934754</ArticleId><ArticleId IdType="pubmed">35337711</ArticleId></ArticleIdList></Reference><Reference><Citation>Patra R., Chandra Das N., Mukherjee S. Targeting human TLRS to combat COVID-19: A solution? J. Med. Virol. 2021;93:615–617. doi: 10.1002/jmv.26387.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26387</ArticleId><ArticleId IdType="pmc">PMC7436140</ArticleId><ArticleId IdType="pubmed">32749702</ArticleId></ArticleIdList></Reference><Reference><Citation>Sohn K.M., Lee S.G., Kim H.J., Cheon S., Jeong H., Lee J., Kim I.S., Silwal P., Kim Y.J., Paik S., et al. COVID-19 patients upregulate toll-like receptor 4-mediated inflammatory signaling that mimics bacterial sepsis. J. Korean Med. Sci. 2020;35:e343. doi: 10.3346/jkms.2020.35.e343.</Citation><ArticleIdList><ArticleId IdType="doi">10.3346/jkms.2020.35.e343</ArticleId><ArticleId IdType="pmc">PMC7521960</ArticleId><ArticleId IdType="pubmed">32989935</ArticleId></ArticleIdList></Reference><Reference><Citation>Kayesh M.E.H., Kohara M., Tsukiyama-Kohara K. An overview of recent insights into the response of TLR to SARS-CoV-2 infection and the potential of TLR agonists as SARS-CoV-2 vaccine adjuvants. Viruses. 2021;13:2302. doi: 10.3390/v13112302.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v13112302</ArticleId><ArticleId IdType="pmc">PMC8622245</ArticleId><ArticleId IdType="pubmed">34835108</ArticleId></ArticleIdList></Reference><Reference><Citation>Veras F.P., Pontelli M.C., Silva C.M., Toller-Kawahisa J.E., de Lima M., Nascimento D.C., Schneider A.H., Caetite D., Tavares L.A., Paiva I.M., et al. SARS-CoV-2-triggered neutrophil extracellular traps mediate COVID-19 pathology. J. Exp. Med. 2020;217:e20201129. doi: 10.1084/jem.20201129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20201129</ArticleId><ArticleId IdType="pmc">PMC7488868</ArticleId><ArticleId IdType="pubmed">32926098</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuevas A.M., Clark J.M., Potter J.J. Increased TLR/MYD88 signaling in patients with obesity: Is there a link to COVID-19 disease severity? Int. J. Obes. 2021;45:1152–1154. doi: 10.1038/s41366-021-00768-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41366-021-00768-8</ArticleId><ArticleId IdType="pmc">PMC7909368</ArticleId><ArticleId IdType="pubmed">33637950</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang M., Chang W., Zhang L., Zhang Y. Pyroptotic cell death in SARS-CoV-2 infection: Revealing its roles during the immunopathogenesis of COVID-19. Int. J. Biol. Sci. 2022;18:5827–5848. doi: 10.7150/ijbs.77561.</Citation><ArticleIdList><ArticleId IdType="doi">10.7150/ijbs.77561</ArticleId><ArticleId IdType="pmc">PMC9576507</ArticleId><ArticleId IdType="pubmed">36263178</ArticleId></ArticleIdList></Reference><Reference><Citation>McGonagle D., Sharif K., O’Regan A., Bridgewood C. The role of cytokines including interleukin-6 in COVID-19 induced pneumonia and macrophage activation syndrome-like disease. Autoimmun. Rev. 2020;19:102537. doi: 10.1016/j.autrev.2020.102537.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2020.102537</ArticleId><ArticleId IdType="pmc">PMC7195002</ArticleId><ArticleId IdType="pubmed">32251717</ArticleId></ArticleIdList></Reference><Reference><Citation>Tavakolpour S., Rakhshandehroo T., Wei E.X., Rashidian M. Lymphopenia during the COVID-19 infection: What it shows and what can be learned. Immunol. Lett. 2020;225:31–32. doi: 10.1016/j.imlet.2020.06.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imlet.2020.06.013</ArticleId><ArticleId IdType="pmc">PMC7305732</ArticleId><ArticleId IdType="pubmed">32569607</ArticleId></ArticleIdList></Reference><Reference><Citation>Wulandari S., Hartono, Wibawa T. The role of hmgb1 in COVID-19-induced cytokine storm and its potential therapeutic targets: A review. Immunology. 2023;169:117–131. doi: 10.1111/imm.13623.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13623</ArticleId><ArticleId IdType="pmc">PMC9880760</ArticleId><ArticleId IdType="pubmed">36571562</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H., Wang H., Ju Z., Ragab A.A., Lundback P., Long W., Valdes-Ferrer S.I., He M., Pribis J.P., Li J., et al. Md-2 is required for disulfide hmgb1-dependent TLR4 signaling. J. Exp. Med. 2015;212:5–14. doi: 10.1084/jem.20141318.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20141318</ArticleId><ArticleId IdType="pmc">PMC4291531</ArticleId><ArticleId IdType="pubmed">25559892</ArticleId></ArticleIdList></Reference><Reference><Citation>Cicco S., Cicco G., Racanelli V., Vacca A. Neutrophil extracellular traps (nets) and damage-associated molecular patterns (damps): Two potential targets for COVID-19 treatment. Mediat. Inflamm. 2020;2020:7527953. doi: 10.1155/2020/7527953.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2020/7527953</ArticleId><ArticleId IdType="pmc">PMC7366221</ArticleId><ArticleId IdType="pubmed">32724296</ArticleId></ArticleIdList></Reference><Reference><Citation>Mellett L., Khader S.A. S100a8/a9 in COVID-19 pathogenesis: Impact on clinical outcomes. Cytokine Growth Factor. Rev. 2022;63:90–97. doi: 10.1016/j.cytogfr.2021.10.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cytogfr.2021.10.004</ArticleId><ArticleId IdType="pmc">PMC8520505</ArticleId><ArticleId IdType="pubmed">34728150</ArticleId></ArticleIdList></Reference><Reference><Citation>Targhetta V.P., Amaral M.A., Camara N.O.S. Through DNA sensors and hidden mitochondrial effects of SARS-CoV-2. J. Venom. Anim. Toxins Incl. Trop. Dis. 2021;27:e20200183. doi: 10.1590/1678-9199-jvatitd-2020-0183.</Citation><ArticleIdList><ArticleId IdType="doi">10.1590/1678-9199-jvatitd-2020-0183</ArticleId><ArticleId IdType="pmc">PMC8383803</ArticleId><ArticleId IdType="pubmed">34471404</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumagai Y., Takeuchi O., Akira S. TLR9 as a key receptor for the recognition of DNA. Adv. Drug Deliv. Rev. 2008;60:795–804. doi: 10.1016/j.addr.2007.12.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.addr.2007.12.004</ArticleId><ArticleId IdType="pubmed">18262306</ArticleId></ArticleIdList></Reference><Reference><Citation>Miyake K., Onji M. Endocytosis-free DNA sensing by cell surface TLR9 in neutrophils: Rapid defense with autoimmune risks. Eur. J. Immunol. 2013;43:2006–2009. doi: 10.1002/eji.201343882.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201343882</ArticleId><ArticleId IdType="pubmed">23928965</ArticleId></ArticleIdList></Reference><Reference><Citation>Andargie T.E., Tsuji N., Seifuddin F., Jang M.K., Yuen P.S., Kong H., Tunc I., Singh K., Charya A., Wilkins K., et al. Cell-free DNA maps COVID-19 tissue injury and risk of death and can cause tissue injury. JCI Insight. 2021;6:e147610. doi: 10.1172/jci.insight.147610.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/jci.insight.147610</ArticleId><ArticleId IdType="pmc">PMC8119224</ArticleId><ArticleId IdType="pubmed">33651717</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalier E., Guiot J., Lechner K., Dutsch A., Eccleston M., Herzog M., Bygott T., Schomburg A., Kelly T., Holdenrieder S. Circulating nucleosomes as potential markers to monitor COVID-19 disease progression. Front. Mol. Biosci. 2021;8:600881. doi: 10.3389/fmolb.2021.600881.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmolb.2021.600881</ArticleId><ArticleId IdType="pmc">PMC8012533</ArticleId><ArticleId IdType="pubmed">33816549</ArticleId></ArticleIdList></Reference><Reference><Citation>Melis J.P., Strumane K., Ruuls S.R., Beurskens F.J., Schuurman J., Parren P.W. Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics. Mol. Immunol. 2015;67:117–130. doi: 10.1016/j.molimm.2015.01.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2015.01.028</ArticleId><ArticleId IdType="pubmed">25697848</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajishengallis G., Reis E.S., Mastellos D.C., Ricklin D., Lambris J.D. Novel mechanisms and functions of complement. Nat. Immunol. 2017;18:1288–1298. doi: 10.1038/ni.3858.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.3858</ArticleId><ArticleId IdType="pmc">PMC5706779</ArticleId><ArticleId IdType="pubmed">29144501</ArticleId></ArticleIdList></Reference><Reference><Citation>Vandendriessche S., Cambier S., Proost P., Marques P.E. Complement receptors and their role in leukocyte recruitment and phagocytosis. Front. Cell Dev. Biol. 2021;9:624025. doi: 10.3389/fcell.2021.624025.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fcell.2021.624025</ArticleId><ArticleId IdType="pmc">PMC7905230</ArticleId><ArticleId IdType="pubmed">33644062</ArticleId></ArticleIdList></Reference><Reference><Citation>Pouw R.B., Ricklin D. Tipping the balance: Intricate roles of the complement system in disease and therapy. Semin. Immunopathol. 2021;43:757–771. doi: 10.1007/s00281-021-00892-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-021-00892-7</ArticleId><ArticleId IdType="pmc">PMC8547127</ArticleId><ArticleId IdType="pubmed">34698894</ArticleId></ArticleIdList></Reference><Reference><Citation>Killick J., Morisse G., Sieger D., Astier A.L. Complement as a regulator of adaptive immunity. Semin. Immunopathol. 2018;40:37–48. doi: 10.1007/s00281-017-0644-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00281-017-0644-y</ArticleId><ArticleId IdType="pmc">PMC5794818</ArticleId><ArticleId IdType="pubmed">28842749</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwan W.H., van der Touw W., Heeger P.S. Complement regulation of t cell immunity. Immunol. Res. 2012;54:247–253. doi: 10.1007/s12026-012-8327-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12026-012-8327-1</ArticleId><ArticleId IdType="pmc">PMC4081859</ArticleId><ArticleId IdType="pubmed">22477527</ArticleId></ArticleIdList></Reference><Reference><Citation>Strainic M.G., Liu J., Huang D., An F., Lalli P.N., Muqim N., Shapiro V.S., Dubyak G.R., Heeger P.S., Medof M.E. Locally produced complement fragments c5a and c3a provide both costimulatory and survival signals to naive cd4+ t cells. Immunity. 2008;28:425–435. doi: 10.1016/j.immuni.2008.02.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2008.02.001</ArticleId><ArticleId IdType="pmc">PMC2646383</ArticleId><ArticleId IdType="pubmed">18328742</ArticleId></ArticleIdList></Reference><Reference><Citation>Ricklin D., Hajishengallis G., Yang K., Lambris J.D. Complement: A key system for immune surveillance and homeostasis. Nat. Immunol. 2010;11:785–797. doi: 10.1038/ni.1923.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1923</ArticleId><ArticleId IdType="pmc">PMC2924908</ArticleId><ArticleId IdType="pubmed">20720586</ArticleId></ArticleIdList></Reference><Reference><Citation>West E.E., Kemper C. Complosome—The intracellular complement system. Nat. Rev. Nephrol. 2023;19:426–439. doi: 10.1038/s41581-023-00704-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-023-00704-1</ArticleId><ArticleId IdType="pmc">PMC10100629</ArticleId><ArticleId IdType="pubmed">37055581</ArticleId></ArticleIdList></Reference><Reference><Citation>Nesargikar P.N., Spiller B., Chavez R. The complement system: History, pathways, cascade and inhibitors. Eur. J. Microbiol. Immunol. 2012;2:103–111. doi: 10.1556/EuJMI.2.2012.2.2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1556/EuJMI.2.2012.2.2</ArticleId><ArticleId IdType="pmc">PMC3956958</ArticleId><ArticleId IdType="pubmed">24672678</ArticleId></ArticleIdList></Reference><Reference><Citation>Ehrnthaller C., Ignatius A., Gebhard F., Huber-Lang M. New insights of an old defense system: Structure, function, and clinical relevance of the complement system. Mol. Med. 2011;17:317–329. doi: 10.2119/molmed.2010.00149.</Citation><ArticleIdList><ArticleId IdType="doi">10.2119/molmed.2010.00149</ArticleId><ArticleId IdType="pmc">PMC3060978</ArticleId><ArticleId IdType="pubmed">21046060</ArticleId></ArticleIdList></Reference><Reference><Citation>Pillemer L., Blum L., Lepow I.H., Ross O.A., Todd E.W., Wardlaw A.C. The properdin system and immunity. I. Demonstration and isolation of a new serum protein, properdin, and its role in immune phenomena. Science. 1954;120:279–285. doi: 10.1126/science.120.3112.279.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.120.3112.279</ArticleId><ArticleId IdType="pubmed">13186838</ArticleId></ArticleIdList></Reference><Reference><Citation>Kawasaki T., Etoh R., Yamashina I. Isolation and characterization of a mannan-binding protein from rabbit liver. Biochem. Biophys. Res. Commun. 1978;81:1018–1024. doi: 10.1016/0006-291X(78)91452-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0006-291X(78)91452-3</ArticleId><ArticleId IdType="pubmed">666781</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsushita M., Endo Y., Fujita T. Cutting edge: Complement-activating complex of ficolin and mannose-binding lectin-associated serine protease. J. Immunol. 2000;164:2281–2284. doi: 10.4049/jimmunol.164.5.2281.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.164.5.2281</ArticleId><ArticleId IdType="pubmed">10679061</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsushita M., Fujita T. Activation of the classical complement pathway by mannose-binding protein in association with a novel c1s-like serine protease. J. Exp. Med. 1992;176:1497–1502. doi: 10.1084/jem.176.6.1497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.176.6.1497</ArticleId><ArticleId IdType="pmc">PMC2119445</ArticleId><ArticleId IdType="pubmed">1460414</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsushita M., Kuraya M., Hamasaki N., Tsujimura M., Shiraki H., Fujita T. Activation of the lectin complement pathway by h-ficolin (hakata antigen) J. Immunol. 2002;168:3502–3506. doi: 10.4049/jimmunol.168.7.3502.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.168.7.3502</ArticleId><ArticleId IdType="pubmed">11907111</ArticleId></ArticleIdList></Reference><Reference><Citation>Matsushita M., Thiel S., Jensenius J.C., Terai I., Fujita T. Proteolytic activities of two types of mannose-binding lectin-associated serine protease. J. Immunol. 2000;165:2637–2642. doi: 10.4049/jimmunol.165.5.2637.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.165.5.2637</ArticleId><ArticleId IdType="pubmed">10946292</ArticleId></ArticleIdList></Reference><Reference><Citation>Xie C.B., Jane-Wit D., Pober J.S. Complement membrane attack complex: New roles, mechanisms of action, and therapeutic targets. Am. J. Pathol. 2020;190:1138–1150. doi: 10.1016/j.ajpath.2020.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajpath.2020.02.006</ArticleId><ArticleId IdType="pmc">PMC7280757</ArticleId><ArticleId IdType="pubmed">32194049</ArticleId></ArticleIdList></Reference><Reference><Citation>Biro A., Rovo Z., Papp D., Cervenak L., Varga L., Fust G., Thielens N.M., Arlaud G.J., Prohaszka Z. Studies on the interactions between c-reactive protein and complement proteins. Immunology. 2007;121:40–50. doi: 10.1111/j.1365-2567.2007.02535.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2007.02535.x</ArticleId><ArticleId IdType="pmc">PMC2265924</ArticleId><ArticleId IdType="pubmed">17244159</ArticleId></ArticleIdList></Reference><Reference><Citation>Sjoberg A.P., Trouw L.A., Blom A.M. Complement activation and inhibition: A delicate balance. Trends Immunol. 2009;30:83–90. doi: 10.1016/j.it.2008.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2008.11.003</ArticleId><ArticleId IdType="pubmed">19144569</ArticleId></ArticleIdList></Reference><Reference><Citation>Budayova-Spano M., Lacroix M., Thielens N.M., Arlaud G.J., Fontecilla-Camps J.C., Gaboriaud C. The crystal structure of the zymogen catalytic domain of complement protease c1r reveals that a disruptive mechanical stress is required to trigger activation of the c1 complex. EMBO J. 2002;21:231–239. doi: 10.1093/emboj/21.3.231.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/emboj/21.3.231</ArticleId><ArticleId IdType="pmc">PMC125823</ArticleId><ArticleId IdType="pubmed">11823416</ArticleId></ArticleIdList></Reference><Reference><Citation>Kardos J., Harmat V., Pallo A., Barabas O., Szilagyi K., Graf L., Naray-Szabo G., Goto Y., Zavodszky P., Gal P. Revisiting the mechanism of the autoactivation of the complement protease c1r in the c1 complex: Structure of the active catalytic region of c1r. Mol. Immunol. 2008;45:1752–1760. doi: 10.1016/j.molimm.2007.09.031.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2007.09.031</ArticleId><ArticleId IdType="pubmed">17996945</ArticleId></ArticleIdList></Reference><Reference><Citation>Mortensen S.A., Sander B., Jensen R.K., Pedersen J.S., Golas M.M., Jensenius J.C., Hansen A.G., Thiel S., Andersen G.R. Structure and activation of c1, the complex initiating the classical pathway of the complement cascade. Proc. Natl. Acad. Sci. USA. 2017;114:986–991. doi: 10.1073/pnas.1616998114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1616998114</ArticleId><ArticleId IdType="pmc">PMC5293073</ArticleId><ArticleId IdType="pubmed">28104818</ArticleId></ArticleIdList></Reference><Reference><Citation>Ling M., Murali M. Analysis of the complement system in the clinical immunology laboratory. Clin. Lab. Med. 2019;39:579–590. doi: 10.1016/j.cll.2019.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cll.2019.07.006</ArticleId><ArticleId IdType="pubmed">31668271</ArticleId></ArticleIdList></Reference><Reference><Citation>Heja D., Kocsis A., Dobo J., Szilagyi K., Szasz R., Zavodszky P., Pal G., Gal P. Revised mechanism of complement lectin-pathway activation revealing the role of serine protease masp-1 as the exclusive activator of masp-2. Proc. Natl. Acad. Sci. USA. 2012;109:10498–10503. doi: 10.1073/pnas.1202588109.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1202588109</ArticleId><ArticleId IdType="pmc">PMC3387078</ArticleId><ArticleId IdType="pubmed">22691502</ArticleId></ArticleIdList></Reference><Reference><Citation>Dommett R.M., Klein N., Turner M.W. Mannose-binding lectin in innate immunity: Past, present and future. Tissue Antigens. 2006;68:193–209. doi: 10.1111/j.1399-0039.2006.00649.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1399-0039.2006.00649.x</ArticleId><ArticleId IdType="pmc">PMC7169806</ArticleId><ArticleId IdType="pubmed">16948640</ArticleId></ArticleIdList></Reference><Reference><Citation>Endo Y., Matsushita M., Fujita T. The role of ficolins in the lectin pathway of innate immunity. Int. J. Biochem. Cell Biol. 2011;43:705–712. doi: 10.1016/j.biocel.2011.02.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.biocel.2011.02.003</ArticleId><ArticleId IdType="pubmed">21315829</ArticleId></ArticleIdList></Reference><Reference><Citation>Hansen S., Selman L., Palaniyar N., Ziegler K., Brandt J., Kliem A., Jonasson M., Skjoedt M.O., Nielsen O., Hartshorn K., et al. Collectin 11 (cl-11, cl-k1) is a masp-1/3-associated plasma collectin with microbial-binding activity. J. Immunol. 2010;185:6096–6104. doi: 10.4049/jimmunol.1002185.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1002185</ArticleId><ArticleId IdType="pubmed">20956340</ArticleId></ArticleIdList></Reference><Reference><Citation>Stoermer K.A., Morrison T.E. Complement and viral pathogenesis. Virology. 2011;411:362–373. doi: 10.1016/j.virol.2010.12.045.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.virol.2010.12.045</ArticleId><ArticleId IdType="pmc">PMC3073741</ArticleId><ArticleId IdType="pubmed">21292294</ArticleId></ArticleIdList></Reference><Reference><Citation>Thurman J.M., Holers V.M. The central role of the alternative complement pathway in human disease. J. Immunol. 2006;176:1305–1310. doi: 10.4049/jimmunol.176.3.1305.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.176.3.1305</ArticleId><ArticleId IdType="pubmed">16424154</ArticleId></ArticleIdList></Reference><Reference><Citation>Pangburn M.K., Schreiber R.D., Muller-Eberhard H.J. Formation of the initial c3 convertase of the alternative complement pathway. Acquisition of c3b-like activities by spontaneous hydrolysis of the putative thioester in native c3. J. Exp. Med. 1981;154:856–867. doi: 10.1084/jem.154.3.856.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.154.3.856</ArticleId><ArticleId IdType="pmc">PMC2186450</ArticleId><ArticleId IdType="pubmed">6912277</ArticleId></ArticleIdList></Reference><Reference><Citation>Fromell K., Adler A., Aman A., Manivel V.A., Huang S., Duhrkop C., Sandholm K., Ekdahl K.N., Nilsson B. Assessment of the role of C3(H2O) in the alternative pathway. Front. Immunol. 2020;11:530. doi: 10.3389/fimmu.2020.00530.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.00530</ArticleId><ArticleId IdType="pmc">PMC7136553</ArticleId><ArticleId IdType="pubmed">32296436</ArticleId></ArticleIdList></Reference><Reference><Citation>Bexborn F., Andersson P.O., Chen H., Nilsson B., Ekdahl K.N. The tick-over theory revisited: Formation and regulation of the soluble alternative complement c3 convertase (C3(H2O)Bb) Mol. Immunol. 2008;45:2370–2379. doi: 10.1016/j.molimm.2007.11.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2007.11.003</ArticleId><ArticleId IdType="pmc">PMC2701500</ArticleId><ArticleId IdType="pubmed">18096230</ArticleId></ArticleIdList></Reference><Reference><Citation>Milder F.J., Gomes L., Schouten A., Janssen B.J., Huizinga E.G., Romijn R.A., Hemrika W., Roos A., Daha M.R., Gros P. Factor b structure provides insights into activation of the central protease of the complement system. Nat. Struct. Mol. Biol. 2007;14:224–228. doi: 10.1038/nsmb1210.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nsmb1210</ArticleId><ArticleId IdType="pubmed">17310251</ArticleId></ArticleIdList></Reference><Reference><Citation>Forneris F., Ricklin D., Wu J., Tzekou A., Wallace R.S., Lambris J.D., Gros P. Structures of c3b in complex with factors b and d give insight into complement convertase formation. Science. 2010;330:1816–1820. doi: 10.1126/science.1195821.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.1195821</ArticleId><ArticleId IdType="pmc">PMC3087196</ArticleId><ArticleId IdType="pubmed">21205667</ArticleId></ArticleIdList></Reference><Reference><Citation>Janssen B.J., Gomes L., Koning R.I., Svergun D.I., Koster A.J., Fritzinger D.C., Vogel C.W., Gros P. Insights into complement convertase formation based on the structure of the factor b-cobra venom factor complex. EMBO J. 2009;28:2469–2478. doi: 10.1038/emboj.2009.184.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/emboj.2009.184</ArticleId><ArticleId IdType="pmc">PMC2735180</ArticleId><ArticleId IdType="pubmed">19574954</ArticleId></ArticleIdList></Reference><Reference><Citation>Klos A., Tenner A.J., Johswich K.O., Ager R.R., Reis E.S., Kohl J. The role of the anaphylatoxins in health and disease. Mol. Immunol. 2009;46:2753–2766. doi: 10.1016/j.molimm.2009.04.027.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2009.04.027</ArticleId><ArticleId IdType="pmc">PMC2725201</ArticleId><ArticleId IdType="pubmed">19477527</ArticleId></ArticleIdList></Reference><Reference><Citation>Rooijakkers S.H., Wu J., Ruyken M., van Domselaar R., Planken K.L., Tzekou A., Ricklin D., Lambris J.D., Janssen B.J., van Strijp J.A., et al. Structural and functional implications of the alternative complement pathway c3 convertase stabilized by a staphylococcal inhibitor. Nat. Immunol. 2009;10:721–727. doi: 10.1038/ni.1756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ni.1756</ArticleId><ArticleId IdType="pmc">PMC2729104</ArticleId><ArticleId IdType="pubmed">19503103</ArticleId></ArticleIdList></Reference><Reference><Citation>Zwarthoff S.A., Berends E.T.M., Mol S., Ruyken M., Aerts P.C., Jozsi M., de Haas C.J.C., Rooijakkers S.H.M., Gorham R.D., Jr. Functional characterization of alternative and classical pathway c3/c5 convertase activity and inhibition using purified models. Front. Immunol. 2018;9:1691. doi: 10.3389/fimmu.2018.01691.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01691</ArticleId><ArticleId IdType="pmc">PMC6064732</ArticleId><ArticleId IdType="pubmed">30083158</ArticleId></ArticleIdList></Reference><Reference><Citation>Harboe M., Mollnes T.E. The alternative complement pathway revisited. J. Cell. Mol. Med. 2008;12:1074–1084. doi: 10.1111/j.1582-4934.2008.00350.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1582-4934.2008.00350.x</ArticleId><ArticleId IdType="pmc">PMC3865650</ArticleId><ArticleId IdType="pubmed">18419792</ArticleId></ArticleIdList></Reference><Reference><Citation>Boero E., Gorham R.D., Jr., Francis E.A., Brand J., Teng L.H., Doorduijn D.J., Ruyken M., Muts R.M., Lehmann C., Verschoor A., et al. Purified complement c3b triggers phagocytosis and activation of human neutrophils via complement receptor 1. Sci. Rep. 2023;13:274. doi: 10.1038/s41598-022-27279-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-022-27279-4</ArticleId><ArticleId IdType="pmc">PMC9822988</ArticleId><ArticleId IdType="pubmed">36609665</ArticleId></ArticleIdList></Reference><Reference><Citation>Kinoshita T., Takata Y., Kozono H., Takeda J., Hong K.S., Inoue K. C5 convertase of the alternative complement pathway: Covalent linkage between two c3b molecules within the trimolecular complex enzyme. J. Immunol. 1988;141:3895–3901. doi: 10.4049/jimmunol.141.11.3895.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.141.11.3895</ArticleId><ArticleId IdType="pubmed">3183384</ArticleId></ArticleIdList></Reference><Reference><Citation>Rawal N., Pangburn M.K. Structure/function of c5 convertases of complement. Int. Immunopharmacol. 2001;1:415–422. doi: 10.1016/S1567-5769(00)00039-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1567-5769(00)00039-4</ArticleId><ArticleId IdType="pubmed">11367526</ArticleId></ArticleIdList></Reference><Reference><Citation>Pangburn M.K., Rawal N. Structure and function of complement c5 convertase enzymes. Biochem. Soc. Trans. 2002;30:1006–1010. doi: 10.1042/bst0301006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bst0301006</ArticleId><ArticleId IdType="pubmed">12440962</ArticleId></ArticleIdList></Reference><Reference><Citation>Bubeck D. The making of a macromolecular machine: Assembly of the membrane attack complex. Biochemistry. 2014;53:1908–1915. doi: 10.1021/bi500157z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/bi500157z</ArticleId><ArticleId IdType="pubmed">24597946</ArticleId></ArticleIdList></Reference><Reference><Citation>Preissner K.T., Podack E.R., Muller-Eberhard H.J. The membrane attack complex of complement: Relation of c7 to the metastable membrane binding site of the intermediate complex c5b-7. J. Immunol. 1985;135:445–451. doi: 10.4049/jimmunol.135.1.445.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.135.1.445</ArticleId><ArticleId IdType="pubmed">3998468</ArticleId></ArticleIdList></Reference><Reference><Citation>Menny A., Serna M., Boyd C.M., Gardner S., Joseph A.P., Morgan B.P., Topf M., Brooks N.J., Bubeck D. Cryoem reveals how the complement membrane attack complex ruptures lipid bilayers. Nat. Commun. 2018;9:5316. doi: 10.1038/s41467-018-07653-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-018-07653-5</ArticleId><ArticleId IdType="pmc">PMC6294249</ArticleId><ArticleId IdType="pubmed">30552328</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen Y., Yang C., Jin N., Xie Z., Tang Y., Fei L., Jia Z., Wu Y. Terminal complement complex c5b-9-treated human monocyte-derived dendritic cells undergo maturation and induce th1 polarization. Eur. J. Immunol. 2007;37:167–176. doi: 10.1002/eji.200636285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.200636285</ArticleId><ArticleId IdType="pubmed">17171756</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber-Lang M., Sarma J.V., Zetoune F.S., Rittirsch D., Neff T.A., McGuire S.R., Lambris J.D., Warner R.L., Flierl M.A., Hoesel L.M., et al. Generation of c5a in the absence of c3: A new complement activation pathway. Nat. Med. 2006;12:682–687. doi: 10.1038/nm1419.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm1419</ArticleId><ArticleId IdType="pubmed">16715088</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim D.D., Song W.C. Membrane complement regulatory proteins. Clin. Immunol. 2006;118:127–136. doi: 10.1016/j.clim.2005.10.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2005.10.014</ArticleId><ArticleId IdType="pubmed">16338172</ArticleId></ArticleIdList></Reference><Reference><Citation>Noris M., Remuzzi G. Overview of complement activation and regulation. Semin. Nephrol. 2013;33:479–492. doi: 10.1016/j.semnephrol.2013.08.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.semnephrol.2013.08.001</ArticleId><ArticleId IdType="pmc">PMC3820029</ArticleId><ArticleId IdType="pubmed">24161035</ArticleId></ArticleIdList></Reference><Reference><Citation>Davis A.E., 3rd, Mejia P., Lu F. Biological activities of c1 inhibitor. Mol. Immunol. 2008;45:4057–4063. doi: 10.1016/j.molimm.2008.06.028.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2008.06.028</ArticleId><ArticleId IdType="pmc">PMC2626406</ArticleId><ArticleId IdType="pubmed">18674818</ArticleId></ArticleIdList></Reference><Reference><Citation>Lublin D.M., Atkinson J.P. Decay-accelerating factor: Biochemistry, molecular biology, and function. Annu. Rev. Immunol. 1989;7:35–58. doi: 10.1146/annurev.iy.07.040189.000343.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.iy.07.040189.000343</ArticleId><ArticleId IdType="pubmed">2469439</ArticleId></ArticleIdList></Reference><Reference><Citation>Barilla-LaBarca M.L., Liszewski M.K., Lambris J.D., Hourcade D., Atkinson J.P. Role of membrane cofactor protein (cd46) in regulation of c4b and c3b deposited on cells. J. Immunol. 2002;168:6298–6304. doi: 10.4049/jimmunol.168.12.6298.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.168.12.6298</ArticleId><ArticleId IdType="pubmed">12055245</ArticleId></ArticleIdList></Reference><Reference><Citation>Liszewski M.K., Leung M., Cui W., Subramanian V.B., Parkinson J., Barlow P.N., Manchester M., Atkinson J.P. Dissecting sites important for complement regulatory activity in membrane cofactor protein (mcp; cd46) J. Biol. Chem. 2000;275:37692–37701. doi: 10.1074/jbc.M004650200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M004650200</ArticleId><ArticleId IdType="pubmed">10960475</ArticleId></ArticleIdList></Reference><Reference><Citation>Hardy M.P., Mansour M., Rowe T., Wymann S. The molecular mechanisms of complement receptor 1-it is complicated. Biomolecules. 2023;13:1522. doi: 10.3390/biom13101522.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom13101522</ArticleId><ArticleId IdType="pmc">PMC10605242</ArticleId><ArticleId IdType="pubmed">37892204</ArticleId></ArticleIdList></Reference><Reference><Citation>Iida K., Nussenzweig V. Complement receptor is an inhibitor of the complement cascade. J. Exp. Med. 1981;153:1138–1150. doi: 10.1084/jem.153.5.1138.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.153.5.1138</ArticleId><ArticleId IdType="pmc">PMC2186151</ArticleId><ArticleId IdType="pubmed">6910481</ArticleId></ArticleIdList></Reference><Reference><Citation>Wong W.W., Farrell S.A. Proposed structure of the f’ allotype of human cr1. Loss of a c3b binding site may be associated with altered function. J. Immunol. 1991;146:656–662. doi: 10.4049/jimmunol.146.2.656.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.146.2.656</ArticleId><ArticleId IdType="pubmed">1670949</ArticleId></ArticleIdList></Reference><Reference><Citation>Nilsson S.C., Sim R.B., Lea S.M., Fremeaux-Bacchi V., Blom A.M. Complement factor i in health and disease. Mol. Immunol. 2011;48:1611–1620. doi: 10.1016/j.molimm.2011.04.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2011.04.004</ArticleId><ArticleId IdType="pubmed">21529951</ArticleId></ArticleIdList></Reference><Reference><Citation>Parente R., Clark S.J., Inforzato A., Day A.J. Complement factor h in host defense and immune evasion. Cell. Mol. Life Sci. CMLS. 2017;74:1605–1624. doi: 10.1007/s00018-016-2418-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-016-2418-4</ArticleId><ArticleId IdType="pmc">PMC5378756</ArticleId><ArticleId IdType="pubmed">27942748</ArticleId></ArticleIdList></Reference><Reference><Citation>Kazatchkine M.D., Fearon D.T., Austen K.F. Human alternative complement pathway: Membrane-associated sialic acid regulates the competition between b and beta1 h for cell-bound c3b. J. Immunol. 1979;122:75–81. doi: 10.4049/jimmunol.122.1.75.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.122.1.75</ArticleId><ArticleId IdType="pubmed">762425</ArticleId></ArticleIdList></Reference><Reference><Citation>Manuelian T., Hellwage J., Meri S., Caprioli J., Noris M., Heinen S., Jozsi M., Neumann H.P., Remuzzi G., Zipfel P.F. Mutations in factor h reduce binding affinity to c3b and heparin and surface attachment to endothelial cells in hemolytic uremic syndrome. J. Clin. Investig. 2003;111:1181–1190. doi: 10.1172/JCI16651.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI16651</ArticleId><ArticleId IdType="pmc">PMC152934</ArticleId><ArticleId IdType="pubmed">12697737</ArticleId></ArticleIdList></Reference><Reference><Citation>Podack E.R., Kolb W.P., Muller-Eberhard H.J. The sc5b-7 complex: Formation, isolation, properties, and subunit composition. J. Immunol. 1977;119:2024–2029. doi: 10.4049/jimmunol.119.6.2024.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.119.6.2024</ArticleId><ArticleId IdType="pubmed">410885</ArticleId></ArticleIdList></Reference><Reference><Citation>Tschopp J., Chonn A., Hertig S., French L.E. Clusterin, the human apolipoprotein and complement inhibitor, binds to complement c7, c8 beta, and the b domain of c9. J. Immunol. 1993;151:2159–2165. doi: 10.4049/jimmunol.151.4.2159.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.151.4.2159</ArticleId><ArticleId IdType="pubmed">8345200</ArticleId></ArticleIdList></Reference><Reference><Citation>Zipfel P.F., Skerka C. Complement regulators and inhibitory proteins. Nat. Rev. Immunol. 2009;9:729–740. doi: 10.1038/nri2620.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2620</ArticleId><ArticleId IdType="pubmed">19730437</ArticleId></ArticleIdList></Reference><Reference><Citation>Whinnery C.D., Nie Y., Boskovic D.S., Soriano S., Kirsch W.M. Cd59 protects primary human cerebrovascular smooth muscle cells from cytolytic membrane attack complex. Brain Sci. 2024;14:601. doi: 10.3390/brainsci14060601.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/brainsci14060601</ArticleId><ArticleId IdType="pmc">PMC11202098</ArticleId><ArticleId IdType="pubmed">38928601</ArticleId></ArticleIdList></Reference><Reference><Citation>Avdonin P.P., Blinova M.S., Generalova G.A., Emirova K.M., Avdonin P.V. The role of the complement system in the pathogenesis of infectious forms of hemolytic uremic syndrome. Biomolecules. 2023;14:39. doi: 10.3390/biom14010039.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biom14010039</ArticleId><ArticleId IdType="pmc">PMC10813406</ArticleId><ArticleId IdType="pubmed">38254639</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang S.S.Y., Tang H., Loe M.W.C., Yeo S.C., Javaid M.M. Complements and their role in systemic disorders. Cureus. 2024;16:e52991. doi: 10.7759/cureus.52991.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.52991</ArticleId><ArticleId IdType="pmc">PMC10894639</ArticleId><ArticleId IdType="pubmed">38406130</ArticleId></ArticleIdList></Reference><Reference><Citation>de Nooijer A.H., Grondman I., Janssen N.A.F., Netea M.G., Willems L., van de Veerdonk F.L., Giamarellos-Bourboulis E.J., Toonen E.J.M., Joosten L.A.B., RCI-COVID-19 Study Group Complement activation in the disease course of coronavirus disease 2019 and its effects on clinical outcomes. J. Infect. Dis. 2021;223:214–224. doi: 10.1093/infdis/jiaa646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa646</ArticleId><ArticleId IdType="pmc">PMC7797765</ArticleId><ArticleId IdType="pubmed">33038254</ArticleId></ArticleIdList></Reference><Reference><Citation>Holter J.C., Pischke S.E., de Boer E., Lind A., Jenum S., Holten A.R., Tonby K., Barratt-Due A., Sokolova M., Schjalm C., et al. Systemic complement activation is associated with respiratory failure in COVID-19 hospitalized patients. Proc. Natl. Acad. Sci. USA. 2020;117:25018–25025. doi: 10.1073/pnas.2010540117.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2010540117</ArticleId><ArticleId IdType="pmc">PMC7547220</ArticleId><ArticleId IdType="pubmed">32943538</ArticleId></ArticleIdList></Reference><Reference><Citation>Lo M.W., Amarilla A.A., Lee J.D., Albornoz E.A., Modhiran N., Clark R.J., Ferro V., Chhabra M., Khromykh A.A., Watterson D., et al. SARS-CoV-2 triggers complement activation through interactions with heparan sulfate. Clin. Transl. Immunol. 2022;11:e1413. doi: 10.1002/cti2.1413.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/cti2.1413</ArticleId><ArticleId IdType="pmc">PMC9387400</ArticleId><ArticleId IdType="pubmed">35999893</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu J., Yuan X., Chen H., Chaturvedi S., Braunstein E.M., Brodsky R.A. Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor d inhibition. Blood. 2020;136:2080–2089. doi: 10.1182/blood.2020008248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020008248</ArticleId><ArticleId IdType="pmc">PMC7596849</ArticleId><ArticleId IdType="pubmed">32877502</ArticleId></ArticleIdList></Reference><Reference><Citation>Gao T., Zhu L., Liu H., Zhang X., Wang T., Fu Y., Li H., Dong Q., Hu Y., Zhang Z., et al. Highly pathogenic coronavirus n protein aggravates inflammation by masp-2-mediated lectin complement pathway overactivation. Signal Transduct. Target. Ther. 2022;7:318. doi: 10.1038/s41392-022-01133-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01133-5</ArticleId><ArticleId IdType="pmc">PMC9470675</ArticleId><ArticleId IdType="pubmed">36100602</ArticleId></ArticleIdList></Reference><Reference><Citation>Hernandez A.M., Holodick N.E. Editorial: Natural antibodies in health and disease. Front. Immunol. 2017;8:1795. doi: 10.3389/fimmu.2017.01795.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01795</ArticleId><ArticleId IdType="pmc">PMC5733483</ArticleId><ArticleId IdType="pubmed">29326696</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao J., Yang Y., Huang H., Li D., Gu D., Lu X., Zhang Z., Liu L., Liu T., Liu Y., et al. Relationship between the abo blood group and the coronavirus disease 2019 (COVID-19) susceptibility. Clin. Infect. Dis. 2021;73:328–331. doi: 10.1093/cid/ciaa1150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa1150</ArticleId><ArticleId IdType="pmc">PMC7454371</ArticleId><ArticleId IdType="pubmed">32750119</ArticleId></ArticleIdList></Reference><Reference><Citation>Zietz M., Zucker J., Tatonetti N.P. Testing the association between blood type and COVID-19 infection, intubation, and death. medRxiv Prepr. Serv. Health Sci. 2020;99:2113–2118. doi: 10.1101/2020.04.08.20058073.</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2020.04.08.20058073</ArticleId><ArticleId IdType="pmc">PMC7666188</ArticleId><ArticleId IdType="pubmed">33188185</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang Y., Garner R., Salehi S., La Rocca M., Duncan D. Association between abo blood types and coronavirus disease 2019 (COVID-19), genetic associations, and underlying molecular mechanisms: A literature review of 23 studies. Ann. Hematol. 2021;100:1123–1132. doi: 10.1007/s00277-021-04489-w.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-021-04489-w</ArticleId><ArticleId IdType="pmc">PMC7939543</ArticleId><ArticleId IdType="pubmed">33686492</ArticleId></ArticleIdList></Reference><Reference><Citation>Preece A.F., Strahan K.M., Devitt J., Yamamoto F., Gustafsson K. Expression of abo or related antigenic carbohydrates on viral envelopes leads to neutralization in the presence of serum containing specific natural antibodies and complement. Blood. 2002;99:2477–2482. doi: 10.1182/blood.V99.7.2477.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V99.7.2477</ArticleId><ArticleId IdType="pubmed">11895782</ArticleId></ArticleIdList></Reference><Reference><Citation>Guillon P., Clement M., Sebille V., Rivain J.G., Chou C.F., Ruvoen-Clouet N., Le Pendu J. Inhibition of the interaction between the SARS-CoV spike protein and its cellular receptor by anti-histo-blood group antibodies. Glycobiology. 2008;18:1085–1093. doi: 10.1093/glycob/cwn093.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/glycob/cwn093</ArticleId><ArticleId IdType="pmc">PMC7108609</ArticleId><ArticleId IdType="pubmed">18818423</ArticleId></ArticleIdList></Reference><Reference><Citation>Ma L., Sahu S.K., Cano M., Kuppuswamy V., Bajwa J., McPhatter J., Pine A., Meizlish M.L., Goshua G., Chang C.H., et al. Increased complement activation is a distinctive feature of severe SARS-CoV-2 infection. Sci. Immunol. 2021;6:eabh2259. doi: 10.1126/sciimmunol.abh2259.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abh2259</ArticleId><ArticleId IdType="pmc">PMC8158979</ArticleId><ArticleId IdType="pubmed">34446527</ArticleId></ArticleIdList></Reference><Reference><Citation>Afzali B., Noris M., Lambrecht B.N., Kemper C. The state of complement in COVID-19. Nat. Rev. Immunol. 2022;22:77–84. doi: 10.1038/s41577-021-00665-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-021-00665-1</ArticleId><ArticleId IdType="pmc">PMC8672651</ArticleId><ArticleId IdType="pubmed">34912108</ArticleId></ArticleIdList></Reference><Reference><Citation>Carvelli J., Demaria O., Vely F., Batista L., Chouaki Benmansour N., Fares J., Carpentier S., Thibult M.L., Morel A., Remark R., et al. Association of COVID-19 inflammation with activation of the c5a-c5ar1 axis. Nature. 2020;588:146–150. doi: 10.1038/s41586-020-2600-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41586-020-2600-6</ArticleId><ArticleId IdType="pmc">PMC7116884</ArticleId><ArticleId IdType="pubmed">32726800</ArticleId></ArticleIdList></Reference><Reference><Citation>Hajishengallis G., Lambris J.D. Crosstalk pathways between toll-like receptors and the complement system. Trends Immunol. 2010;31:154–163. doi: 10.1016/j.it.2010.01.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.it.2010.01.002</ArticleId><ArticleId IdType="pmc">PMC2849859</ArticleId><ArticleId IdType="pubmed">20153254</ArticleId></ArticleIdList></Reference><Reference><Citation>Bjornson A.B., Bjornson H.S. Activation of complement by opportunist pathogens and chemotypes of salmonella minnesota. Infect. Immun. 1977;16:748–753. doi: 10.1128/iai.16.3.748-753.1977.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/iai.16.3.748-753.1977</ArticleId><ArticleId IdType="pmc">PMC421025</ArticleId><ArticleId IdType="pubmed">408268</ArticleId></ArticleIdList></Reference><Reference><Citation>Morrison D.C., Kline L.F. Activation of the classical and properdin pathways of complement by bacterial lipopolysaccharides (lps) J. Immunol. 1977;118:362–368. doi: 10.4049/jimmunol.118.1.362.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.118.1.362</ArticleId><ArticleId IdType="pubmed">318670</ArticleId></ArticleIdList></Reference><Reference><Citation>Volman T.J., Hendriks T., Goris R.J. Zymosan-induced generalized inflammation: Experimental studies into mechanisms leading to multiple organ dysfunction syndrome. Shock. 2005;23:291–297. doi: 10.1097/01.shk.0000155350.95435.28.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/01.shk.0000155350.95435.28</ArticleId><ArticleId IdType="pubmed">15803050</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang X., Kimura Y., Fang C., Zhou L., Sfyroera G., Lambris J.D., Wetsel R.A., Miwa T., Song W.C. Regulation of toll-like receptor-mediated inflammatory response by complement in vivo. Blood. 2007;110:228–236. doi: 10.1182/blood-2006-12-063636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2006-12-063636</ArticleId><ArticleId IdType="pmc">PMC1896115</ArticleId><ArticleId IdType="pubmed">17363730</ArticleId></ArticleIdList></Reference><Reference><Citation>Waggoner S.N., Cruise M.W., Kassel R., Hahn Y.S. Gc1q receptor ligation selectively down-regulates human il-12 production through activation of the phosphoinositide 3-kinase pathway. J. Immunol. 2005;175:4706–4714. doi: 10.4049/jimmunol.175.7.4706.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.175.7.4706</ArticleId><ArticleId IdType="pubmed">16177118</ArticleId></ArticleIdList></Reference><Reference><Citation>Karp C.L., Wysocka M., Wahl L.M., Ahearn J.M., Cuomo P.J., Sherry B., Trinchieri G., Griffin D.E. Mechanism of suppression of cell-mediated immunity by measles virus. Science. 1996;273:228–231. doi: 10.1126/science.273.5272.228.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.273.5272.228</ArticleId><ArticleId IdType="pubmed">8662504</ArticleId></ArticleIdList></Reference><Reference><Citation>Marth T., Kelsall B.L. Regulation of interleukin-12 by complement receptor 3 signaling. J. Exp. Med. 1997;185:1987–1995. doi: 10.1084/jem.185.11.1987.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.185.11.1987</ArticleId><ArticleId IdType="pmc">PMC2196332</ArticleId><ArticleId IdType="pubmed">9166428</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawlisch H., Belkaid Y., Baelder R., Hildeman D., Gerard C., Kohl J. C5a negatively regulates toll-like receptor 4-induced immune responses. Immunity. 2005;22:415–426. doi: 10.1016/j.immuni.2005.02.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.immuni.2005.02.006</ArticleId><ArticleId IdType="pubmed">15845447</ArticleId></ArticleIdList></Reference><Reference><Citation>la Sala A., Gadina M., Kelsall B.L. G(i)-protein-dependent inhibition of il-12 production is mediated by activation of the phosphatidylinositol 3-kinase-protein 3 kinase b/akt pathway and jnk. J. Immunol. 2005;175:2994–2999. doi: 10.4049/jimmunol.175.5.2994.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.175.5.2994</ArticleId><ArticleId IdType="pubmed">16116186</ArticleId></ArticleIdList></Reference><Reference><Citation>Sacks S.H. Complement fragments c3a and c5a: The salt and pepper of the immune response. Eur. J. Immunol. 2010;40:668–670. doi: 10.1002/eji.201040355.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201040355</ArticleId><ArticleId IdType="pubmed">20186746</ArticleId></ArticleIdList></Reference><Reference><Citation>Li K., Anderson K.J., Peng Q., Noble A., Lu B., Kelly A.P., Wang N., Sacks S.H., Zhou W. Cyclic amp plays a critical role in c3a-receptor-mediated regulation of dendritic cells in antigen uptake and t-cell stimulation. Blood. 2008;112:5084–5094. doi: 10.1182/blood-2008-05-156646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2008-05-156646</ArticleId><ArticleId IdType="pubmed">18812470</ArticleId></ArticleIdList></Reference><Reference><Citation>Peng Q., Li K., Wang N., Li Q., Asgari E., Lu B., Woodruff T.M., Sacks S.H., Zhou W. Dendritic cell function in allostimulation is modulated by c5ar signaling. J. Immunol. 2009;183:6058–6068. doi: 10.4049/jimmunol.0804186.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0804186</ArticleId><ArticleId IdType="pubmed">19864610</ArticleId></ArticleIdList></Reference><Reference><Citation>Braun M.C., Lahey E., Kelsall B.L. Selective suppression of il-12 production by chemoattractants. J. Immunol. 2000;164:3009–3017. doi: 10.4049/jimmunol.164.6.3009.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.164.6.3009</ArticleId><ArticleId IdType="pubmed">10706689</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutcher I., Becher B. Apc-derived cytokines and t cell polarization in autoimmune inflammation. J. Clin. Investig. 2007;117:1119–1127. doi: 10.1172/JCI31720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI31720</ArticleId><ArticleId IdType="pmc">PMC1857272</ArticleId><ArticleId IdType="pubmed">17476341</ArticleId></ArticleIdList></Reference><Reference><Citation>Visperas A., Do J., Min B. Cellular factors targeting apcs to modulate adaptive t cell immunity. J. Immunol. Res. 2014;2014:750374. doi: 10.1155/2014/750374.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2014/750374</ArticleId><ArticleId IdType="pmc">PMC4122108</ArticleId><ArticleId IdType="pubmed">25126585</ArticleId></ArticleIdList></Reference><Reference><Citation>Gaudino S.J., Kumar P. Cross-talk between antigen presenting cells and t cells impacts intestinal homeostasis, bacterial infections, and tumorigenesis. Front. Immunol. 2019;10:360. doi: 10.3389/fimmu.2019.00360.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.00360</ArticleId><ArticleId IdType="pmc">PMC6414782</ArticleId><ArticleId IdType="pubmed">30894857</ArticleId></ArticleIdList></Reference><Reference><Citation>Kimura A., Kishimoto T. Il-6: Regulator of treg/th17 balance. Eur. J. Immunol. 2010;40:1830–1835. doi: 10.1002/eji.201040391.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201040391</ArticleId><ArticleId IdType="pubmed">20583029</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang C., Zhang X., Miwa T., Song W.C. Complement promotes the development of inflammatory t-helper 17 cells through synergistic interaction with toll-like receptor signaling and interleukin-6 production. Blood. 2009;114:1005–1015. doi: 10.1182/blood-2009-01-198283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2009-01-198283</ArticleId><ArticleId IdType="pmc">PMC2721782</ArticleId><ArticleId IdType="pubmed">19491392</ArticleId></ArticleIdList></Reference><Reference><Citation>Goriely S., Neurath M.F., Goldman M. How microorganisms tip the balance between interleukin-12 family members. Nat. Rev. Immunol. 2008;8:81–86. doi: 10.1038/nri2225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nri2225</ArticleId><ArticleId IdType="pubmed">18084185</ArticleId></ArticleIdList></Reference><Reference><Citation>Larosa M., Zen M., Gatto M., Jesus D., Zanatta E., Iaccarino L., Ines L., Doria A. Il-12 and il-23/th17 axis in systemic lupus erythematosus. Exp. Biol. Med. 2019;244:42–51. doi: 10.1177/1535370218824547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1535370218824547</ArticleId><ArticleId IdType="pmc">PMC6362534</ArticleId><ArticleId IdType="pubmed">30664357</ArticleId></ArticleIdList></Reference><Reference><Citation>Revu S., Wu J., Henkel M., Rittenhouse N., Menk A., Delgoffe G.M., Poholek A.C., McGeachy M.J. Il-23 and il-1beta drive human th17 cell differentiation and metabolic reprogramming in absence of cd28 costimulation. Cell Rep. 2018;22:2642–2653. doi: 10.1016/j.celrep.2018.02.044.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.celrep.2018.02.044</ArticleId><ArticleId IdType="pmc">PMC5884137</ArticleId><ArticleId IdType="pubmed">29514093</ArticleId></ArticleIdList></Reference><Reference><Citation>Yoshimura T., Takeda A., Hamano S., Miyazaki Y., Kinjyo I., Ishibashi T., Yoshimura A., Yoshida H. Two-sided roles of il-27: Induction of th1 differentiation on naive cd4+ t cells versus suppression of proinflammatory cytokine production including il-23-induced il-17 on activated cd4+ t cells partially through stat3-dependent mechanism. J. Immunol. 2006;177:5377–5385. doi: 10.4049/jimmunol.177.8.5377.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.177.8.5377</ArticleId><ArticleId IdType="pubmed">17015723</ArticleId></ArticleIdList></Reference><Reference><Citation>Hashimoto M., Hirota K., Yoshitomi H., Maeda S., Teradaira S., Akizuki S., Prieto-Martin P., Nomura T., Sakaguchi N., Kohl J., et al. Complement drives th17 cell differentiation and triggers autoimmune arthritis. J. Exp. Med. 2010;207:1135–1143. doi: 10.1084/jem.20092301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20092301</ArticleId><ArticleId IdType="pmc">PMC2882841</ArticleId><ArticleId IdType="pubmed">20457757</ArticleId></ArticleIdList></Reference><Reference><Citation>Kaczorowski D.J., Afrazi A., Scott M.J., Kwak J.H., Gill R., Edmonds R.D., Liu Y., Fan J., Billiar T.R. Pivotal advance: The pattern recognition receptor ligands lipopolysaccharide and polyinosine-polycytidylic acid stimulate factor b synthesis by the macrophage through distinct but overlapping mechanisms. J. Leukoc. Biol. 2010;88:609–618. doi: 10.1189/jlb.0809588.</Citation><ArticleIdList><ArticleId IdType="doi">10.1189/jlb.0809588</ArticleId><ArticleId IdType="pmc">PMC2974428</ArticleId><ArticleId IdType="pubmed">20413727</ArticleId></ArticleIdList></Reference><Reference><Citation>Raby A.C., Holst B., Davies J., Colmont C., Laumonnier Y., Coles B., Shah S., Hall J., Topley N., Kohl J., et al. TLR activation enhances c5a-induced pro-inflammatory responses by negatively modulating the second c5a receptor, c5l2. Eur. J. Immunol. 2011;41:2741–2752. doi: 10.1002/eji.201041350.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201041350</ArticleId><ArticleId IdType="pmc">PMC3638321</ArticleId><ArticleId IdType="pubmed">21630250</ArticleId></ArticleIdList></Reference><Reference><Citation>Choudhury A., Das N.C., Patra R., Mukherjee S. In silico analyses on the comparative sensing of SARS-CoV-2 MRNA by the intracellular TLRS of humans. J. Med. Virol. 2021;93:2476–2486. doi: 10.1002/jmv.26776.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26776</ArticleId><ArticleId IdType="pubmed">33404091</ArticleId></ArticleIdList></Reference><Reference><Citation>Han H., Ma Q., Li C., Liu R., Zhao L., Wang W., Zhang P., Liu X., Gao G., Liu F., et al. Profiling serum cytokines in COVID-19 patients reveals il-6 and il-10 are disease severity predictors. Emerg. Microbes Infect. 2020;9:1123–1130. doi: 10.1080/22221751.2020.1770129.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1770129</ArticleId><ArticleId IdType="pmc">PMC7473317</ArticleId><ArticleId IdType="pubmed">32475230</ArticleId></ArticleIdList></Reference><Reference><Citation>Tjan L.H., Furukawa K., Nagano T., Kiriu T., Nishimura M., Arii J., Hino Y., Iwata S., Nishimura Y., Mori Y. Early differences in cytokine production by severity of coronavirus disease 2019. J. Infect. Dis. 2021;223:1145–1149. doi: 10.1093/infdis/jiab005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiab005</ArticleId><ArticleId IdType="pmc">PMC7928883</ArticleId><ArticleId IdType="pubmed">33411935</ArticleId></ArticleIdList></Reference><Reference><Citation>Toor D., Jain A., Kalhan S., Manocha H., Sharma V.K., Jain P., Tripathi V., Prakash H. Tempering macrophage plasticity for controlling SARS-CoV-2 infection for managing COVID-19 disease. Front. Pharmacol. 2020;11:570698. doi: 10.3389/fphar.2020.570698.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fphar.2020.570698</ArticleId><ArticleId IdType="pmc">PMC7596271</ArticleId><ArticleId IdType="pubmed">33178021</ArticleId></ArticleIdList></Reference><Reference><Citation>Giamarellos-Bourboulis E.J., Netea M.G., Rovina N., Akinosoglou K., Antoniadou A., Antonakos N., Damoraki G., Gkavogianni T., Adami M.E., Katsaounou P., et al. Complex immune dysregulation in COVID-19 patients with severe respiratory failure. Cell Host Microbe. 2020;27:992–1000 e1003. doi: 10.1016/j.chom.2020.04.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chom.2020.04.009</ArticleId><ArticleId IdType="pmc">PMC7172841</ArticleId><ArticleId IdType="pubmed">32320677</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang Z., Li S., Huang B. Alveolar macrophages: Achilles’ heel of SARS-CoV-2 infection. Signal Transduct. Target. Ther. 2022;7:242. doi: 10.1038/s41392-022-01106-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-022-01106-8</ArticleId><ArticleId IdType="pmc">PMC9295089</ArticleId><ArticleId IdType="pubmed">35853858</ArticleId></ArticleIdList></Reference><Reference><Citation>Roy R.K., Sharma U., Wasson M.K., Jain A., Hassan M.I., Prakash H. Macrophage activation syndrome and COVID 19: Impact of mapk driven immune-epigenetic programming by SARS-CoV-2. Front. Immunol. 2021;12:763313. doi: 10.3389/fimmu.2021.763313.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.763313</ArticleId><ArticleId IdType="pmc">PMC8519338</ArticleId><ArticleId IdType="pubmed">34659270</ArticleId></ArticleIdList></Reference><Reference><Citation>Huang C., Wang Y., Li X., Ren L., Zhao J., Hu Y., Zhang L., Fan G., Xu J., Gu X., et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395:497–506. doi: 10.1016/S0140-6736(20)30183-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30183-5</ArticleId><ArticleId IdType="pmc">PMC7159299</ArticleId><ArticleId IdType="pubmed">31986264</ArticleId></ArticleIdList></Reference><Reference><Citation>Lai X., Wang M., Qin C., Tan L., Ran L., Chen D., Zhang H., Shang K., Xia C., Wang S., et al. Coronavirus disease 2019 (COVID-2019) infection among health care workers and implications for prevention measures in a tertiary hospital in Wuhan, China. JAMA Netw. Open. 2020;3:e209666. doi: 10.1001/jamanetworkopen.2020.9666.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.9666</ArticleId><ArticleId IdType="pmc">PMC7243089</ArticleId><ArticleId IdType="pubmed">32437575</ArticleId></ArticleIdList></Reference><Reference><Citation>Hu B., Huang S., Yin L. The cytokine storm and COVID-19. J. Med. Virol. 2021;93:250–256. doi: 10.1002/jmv.26232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jmv.26232</ArticleId><ArticleId IdType="pmc">PMC7361342</ArticleId><ArticleId IdType="pubmed">32592501</ArticleId></ArticleIdList></Reference><Reference><Citation>Coomes E.A., Haghbayan H. Interleukin-6 in COVID-19: A systematic review and meta-analysis. Rev. Med. Virol. 2020;30:1–9. doi: 10.1002/rmv.2141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/rmv.2141</ArticleId><ArticleId IdType="pmc">PMC7460877</ArticleId><ArticleId IdType="pubmed">32845568</ArticleId></ArticleIdList></Reference><Reference><Citation>Murphy K.M., Ouyang W., Farrar J.D., Yang J., Ranganath S., Asnagli H., Afkarian M., Murphy T.L. Signaling and transcription in t helper development. Annu. Rev. Immunol. 2000;18:451–494. doi: 10.1146/annurev.immunol.18.1.451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1146/annurev.immunol.18.1.451</ArticleId><ArticleId IdType="pubmed">10837066</ArticleId></ArticleIdList></Reference><Reference><Citation>Muyayalo K.P., Huang D.H., Zhao S.J., Xie T., Mor G., Liao A.H. COVID-19 and treg/th17 imbalance: Potential relationship to pregnancy outcomes. Am. J. Reprod. Immunol. 2020;84:e13304. doi: 10.1111/aji.13304.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/aji.13304</ArticleId><ArticleId IdType="pmc">PMC7404618</ArticleId><ArticleId IdType="pubmed">32662111</ArticleId></ArticleIdList></Reference><Reference><Citation>Qin C., Zhou L., Hu Z., Zhang S., Yang S., Tao Y., Xie C., Ma K., Shang K., Wang W., et al. Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China. Clin. Infect. Dis. 2020;71:762–768. doi: 10.1093/cid/ciaa248.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciaa248</ArticleId><ArticleId IdType="pmc">PMC7108125</ArticleId><ArticleId IdType="pubmed">32161940</ArticleId></ArticleIdList></Reference><Reference><Citation>Neurath M.F. COVID-19 and immunomodulation in ibd. Gut. 2020;69:1335–1342. doi: 10.1136/gutjnl-2020-321269.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/gutjnl-2020-321269</ArticleId><ArticleId IdType="pmc">PMC7211083</ArticleId><ArticleId IdType="pubmed">32303609</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin S., Wu H., Wang C., Xiao Z., Xu F. Regulatory t cells and acute lung injury: Cytokines, uncontrolled inflammation, and therapeutic implications. Front. Immunol. 2018;9:1545. doi: 10.3389/fimmu.2018.01545.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2018.01545</ArticleId><ArticleId IdType="pmc">PMC6046379</ArticleId><ArticleId IdType="pubmed">30038616</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Z.X., Ji M.S., Yan J., Cai Y., Liu J., Yang H.F., Li Y., Jin Z.C., Zheng J.X. The ratio of th17/treg cells as a risk indicator in early acute respiratory distress syndrome. Crit. Care. 2015;19:82. doi: 10.1186/s13054-015-0811-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-015-0811-2</ArticleId><ArticleId IdType="pmc">PMC4355972</ArticleId><ArticleId IdType="pubmed">25887535</ArticleId></ArticleIdList></Reference><Reference><Citation>De Biasi S., Meschiari M., Gibellini L., Bellinazzi C., Borella R., Fidanza L., Gozzi L., Iannone A., Lo Tartaro D., Mattioli M., et al. Marked t cell activation, senescence, exhaustion and skewing towards th17 in patients with COVID-19 pneumonia. Nat. Commun. 2020;11:3434. doi: 10.1038/s41467-020-17292-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-17292-4</ArticleId><ArticleId IdType="pmc">PMC7338513</ArticleId><ArticleId IdType="pubmed">32632085</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu D., Yang X.O. Th17 responses in cytokine storm of COVID-19: An emerging target of jak2 inhibitor fedratinib. J. Microbiol. Immunol. Infect. Wei Mian Yu Gan Ran Za Zhi. 2020;53:368–370. doi: 10.1016/j.jmii.2020.03.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2020.03.005</ArticleId><ArticleId IdType="pmc">PMC7156211</ArticleId><ArticleId IdType="pubmed">32205092</ArticleId></ArticleIdList></Reference><Reference><Citation>Burgos-Blasco B., Guemes-Villahoz N., Santiago J.L., Fernandez-Vigo J.I., Espino-Paisan L., Sarria B., Garcia-Feijoo J., Martinez-de-la-Casa J.M. Hypercytokinemia in COVID-19: Tear cytokine profile in hospitalized COVID-19 patients. Exp. Eye Res. 2020;200:108253. doi: 10.1016/j.exer.2020.108253.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.exer.2020.108253</ArticleId><ArticleId IdType="pmc">PMC7493729</ArticleId><ArticleId IdType="pubmed">32949577</ArticleId></ArticleIdList></Reference><Reference><Citation>Petrone L., Petruccioli E., Vanini V., Cuzzi G., Najafi Fard S., Alonzi T., Castilletti C., Palmieri F., Gualano G., Vittozzi P., et al. A whole blood test to measure SARS-CoV-2-specific response in COVID-19 patients. Clin. Microbiol. Infect. 2021;27:286.e7–286.e13. doi: 10.1016/j.cmi.2020.09.051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2020.09.051</ArticleId><ArticleId IdType="pmc">PMC7547312</ArticleId><ArticleId IdType="pubmed">33045370</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghazavi A., Ganji A., Keshavarzian N., Rabiemajd S., Mosayebi G. Cytokine profile and disease severity in patients with COVID-19. Cytokine. 2021;137:155323. doi: 10.1016/j.cyto.2020.155323.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2020.155323</ArticleId><ArticleId IdType="pmc">PMC7524708</ArticleId><ArticleId IdType="pubmed">33045526</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiskopf D., Schmitz K.S., Raadsen M.P., Grifoni A., Okba N.M.A., Endeman H., van den Akker J.P.C., Molenkamp R., Koopmans M.P.G., van Gorp E.C.M., et al. Phenotype and kinetics of SARS-CoV-2-specific t cells in COVID-19 patients with acute respiratory distress syndrome. Sci. Immunol. 2020;5:eabd2071. doi: 10.1126/sciimmunol.abd2071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abd2071</ArticleId><ArticleId IdType="pmc">PMC7319493</ArticleId><ArticleId IdType="pubmed">32591408</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu Z., Shi L., Wang Y., Zhang J., Huang L., Zhang C., Liu S., Zhao P., Liu H., Zhu L., et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir. Med. 2020;8:420–422. doi: 10.1016/S2213-2600(20)30076-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30076-X</ArticleId><ArticleId IdType="pmc">PMC7164771</ArticleId><ArticleId IdType="pubmed">32085846</ArticleId></ArticleIdList></Reference><Reference><Citation>Pasrija R., Naime M. The deregulated immune reaction and cytokines release storm (crs) in COVID-19 disease. Int. Immunopharmacol. 2021;90:107225. doi: 10.1016/j.intimp.2020.107225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2020.107225</ArticleId><ArticleId IdType="pmc">PMC7691139</ArticleId><ArticleId IdType="pubmed">33302033</ArticleId></ArticleIdList></Reference><Reference><Citation>Ronit A., Berg R.M.G., Bay J.T., Haugaard A.K., Ahlstrom M.G., Burgdorf K.S., Ullum H., Rorvig S.B., Tjelle K., Foss N.B., et al. Compartmental immunophenotyping in COVID-19 ards: A case series. J. Allergy Clin. Immunol. 2021;147:81–91. doi: 10.1016/j.jaci.2020.09.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jaci.2020.09.009</ArticleId><ArticleId IdType="pmc">PMC7581505</ArticleId><ArticleId IdType="pubmed">32979342</ArticleId></ArticleIdList></Reference><Reference><Citation>Yan B., Freiwald T., Chauss D., Wang L., West E., Mirabelli C., Zhang C.J., Nichols E.M., Malik N., Gregory R., et al. SARS-CoV-2 drives jak1/2-dependent local complement hyperactivation. Sci. Immunol. 2021;6:eabg0833. doi: 10.1126/sciimmunol.abg0833.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/sciimmunol.abg0833</ArticleId><ArticleId IdType="pmc">PMC8139422</ArticleId><ArticleId IdType="pubmed">33827897</ArticleId></ArticleIdList></Reference><Reference><Citation>Montazersaheb S., Hosseiniyan Khatibi S.M., Hejazi M.S., Tarhriz V., Farjami A., Ghasemian Sorbeni F., Farahzadi R., Ghasemnejad T. COVID-19 infection: An overview on cytokine storm and related interventions. Virol. J. 2022;19:92. doi: 10.1186/s12985-022-01814-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-022-01814-1</ArticleId><ArticleId IdType="pmc">PMC9134144</ArticleId><ArticleId IdType="pubmed">35619180</ArticleId></ArticleIdList></Reference><Reference><Citation>Ragab D., Salah Eldin H., Taeimah M., Khattab R., Salem R. The COVID-19 cytokine storm; what we know so far. Front. Immunol. 2020;11:1446. doi: 10.3389/fimmu.2020.01446.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.01446</ArticleId><ArticleId IdType="pmc">PMC7308649</ArticleId><ArticleId IdType="pubmed">32612617</ArticleId></ArticleIdList></Reference><Reference><Citation>Grasselli G., Tonetti T., Filippini C., Slutsky A.S., Pesenti A., Ranieri V.M. Pathophysiology of COVID-19-associated acute respiratory distress syndrome—Authors’ reply. Lancet Respir. Med. 2021;9:e5–e6. doi: 10.1016/S2213-2600(20)30525-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30525-7</ArticleId><ArticleId IdType="pmc">PMC7832136</ArticleId><ArticleId IdType="pubmed">33197387</ArticleId></ArticleIdList></Reference><Reference><Citation>Arsentieva N., Liubimova N., Batsunov O., Korobova Z., Stanevich O., Lebedeva A., Vorobyov E., Vorobyova S., Kulikov A., Lioznov D. Plasma cytokines in patients with COVID-19 during acute phase of the disease and following complete recovery. Med. Immunol. 2021;23:311–326. doi: 10.15789/1563-0625-PCI-2312.</Citation><ArticleIdList><ArticleId IdType="doi">10.15789/1563-0625-PCI-2312</ArticleId></ArticleIdList></Reference><Reference><Citation>Arsentieva N., Liubimova N., Batsunov O., Korobova Z., Kuznetsova R., Rubinstein A., Stanevich O., Lebedeva A., Vorobyov E., Vorobyova S. Predictive value of specific cytokines for lethal COVID-19 outcome. Инфекция И Иммунитет. 2022;12:859–868. doi: 10.15789/2220-7619-PVO-2043.</Citation><ArticleIdList><ArticleId IdType="doi">10.15789/2220-7619-PVO-2043</ArticleId></ArticleIdList></Reference><Reference><Citation>Hasanvand A. COVID-19 and the role of cytokines in this disease. Inflammopharmacology. 2022;30:789–798. doi: 10.1007/s10787-022-00992-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-022-00992-2</ArticleId><ArticleId IdType="pmc">PMC9064717</ArticleId><ArticleId IdType="pubmed">35505267</ArticleId></ArticleIdList></Reference><Reference><Citation>Bassetti M., Vena A., Giacobbe D.R. The novel chinese coronavirus (2019-nCOV) infections: Challenges for fighting the storm. Eur. J. Clin. Investig. 2020;50:e13209. doi: 10.1111/eci.13209.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/eci.13209</ArticleId><ArticleId IdType="pmc">PMC7163647</ArticleId><ArticleId IdType="pubmed">32003000</ArticleId></ArticleIdList></Reference><Reference><Citation>Guan W.J., Ni Z.Y., Hu Y., Liang W.H., Ou C.Q., He J.X., Liu L., Shan H., Lei C.L., Hui D.S.C., et al. Clinical characteristics of coronavirus disease 2019 in China. N. Engl. J. Med. 2020;382:1708–1720. doi: 10.1056/NEJMoa2002032.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2002032</ArticleId><ArticleId IdType="pmc">PMC7092819</ArticleId><ArticleId IdType="pubmed">32109013</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou F., Yu T., Du R., Fan G., Liu Y., Liu Z., Xiang J., Wang Y., Song B., Gu X., et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: A retrospective cohort study. Lancet. 2020;395:1054–1062. doi: 10.1016/S0140-6736(20)30566-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30566-3</ArticleId><ArticleId IdType="pmc">PMC7270627</ArticleId><ArticleId IdType="pubmed">32171076</ArticleId></ArticleIdList></Reference><Reference><Citation>Nahum J., Morichau-Beauchant T., Daviaud F., Echegut P., Fichet J., Maillet J.M., Thierry S. Venous thrombosis among critically ill patients with coronavirus disease 2019 (COVID-19) JAMA Netw. Open. 2020;3:e2010478. doi: 10.1001/jamanetworkopen.2020.10478.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2020.10478</ArticleId><ArticleId IdType="pmc">PMC7260620</ArticleId><ArticleId IdType="pubmed">32469410</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T., Warkentin T.E., Thachil J., Levi M., Levy J.H. Proposal of the definition for COVID-19-associated coagulopathy. J. Clin. Med. 2021;10:191. doi: 10.3390/jcm10020191.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm10020191</ArticleId><ArticleId IdType="pmc">PMC7827226</ArticleId><ArticleId IdType="pubmed">33430431</ArticleId></ArticleIdList></Reference><Reference><Citation>Seo J.W., Kim D.Y., Yun N., Kim D.M. Coronavirus disease 2019-associated coagulopathy. Microorganisms. 2022;10:1556. doi: 10.3390/microorganisms10081556.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms10081556</ArticleId><ArticleId IdType="pmc">PMC9415473</ArticleId><ArticleId IdType="pubmed">36013974</ArticleId></ArticleIdList></Reference><Reference><Citation>Hunt B.J., Jurd K.M. Endothelial cell activation. A central pathophysiological process. BMJ. 1998;316:1328–1329. doi: 10.1136/bmj.316.7141.1328.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmj.316.7141.1328</ArticleId><ArticleId IdType="pmc">PMC1113063</ArticleId><ArticleId IdType="pubmed">9563977</ArticleId></ArticleIdList></Reference><Reference><Citation>Huertas A., Montani D., Savale L., Pichon J., Tu L., Parent F., Guignabert C., Humbert M. Endothelial cell dysfunction: A major player in SARS-CoV-2 infection (COVID-19)? Eur. Respir. J. 2020;56:2001634. doi: 10.1183/13993003.01634-2020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/13993003.01634-2020</ArticleId><ArticleId IdType="pmc">PMC7301835</ArticleId><ArticleId IdType="pubmed">32554538</ArticleId></ArticleIdList></Reference><Reference><Citation>Ackermann M., Verleden S.E., Kuehnel M., Haverich A., Welte T., Laenger F., Vanstapel A., Werlein C., Stark H., Tzankov A., et al. Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in COVID-19. N. Engl. J. Med. 2020;383:120–128. doi: 10.1056/NEJMoa2015432.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2015432</ArticleId><ArticleId IdType="pmc">PMC7412750</ArticleId><ArticleId IdType="pubmed">32437596</ArticleId></ArticleIdList></Reference><Reference><Citation>Varga Z., Flammer A.J., Steiger P., Haberecker M., Andermatt R., Zinkernagel A.S., Mehra M.R., Schuepbach R.A., Ruschitzka F., Moch H. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395:1417–1418. doi: 10.1016/S0140-6736(20)30937-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(20)30937-5</ArticleId><ArticleId IdType="pmc">PMC7172722</ArticleId><ArticleId IdType="pubmed">32325026</ArticleId></ArticleIdList></Reference><Reference><Citation>Puelles V.G., Lutgehetmann M., Lindenmeyer M.T., Sperhake J.P., Wong M.N., Allweiss L., Chilla S., Heinemann A., Wanner N., Liu S., et al. Multiorgan and renal tropism of SARS-CoV-2. N. Engl. J. Med. 2020;383:590–592. doi: 10.1056/NEJMc2011400.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMc2011400</ArticleId><ArticleId IdType="pmc">PMC7240771</ArticleId><ArticleId IdType="pubmed">32402155</ArticleId></ArticleIdList></Reference><Reference><Citation>Su H., Yang M., Wan C., Yi L.X., Tang F., Zhu H.Y., Yi F., Yang H.C., Fogo A.B., Nie X., et al. Renal histopathological analysis of 26 postmortem findings of patients with COVID-19 in china. Kidney Int. 2020;98:219–227. doi: 10.1016/j.kint.2020.04.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.kint.2020.04.003</ArticleId><ArticleId IdType="pmc">PMC7194105</ArticleId><ArticleId IdType="pubmed">32327202</ArticleId></ArticleIdList></Reference><Reference><Citation>Gain C., Song S., Angtuaco T., Satta S., Kelesidis T. The role of oxidative stress in the pathogenesis of infections with coronaviruses. Front. Microbiol. 2022;13:1111930. doi: 10.3389/fmicb.2022.1111930.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmicb.2022.1111930</ArticleId><ArticleId IdType="pmc">PMC9880066</ArticleId><ArticleId IdType="pubmed">36713204</ArticleId></ArticleIdList></Reference><Reference><Citation>Madamanchi N.R., Vendrov A., Runge M.S. Oxidative stress and vascular disease. Arterioscler. Thromb. Vasc. Biol. 2005;25:29–38. doi: 10.1161/01.ATV.0000150649.39934.13.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.0000150649.39934.13</ArticleId><ArticleId IdType="pubmed">15539615</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen K., Pittman R.N., Popel A.S. Nitric oxide in the vasculature: Where does it come from and where does it go? A quantitative perspective. Antioxid. Redox Signal. 2008;10:1185–1198. doi: 10.1089/ars.2007.1959.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2007.1959</ArticleId><ArticleId IdType="pmc">PMC2932548</ArticleId><ArticleId IdType="pubmed">18331202</ArticleId></ArticleIdList></Reference><Reference><Citation>Cheung P.Y., Salas E., Schulz R., Radomski M.W. Nitric oxide and platelet function: Implications for neonatology. Semin. Perinatol. 1997;21:409–417. doi: 10.1016/S0146-0005(97)80006-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0146-0005(97)80006-7</ArticleId><ArticleId IdType="pubmed">9352613</ArticleId></ArticleIdList></Reference><Reference><Citation>Moncada S., Palmer R.M., Higgs E.A. Nitric oxide: Physiology, pathophysiology, and pharmacology. Pharmacol. Rev. 1991;43:109–142.</Citation><ArticleIdList><ArticleId IdType="pubmed">1852778</ArticleId></ArticleIdList></Reference><Reference><Citation>Gimbrone M.A., Jr., Garcia-Cardena G. Endothelial cell dysfunction and the pathobiology of atherosclerosis. Circ. Res. 2016;118:620–636. doi: 10.1161/CIRCRESAHA.115.306301.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.115.306301</ArticleId><ArticleId IdType="pmc">PMC4762052</ArticleId><ArticleId IdType="pubmed">26892962</ArticleId></ArticleIdList></Reference><Reference><Citation>Lubos E., Kelly N.J., Oldebeken S.R., Leopold J.A., Zhang Y.Y., Loscalzo J., Handy D.E. Glutathione peroxidase-1 deficiency augments proinflammatory cytokine-induced redox signaling and human endothelial cell activation. J. Biol. Chem. 2011;286:35407–35417. doi: 10.1074/jbc.M110.205708.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M110.205708</ArticleId><ArticleId IdType="pmc">PMC3195617</ArticleId><ArticleId IdType="pubmed">21852236</ArticleId></ArticleIdList></Reference><Reference><Citation>Nagy E., Eaton J.W., Jeney V., Soares M.P., Varga Z., Galajda Z., Szentmiklosi J., Mehes G., Csonka T., Smith A., et al. Red cells, hemoglobin, heme, iron, and atherogenesis. Arterioscler. Thromb. Vasc. Biol. 2010;30:1347–1353. doi: 10.1161/ATVBAHA.110.206433.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.110.206433</ArticleId><ArticleId IdType="pmc">PMC2893144</ArticleId><ArticleId IdType="pubmed">20378845</ArticleId></ArticleIdList></Reference><Reference><Citation>Quan S., Yang L., Abraham N.G., Kappas A. Regulation of human heme oxygenase in endothelial cells by using sense and antisense retroviral constructs. Proc. Natl. Acad. Sci. USA. 2001;98:12203–12208. doi: 10.1073/pnas.211399398.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.211399398</ArticleId><ArticleId IdType="pmc">PMC59792</ArticleId><ArticleId IdType="pubmed">11593038</ArticleId></ArticleIdList></Reference><Reference><Citation>Nguyen Dinh Cat A., Montezano A.C., Burger D., Touyz R.M. Angiotensin ii, nadph oxidase, and redox signaling in the vasculature. Antioxid. Redox Signal. 2013;19:1110–1120. doi: 10.1089/ars.2012.4641.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/ars.2012.4641</ArticleId><ArticleId IdType="pmc">PMC3771549</ArticleId><ArticleId IdType="pubmed">22530599</ArticleId></ArticleIdList></Reference><Reference><Citation>Suhail S., Zajac J., Fossum C., Lowater H., McCracken C., Severson N., Laatsch B., Narkiewicz-Jodko A., Johnson B., Liebau J., et al. Role of oxidative stress on SARS-CoV (sars) and SARS-CoV-2 (COVID-19) infection: A review. Protein J. 2020;39:644–656. doi: 10.1007/s10930-020-09935-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10930-020-09935-8</ArticleId><ArticleId IdType="pmc">PMC7587547</ArticleId><ArticleId IdType="pubmed">33106987</ArticleId></ArticleIdList></Reference><Reference><Citation>Kato T., Kitagawa S. Regulation of neutrophil functions by proinflammatory cytokines. Int. J. Hematol. 2006;84:205–209. doi: 10.1532/IJH97.06141.</Citation><ArticleIdList><ArticleId IdType="doi">10.1532/IJH97.06141</ArticleId><ArticleId IdType="pubmed">17050192</ArticleId></ArticleIdList></Reference><Reference><Citation>Camous L., Roumenina L., Bigot S., Brachemi S., Fremeaux-Bacchi V., Lesavre P., Halbwachs-Mecarelli L. Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood. 2011;117:1340–1349. doi: 10.1182/blood-2010-05-283564.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2010-05-283564</ArticleId><ArticleId IdType="pubmed">21063021</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu J., Yu J., Zhou S., Zhang J., Xu J., Niu C., Qu G., Han B., Hu J., Dong L. What can we learn from a COVID-19 lung biopsy? Int. J. Infect. Dis. IJID. 2020;99:410–413. doi: 10.1016/j.ijid.2020.07.067.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.07.067</ArticleId><ArticleId IdType="pmc">PMC7406425</ArticleId><ArticleId IdType="pubmed">32768699</ArticleId></ArticleIdList></Reference><Reference><Citation>Deisher T.A., Haddix T.L., Montgomery K.F., Pohlman T.H., Kaushansky K., Harlan J.M. The role of protein kinase c in the induction of vcam-1 expression on human umbilical vein endothelial cells. FEBS Lett. 1993;331:285–290. doi: 10.1016/0014-5793(93)80354-W.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(93)80354-W</ArticleId><ArticleId IdType="pubmed">7690717</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang C., Hein T.W., Wang W., Ren Y., Shipley R.D., Kuo L. Activation of jnk and xanthine oxidase by tnf-alpha impairs nitric oxide-mediated dilation of coronary arterioles. J. Mol. Cell. Cardiol. 2006;40:247–257. doi: 10.1016/j.yjmcc.2005.11.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.yjmcc.2005.11.010</ArticleId><ArticleId IdType="pubmed">16413574</ArticleId></ArticleIdList></Reference><Reference><Citation>De Palma C., Meacci E., Perrotta C., Bruni P., Clementi E. Endothelial nitric oxide synthase activation by tumor necrosis factor alpha through neutral sphingomyelinase 2, sphingosine kinase 1, and sphingosine 1 phosphate receptors: A novel pathway relevant to the pathophysiology of endothelium. Arterioscler. Thromb. Vasc. Biol. 2006;26:99–105. doi: 10.1161/01.ATV.0000194074.59584.42.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.0000194074.59584.42</ArticleId><ArticleId IdType="pubmed">16269668</ArticleId></ArticleIdList></Reference><Reference><Citation>Downey J.M., Omar B., Ooiwa H., McCord J. Superoxide dismutase therapy for myocardial ischemia. Pt 2Free Radic. Res. Commun. 1991;12–13:703–720. doi: 10.3109/10715769109145850.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10715769109145850</ArticleId><ArticleId IdType="pubmed">2060842</ArticleId></ArticleIdList></Reference><Reference><Citation>Kolesnick R., Golde D.W. The sphingomyelin pathway in tumor necrosis factor and interleukin-1 signaling. Cell. 1994;77:325–328. doi: 10.1016/0092-8674(94)90147-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0092-8674(94)90147-3</ArticleId><ArticleId IdType="pubmed">8181053</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathias S., Pena L.A., Kolesnick R.N. Signal transduction of stress via ceramide. Pt 3Biochem. J. 1998;335:465–480. doi: 10.1042/bj3350465.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj3350465</ArticleId><ArticleId IdType="pmc">PMC1219804</ArticleId><ArticleId IdType="pubmed">9794783</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang D.X., Yi F.X., Zou A.P., Li P.L. Role of ceramide in tnf-alpha-induced impairment of endothelium-dependent vasorelaxation in coronary arteries. Am. J. Physiol. Heart Circ. Physiol. 2002;283:H1785–H1794. doi: 10.1152/ajpheart.00318.2002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00318.2002</ArticleId><ArticleId IdType="pubmed">12384455</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez P., Lozano P., Ros G., Solano F. Hyperglycemia and oxidative stress: An integral, updated and critical overview of their metabolic interconnections. Int. J. Mol. Sci. 2023;24:9352. doi: 10.3390/ijms24119352.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms24119352</ArticleId><ArticleId IdType="pmc">PMC10253853</ArticleId><ArticleId IdType="pubmed">37298303</ArticleId></ArticleIdList></Reference><Reference><Citation>Valencia J.V., Mone M., Zhang J., Weetall M., Buxton F.P., Hughes T.E. Divergent pathways of gene expression are activated by the rage ligands s100b and age-bsa. Diabetes. 2004;53:743–751. doi: 10.2337/diabetes.53.3.743.</Citation><ArticleIdList><ArticleId IdType="doi">10.2337/diabetes.53.3.743</ArticleId><ArticleId IdType="pubmed">14988260</ArticleId></ArticleIdList></Reference><Reference><Citation>Neeper M., Schmidt A.M., Brett J., Yan S.D., Wang F., Pan Y.C., Elliston K., Stern D., Shaw A. Cloning and expression of a cell surface receptor for advanced glycosylation end products of proteins. J. Biol. Chem. 1992;267:14998–15004. doi: 10.1016/S0021-9258(18)42138-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)42138-2</ArticleId><ArticleId IdType="pubmed">1378843</ArticleId></ArticleIdList></Reference><Reference><Citation>De Martin R., Hoeth M., Hofer-Warbinek R., Schmid J.A. The transcription factor nf-kappa b and the regulation of vascular cell function. Arterioscler. Thromb. Vasc. Biol. 2000;20:E83–E88. doi: 10.1161/01.atv.20.11.e83.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.atv.20.11.e83</ArticleId><ArticleId IdType="pubmed">11073859</ArticleId></ArticleIdList></Reference><Reference><Citation>Tanaka N., Yonekura H., Yamagishi S., Fujimori H., Yamamoto Y., Yamamoto H. The receptor for advanced glycation end products is induced by the glycation products themselves and tumor necrosis factor-alpha through nuclear factor-kappa b, and by 17beta-estradiol through sp-1 in human vascular endothelial cells. J. Biol. Chem. 2000;275:25781–25790. doi: 10.1074/jbc.M001235200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M001235200</ArticleId><ArticleId IdType="pubmed">10829018</ArticleId></ArticleIdList></Reference><Reference><Citation>Wolf G. Free radical production and angiotensin. Curr. Hypertens. Rep. 2000;2:167–173. doi: 10.1007/s11906-000-0078-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11906-000-0078-z</ArticleId><ArticleId IdType="pubmed">10981145</ArticleId></ArticleIdList></Reference><Reference><Citation>Oczypok E.A., Perkins T.N., Oury T.D. All the “rage” in lung disease: The receptor for advanced glycation endproducts (rage) is a major mediator of pulmonary inflammatory responses. Paediatr. Respir. Rev. 2017;23:40–49. doi: 10.1016/j.prrv.2017.03.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.prrv.2017.03.012</ArticleId><ArticleId IdType="pmc">PMC5509466</ArticleId><ArticleId IdType="pubmed">28416135</ArticleId></ArticleIdList></Reference><Reference><Citation>Norouzi M., Norouzi S., Ruggiero A., Khan M.S., Myers S., Kavanagh K., Vemuri R. Type-2 diabetes as a risk factor for severe COVID-19 infection. Microorganisms. 2021;9:1211. doi: 10.3390/microorganisms9061211.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms9061211</ArticleId><ArticleId IdType="pmc">PMC8229474</ArticleId><ArticleId IdType="pubmed">34205044</ArticleId></ArticleIdList></Reference><Reference><Citation>Byun K., Yoo Y., Son M., Lee J., Jeong G.B., Park Y.M., Salekdeh G.H., Lee B. Advanced glycation end-products produced systemically and by macrophages: A common contributor to inflammation and degenerative diseases. Pharmacol. Ther. 2017;177:44–55. doi: 10.1016/j.pharmthera.2017.02.030.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.pharmthera.2017.02.030</ArticleId><ArticleId IdType="pubmed">28223234</ArticleId></ArticleIdList></Reference><Reference><Citation>Yalcin Kehribar D., Cihangiroglu M., Sehmen E., Avci B., Capraz A., Yildirim Bilgin A., Gunaydin C., Ozgen M. The receptor for advanced glycation end product (rage) pathway in COVID-19. Biomark. Biochem. Indic. Expo. Response Susceptibility Chem. 2021;26:114–118. doi: 10.1080/1354750X.2020.1861099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/1354750X.2020.1861099</ArticleId><ArticleId IdType="pmc">PMC7814566</ArticleId><ArticleId IdType="pubmed">33284049</ArticleId></ArticleIdList></Reference><Reference><Citation>Scheen A.J. Metformin and COVID-19: From cellular mechanisms to reduced mortality. Diabetes Metab. 2020;46:423–426. doi: 10.1016/j.diabet.2020.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabet.2020.07.006</ArticleId><ArticleId IdType="pmc">PMC7395819</ArticleId><ArticleId IdType="pubmed">32750451</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodrigues D., Machado M.R., Alves J.V., Fraga-Silva T.F.C., Martins R.B., Campos L.C.B., Francisco D.F., Couto A.E.S., Bonato V.L.D., Arruda E., et al. Cytokine storm in individuals with severe COVID-19 decreases endothelial cell antioxidant defense via downregulation of the nrf2 transcriptional factor. Am. J. Physiol. Heart Circ. Physiol. 2023;325:H252–H263. doi: 10.1152/ajpheart.00096.2023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00096.2023</ArticleId><ArticleId IdType="pmc">PMC10390054</ArticleId><ArticleId IdType="pubmed">37327001</ArticleId></ArticleIdList></Reference><Reference><Citation>Rollins B.J., Yoshimura T., Leonard E.J., Pober J.S. Cytokine-activated human endothelial cells synthesize and secrete a monocyte chemoattractant, mcp-1/je. Am. J. Pathol. 1990;136:1229–1233.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1877579</ArticleId><ArticleId IdType="pubmed">2113354</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner M.D., Nedjai B., Hurst T., Pennington D.J. Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease. Biochim. Biophys. Acta. 2014;1843:2563–2582. doi: 10.1016/j.bbamcr.2014.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbamcr.2014.05.014</ArticleId><ArticleId IdType="pubmed">24892271</ArticleId></ArticleIdList></Reference><Reference><Citation>Sprague A.H., Khalil R.A. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem. Pharmacol. 2009;78:539–552. doi: 10.1016/j.bcp.2009.04.029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcp.2009.04.029</ArticleId><ArticleId IdType="pmc">PMC2730638</ArticleId><ArticleId IdType="pubmed">19413999</ArticleId></ArticleIdList></Reference><Reference><Citation>Xue J., Thippegowda P.B., Hu G., Bachmaier K., Christman J.W., Malik A.B., Tiruppathi C. Nf-kappab regulates thrombin-induced icam-1 gene expression in cooperation with nfat by binding to the intronic nf-kappab site in the icam-1 gene. Physiol. Genom. 2009;38:42–53. doi: 10.1152/physiolgenomics.00012.2009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/physiolgenomics.00012.2009</ArticleId><ArticleId IdType="pmc">PMC2696150</ArticleId><ArticleId IdType="pubmed">19351910</ArticleId></ArticleIdList></Reference><Reference><Citation>Chakraborty S., Hu S.Y., Wu S.H., Karmenyan A., Chiou A. The interaction affinity between vascular cell adhesion molecule-1 (vcam-1) and very late antigen-4 (vla-4) analyzed by quantitative fret. PLoS ONE. 2015;10:e0121399. doi: 10.1371/journal.pone.0121399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0121399</ArticleId><ArticleId IdType="pmc">PMC4368157</ArticleId><ArticleId IdType="pubmed">25793408</ArticleId></ArticleIdList></Reference><Reference><Citation>Imai Y., Shimaoka M., Kurokawa M. Essential roles of vla-4 in the hematopoietic system. Int. J. Hematol. 2010;91:569–575. doi: 10.1007/s12185-010-0555-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s12185-010-0555-3</ArticleId><ArticleId IdType="pubmed">20352381</ArticleId></ArticleIdList></Reference><Reference><Citation>Frank P.G., Lisanti M.P. Icam-1: Role in inflammation and in the regulation of vascular permeability. Am. J. Physiol. Heart Circ. Physiol. 2008;295:H926–H927. doi: 10.1152/ajpheart.00779.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.00779.2008</ArticleId><ArticleId IdType="pmc">PMC2544488</ArticleId><ArticleId IdType="pubmed">18689494</ArticleId></ArticleIdList></Reference><Reference><Citation>Silva M., Videira P.A., Sackstein R. E-selectin ligands in the human mononuclear phagocyte system: Implications for infection, inflammation, and immunotherapy. Front. Immunol. 2017;8:1878. doi: 10.3389/fimmu.2017.01878.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.01878</ArticleId><ArticleId IdType="pmc">PMC5780348</ArticleId><ArticleId IdType="pubmed">29403469</ArticleId></ArticleIdList></Reference><Reference><Citation>Cappenberg A., Kardell M., Zarbock A. Selectin-mediated signaling-shedding light on the regulation of integrin activity in neutrophils. Cells. 2022;11:1310. doi: 10.3390/cells11081310.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/cells11081310</ArticleId><ArticleId IdType="pmc">PMC9025114</ArticleId><ArticleId IdType="pubmed">35455989</ArticleId></ArticleIdList></Reference><Reference><Citation>Milosevic N., Rutter M., David A. Endothelial cell adhesion molecules- (un)attainable targets for nanomedicines. Front. Med. Technol. 2022;4:846065. doi: 10.3389/fmedt.2022.846065.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmedt.2022.846065</ArticleId><ArticleId IdType="pmc">PMC9021548</ArticleId><ArticleId IdType="pubmed">35463298</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhang J., Alcaide P., Liu L., Sun J., He A., Luscinskas F.W., Shi G.P. Regulation of endothelial cell adhesion molecule expression by mast cells, macrophages, and neutrophils. PLoS ONE. 2011;6:e14525. doi: 10.1371/journal.pone.0014525.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0014525</ArticleId><ArticleId IdType="pmc">PMC3021513</ArticleId><ArticleId IdType="pubmed">21264293</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmidt A., Geigenmuller S., Volker W., Buddecke E. The antiatherogenic and antiinflammatory effect of hdl-associated lysosphingolipids operates via akt --&gt;nf-kappab signalling pathways in human vascular endothelial cells. Basic. Res. Cardiol. 2006;101:109–116. doi: 10.1007/s00395-005-0582-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00395-005-0582-z</ArticleId><ArticleId IdType="pubmed">16450077</ArticleId></ArticleIdList></Reference><Reference><Citation>Marcus B.C., Wyble C.W., Hynes K.L., Gewertz B.L. Cytokine-induced increases in endothelial permeability occur after adhesion molecule expression. Surgery. 1996;120:411–416; discussion 416–417. doi: 10.1016/S0039-6060(96)80317-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0039-6060(96)80317-5</ArticleId><ArticleId IdType="pubmed">8751612</ArticleId></ArticleIdList></Reference><Reference><Citation>Stolpen A.H., Guinan E.C., Fiers W., Pober J.S. Recombinant tumor necrosis factor and immune interferon act singly and in combination to reorganize human vascular endothelial cell monolayers. Am. J. Pathol. 1986;123:16–24.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1888144</ArticleId><ArticleId IdType="pubmed">2421578</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu F., Zou Q., Ding X., Shi D., Zhu X., Hu W., Liu L., Zhou H. Complement component c3a plays a critical role in endothelial activation and leukocyte recruitment into the brain. J. Neuroinflamm. 2016;13:23. doi: 10.1186/s12974-016-0485-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12974-016-0485-y</ArticleId><ArticleId IdType="pmc">PMC4731990</ArticleId><ArticleId IdType="pubmed">26822321</ArticleId></ArticleIdList></Reference><Reference><Citation>Albrecht E.A., Chinnaiyan A.M., Varambally S., Kumar-Sinha C., Barrette T.R., Sarma J.V., Ward P.A. C5a-induced gene expression in human umbilical vein endothelial cells. Am. J. Pathol. 2004;164:849–859. doi: 10.1016/S0002-9440(10)63173-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0002-9440(10)63173-2</ArticleId><ArticleId IdType="pmc">PMC1613300</ArticleId><ArticleId IdType="pubmed">14982839</ArticleId></ArticleIdList></Reference><Reference><Citation>Jani P.K., Schwaner E., Kajdacsi E., Debreczeni M.L., Ungai-Salanki R., Dobo J., Doleschall Z., Rigo J., Jr., Geiszt M., Szabo B., et al. Complement masp-1 enhances adhesion between endothelial cells and neutrophils by up-regulating e-selectin expression. Mol. Immunol. 2016;75:38–47. doi: 10.1016/j.molimm.2016.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2016.05.007</ArticleId><ArticleId IdType="pubmed">27219453</ArticleId></ArticleIdList></Reference><Reference><Citation>Passi R., Cholewa-Waclaw J., Wereski R., Bennett M., Veizades S., Berkeley B., Caporali A., Li Z., Rodor J., Dewerchin M., et al. COVID-19 plasma induces subcellular remodelling within the pulmonary microvascular endothelium. Vasc. Pharmacol. 2024;154:107277. doi: 10.1016/j.vph.2024.107277.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.vph.2024.107277</ArticleId><ArticleId IdType="pubmed">38266794</ArticleId></ArticleIdList></Reference><Reference><Citation>Fabis M., Gorzelak-Pabis P., Satala J., Pawlos A., Fabis J., Broncel M. Relationship between COVID-19 severity, markers of endothelial impairment, and simple COVID risk index. Pol. Arch. Intern. Med. 2022;132:10–20452. doi: 10.20452/pamw.16348.</Citation><ArticleIdList><ArticleId IdType="doi">10.20452/pamw.16348</ArticleId><ArticleId IdType="pubmed">36169165</ArticleId></ArticleIdList></Reference><Reference><Citation>Bohorquez A., Rostam N., Ortiz-Sandoval C., Howard C., Kahr W.H., Campbell C.J., Licht C. The complement system mediates COVID-19 endothelial cell injury, modifying cell permeability. Blood. 2022;140:2665–2666. doi: 10.1182/blood-2022-169506.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2022-169506</ArticleId></ArticleIdList></Reference><Reference><Citation>Matricardi P.M., Dal Negro R.W., Nisini R. The first, holistic immunological model of COVID-19: Implications for prevention, diagnosis, and public health measures. Pediatr. Allergy Immunol. 2020;31:454–470. doi: 10.1111/pai.13271.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/pai.13271</ArticleId><ArticleId IdType="pmc">PMC7267459</ArticleId><ArticleId IdType="pubmed">32359201</ArticleId></ArticleIdList></Reference><Reference><Citation>Satyam A., Tsokos M.G., Brook O.R., Hecht J.L., Moulton V.R., Tsokos G.C. Activation of classical and alternative complement pathways in the pathogenesis of lung injury in COVID-19. Clin. Immunol. 2021;226:108716. doi: 10.1016/j.clim.2021.108716.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2021.108716</ArticleId><ArticleId IdType="pmc">PMC7989127</ArticleId><ArticleId IdType="pubmed">33774179</ArticleId></ArticleIdList></Reference><Reference><Citation>Baena Carstens L., Campos D’amico R., Fernandes de Moura K., Morais de Castro E., Centenaro F., Silva Barbosa G., Vieira Cavalcante da Silva G., Brenny I., Honorio D’Agostini J.C., Hlatchuk E.C., et al. Lung inflammasome activation in SARS-CoV-2 post-mortem biopsies. Int. J. Mol. Sci. 2022;23:13033. doi: 10.3390/ijms232113033.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms232113033</ArticleId><ArticleId IdType="pmc">PMC9659061</ArticleId><ArticleId IdType="pubmed">36361818</ArticleId></ArticleIdList></Reference><Reference><Citation>Neubauer K., Zieger B. Endothelial cells and coagulation. Cell Tissue Res. 2022;387:391–398. doi: 10.1007/s00441-021-03471-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00441-021-03471-2</ArticleId><ArticleId IdType="pmc">PMC8975780</ArticleId><ArticleId IdType="pubmed">34014399</ArticleId></ArticleIdList></Reference><Reference><Citation>Yau J.W., Teoh H., Verma S. Endothelial cell control of thrombosis. BMC Cardiovasc. Disord. 2015;15:130. doi: 10.1186/s12872-015-0124-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12872-015-0124-z</ArticleId><ArticleId IdType="pmc">PMC4617895</ArticleId><ArticleId IdType="pubmed">26481314</ArticleId></ArticleIdList></Reference><Reference><Citation>Brown M.A., Stenberg L.M., Stenflo J. Coagulation factor xa. Handb. Proteolytic Enzym. 2013:2908.</Citation></Reference><Reference><Citation>Stearns-Kurosawa D.J., Kurosawa S., Mollica J.S., Ferrell G.L., Esmon C.T. The endothelial cell protein c receptor augments protein c activation by the thrombin-thrombomodulin complex. Proc. Natl. Acad. Sci. USA. 1996;93:10212–10216. doi: 10.1073/pnas.93.19.10212.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.93.19.10212</ArticleId><ArticleId IdType="pmc">PMC38363</ArticleId><ArticleId IdType="pubmed">8816778</ArticleId></ArticleIdList></Reference><Reference><Citation>Sayyadi M., Hassani S., Shams M., Dorgalaleh A. Status of major hemostatic components in the setting of COVID-19: The effect on endothelium, platelets, coagulation factors, fibrinolytic system, and complement. Ann. Hematol. 2023;102:1307–1322. doi: 10.1007/s00277-023-05234-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00277-023-05234-1</ArticleId><ArticleId IdType="pmc">PMC10115391</ArticleId><ArticleId IdType="pubmed">37074380</ArticleId></ArticleIdList></Reference><Reference><Citation>Rose S.L., Babensee J.E. Procoagulant phenotype of endothelial cells after coculture with biomaterial-treated blood cells. J. Biomed. Mater. Res. Part A. 2005;72:269–278. doi: 10.1002/jbm.a.30222.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jbm.a.30222</ArticleId><ArticleId IdType="pubmed">15657946</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen J., Chung D.W. Inflammation, von willebrand factor, and adamts13. Blood. 2018;132:141–147. doi: 10.1182/blood-2018-02-769000.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2018-02-769000</ArticleId><ArticleId IdType="pmc">PMC6043979</ArticleId><ArticleId IdType="pubmed">29866815</ArticleId></ArticleIdList></Reference><Reference><Citation>Subrahmanian S., Borczuk A., Salvatore S., Fung K.M., Merrill J.T., Laurence J., Ahamed J. Tissue factor upregulation is associated with SARS-CoV-2 in the lungs of COVID-19 patients. J. Thromb. Haemost. JTH. 2021;19:2268–2274. doi: 10.1111/jth.15451.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15451</ArticleId><ArticleId IdType="pmc">PMC8565501</ArticleId><ArticleId IdType="pubmed">34236752</ArticleId></ArticleIdList></Reference><Reference><Citation>Won T., Wood M.K., Hughes D.M., Talor M.V., Ma Z., Schneider J., Skinner J.T., Asady B., Goerlich E., Halushka M.K., et al. Endothelial thrombomodulin downregulation caused by hypoxia contributes to severe infiltration and coagulopathy in COVID-19 patient lungs. EBioMedicine. 2022;75:103812. doi: 10.1016/j.ebiom.2022.103812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2022.103812</ArticleId><ArticleId IdType="pmc">PMC8756077</ArticleId><ArticleId IdType="pubmed">35033854</ArticleId></ArticleIdList></Reference><Reference><Citation>Nawroth P.P., Stern D.M. Modulation of endothelial cell hemostatic properties by tumor necrosis factor. J. Exp. Med. 1986;163:740–745. doi: 10.1084/jem.163.3.740.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.163.3.740</ArticleId><ArticleId IdType="pmc">PMC2188058</ArticleId><ArticleId IdType="pubmed">3753996</ArticleId></ArticleIdList></Reference><Reference><Citation>Nawroth P.P., Handley D.A., Esmon C.T., Stern D.M. Interleukin 1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc. Natl. Acad. Sci. USA. 1986;83:3460–3464. doi: 10.1073/pnas.83.10.3460.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.83.10.3460</ArticleId><ArticleId IdType="pmc">PMC323535</ArticleId><ArticleId IdType="pubmed">3486418</ArticleId></ArticleIdList></Reference><Reference><Citation>Scarpati E.M., Sadler J.E. Regulation of endothelial cell coagulant properties. Modulation of tissue factor, plasminogen activator inhibitors, and thrombomodulin by phorbol 12-myristate 13-acetate and tumor necrosis factor. J. Biol. Chem. 1989;264:20705–20713. doi: 10.1016/S0021-9258(19)47120-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(19)47120-2</ArticleId><ArticleId IdType="pubmed">2555368</ArticleId></ArticleIdList></Reference><Reference><Citation>Conkling P.R., Greenberg C.S., Weinberg J.B. Tumor necrosis factor induces tissue factor-like activity in human leukemia cell line u937 and peripheral blood monocytes. Blood. 1988;72:128–133. doi: 10.1182/blood.V72.1.128.bloodjournal721128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V72.1.128.bloodjournal721128</ArticleId><ArticleId IdType="pubmed">3134064</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbert J.M., Savi P., Laplace M.C., Lale A. Il-4 inhibits lps-, il-1 beta- and tnf alpha-induced expression of tissue factor in endothelial cells and monocytes. FEBS Lett. 1992;310:31–33. doi: 10.1016/0014-5793(92)81139-D.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(92)81139-D</ArticleId><ArticleId IdType="pubmed">1526281</ArticleId></ArticleIdList></Reference><Reference><Citation>Herbert J.M., Savi P., Laplace M.C., Lale A., Dol F., Dumas A., Labit C., Minty A. Il-4 and il-13 exhibit comparable abilities to reduce pyrogen-induced expression of procoagulant activity in endothelial cells and monocytes. FEBS Lett. 1993;328:268–270. doi: 10.1016/0014-5793(93)80941-M.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(93)80941-M</ArticleId><ArticleId IdType="pubmed">8102337</ArticleId></ArticleIdList></Reference><Reference><Citation>Martin N.B., Jamieson A., Tuffin D.P. The effect of interleukin-4 on tumour necrosis factor-alpha induced expression of tissue factor and plasminogen activator inhibitor-1 in human umbilical vein endothelial cells. Thromb. Haemost. 1993;70:1037–1042. doi: 10.1055/s-0038-1649721.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1649721</ArticleId><ArticleId IdType="pubmed">8165597</ArticleId></ArticleIdList></Reference><Reference><Citation>Schwager I., Jungi T.W. Effect of human recombinant cytokines on the induction of macrophage procoagulant activity. Blood. 1994;83:152–160. doi: 10.1182/blood.V83.1.152.152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V83.1.152.152</ArticleId><ArticleId IdType="pubmed">8274733</ArticleId></ArticleIdList></Reference><Reference><Citation>Kirchhofer D., Tschopp T.B., Hadvary P., Baumgartner H.R. Endothelial cells stimulated with tumor necrosis factor-alpha express varying amounts of tissue factor resulting in inhomogenous fibrin deposition in a native blood flow system. Effects of thrombin inhibitors. J. Clin. Investig. 1994;93:2073–2083. doi: 10.1172/JCI117202.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI117202</ArticleId><ArticleId IdType="pmc">PMC294327</ArticleId><ArticleId IdType="pubmed">8182139</ArticleId></ArticleIdList></Reference><Reference><Citation>Paleolog E.M., Delasalle S.A., Buurman W.A., Feldmann M. Functional activities of receptors for tumor necrosis factor-alpha on human vascular endothelial cells. Blood. 1994;84:2578–2590. doi: 10.1182/blood.V84.8.2578.2578.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V84.8.2578.2578</ArticleId><ArticleId IdType="pubmed">7919375</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Prete G., De Carli M., Lammel R.M., D’Elios M.M., Daniel K.C., Giusti B., Abbate R., Romagnani S. Th1 and th2 t-helper cells exert opposite regulatory effects on procoagulant activity and tissue factor production by human monocytes. Blood. 1995;86:250–257. doi: 10.1182/blood.V86.1.250.bloodjournal861250.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V86.1.250.bloodjournal861250</ArticleId><ArticleId IdType="pubmed">7795230</ArticleId></ArticleIdList></Reference><Reference><Citation>Osnes L.T., Westvik A.B., Joo G.B., Okkenhaug C., Kierulf P. Inhibition of il-1 induced tissue factor (tf) synthesis and procoagulant activity (pca) in purified human monocytes by il-4, il-10 and il-13. Cytokine. 1996;8:822–827. doi: 10.1006/cyto.1996.0110.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/cyto.1996.0110</ArticleId><ArticleId IdType="pubmed">9047078</ArticleId></ArticleIdList></Reference><Reference><Citation>Ernofsson M., Tenno T., Siegbahn A. Inhibition of tissue factor surface expression in human peripheral blood monocytes exposed to cytokines. Br. J. Haematol. 1996;95:249–257. doi: 10.1046/j.1365-2141.1996.d01-1893.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2141.1996.d01-1893.x</ArticleId><ArticleId IdType="pubmed">8904877</ArticleId></ArticleIdList></Reference><Reference><Citation>Schecter A.D., Rollins B.J., Zhang Y.J., Charo I.F., Fallon J.T., Rossikhina M., Giesen P.L., Nemerson Y., Taubman M.B. Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and thp-1 cells. J. Biol. Chem. 1997;272:28568–28573. doi: 10.1074/jbc.272.45.28568.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.272.45.28568</ArticleId><ArticleId IdType="pubmed">9353321</ArticleId></ArticleIdList></Reference><Reference><Citation>Neumann F.J., Ott I., Marx N., Luther T., Kenngott S., Gawaz M., Kotzsch M., Schomig A. Effect of human recombinant interleukin-6 and interleukin-8 on monocyte procoagulant activity. Arterioscler. Thromb. Vasc. Biol. 1997;17:3399–3405. doi: 10.1161/01.ATV.17.12.3399.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/01.ATV.17.12.3399</ArticleId><ArticleId IdType="pubmed">9437185</ArticleId></ArticleIdList></Reference><Reference><Citation>Meisel S.R., Shimon I., Edgington T.S., Melmed S., Cercek B., Shah P.K. Leukaemia inhibitory factor enhances tissue factor expression in human monocyte-derived macrophages: A gp130-mediated mechanism. Br. J. Haematol. 1999;107:747–755. doi: 10.1046/j.1365-2141.1999.01782.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2141.1999.01782.x</ArticleId><ArticleId IdType="pubmed">10606879</ArticleId></ArticleIdList></Reference><Reference><Citation>Veltrop M.H., Beekhuizen H., Thompson J. Bacterial species- and strain-dependent induction of tissue factor in human vascular endothelial cells. Infect. Immun. 1999;67:6130–6138. doi: 10.1128/IAI.67.11.6130-6138.1999.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/IAI.67.11.6130-6138.1999</ArticleId><ArticleId IdType="pmc">PMC97002</ArticleId><ArticleId IdType="pubmed">10531276</ArticleId></ArticleIdList></Reference><Reference><Citation>Lentz S.R., Tsiang M., Sadler J.E. Regulation of thrombomodulin by tumor necrosis factor-alpha: Comparison of transcriptional and posttranscriptional mechanisms. Blood. 1991;77:542–550. doi: 10.1182/blood.V77.3.542.542.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V77.3.542.542</ArticleId><ArticleId IdType="pubmed">1846763</ArticleId></ArticleIdList></Reference><Reference><Citation>Raife T.J., Demetroulis E.M., Lentz S.R. Regulation of thrombomodulin expression by all-trans retinoic acid and tumor necrosis factor-alpha: Differential responses in keratinocytes and endothelial cells. Blood. 1996;88:2043–2049. doi: 10.1182/blood.V88.6.2043.bloodjournal8862043.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V88.6.2043.bloodjournal8862043</ArticleId><ArticleId IdType="pubmed">8822923</ArticleId></ArticleIdList></Reference><Reference><Citation>Regan L.M., Stearns-Kurosawa D.J., Kurosawa S., Mollica J., Fukudome K., Esmon C.T. The endothelial cell protein c receptor. Inhibition of activated protein c anticoagulant function without modulation of reaction with proteinase inhibitors. J. Biol. Chem. 1996;271:17499–17503. doi: 10.1074/jbc.271.29.17499.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.271.29.17499</ArticleId><ArticleId IdType="pubmed">8663474</ArticleId></ArticleIdList></Reference><Reference><Citation>Xu J., Qu D., Esmon N.L., Esmon C.T. Metalloproteolytic release of endothelial cell protein c receptor. J. Biol. Chem. 2000;275:6038–6044. doi: 10.1074/jbc.275.8.6038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.275.8.6038</ArticleId><ArticleId IdType="pubmed">10681599</ArticleId></ArticleIdList></Reference><Reference><Citation>Vassiliou A.G., Keskinidou C., Jahaj E., Gallos P., Zacharis A., Athanasiou N., Tsipilis S., Mastora Z., Dimopoulou I., Kotanidou A., et al. Could soluble endothelial protein c receptor levels recognize SARS-CoV2-positive patients requiring hospitalization? Shock. 2021;56:733–736. doi: 10.1097/SHK.0000000000001780.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/SHK.0000000000001780</ArticleId><ArticleId IdType="pmc">PMC8518207</ArticleId><ArticleId IdType="pubmed">33756504</ArticleId></ArticleIdList></Reference><Reference><Citation>Fukudome K., Esmon C.T. Identification, cloning, and regulation of a novel endothelial cell protein c/activated protein c receptor. J. Biol. Chem. 1994;269:26486–26491. doi: 10.1016/S0021-9258(18)47220-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)47220-1</ArticleId><ArticleId IdType="pubmed">7929370</ArticleId></ArticleIdList></Reference><Reference><Citation>Sawdey M., Podor T.J., Loskutoff D.J. Regulation of type 1 plasminogen activator inhibitor gene expression in cultured bovine aortic endothelial cells. Induction by transforming growth factor-beta, lipopolysaccharide, and tumor necrosis factor-alpha. J. Biol. Chem. 1989;264:10396–10401. doi: 10.1016/S0021-9258(18)81633-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)81633-7</ArticleId><ArticleId IdType="pubmed">2499579</ArticleId></ArticleIdList></Reference><Reference><Citation>van Hinsbergh V.W., van den Berg E.A., Fiers W., Dooijewaard G. Tumor necrosis factor induces the production of urokinase-type plasminogen activator by human endothelial cells. Blood. 1990;75:1991–1998. doi: 10.1182/blood.V75.10.1991.1991.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V75.10.1991.1991</ArticleId><ArticleId IdType="pubmed">2140060</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K., Uwabe Y., Sawasaki Y., Kiguchi T., Nakamura H., Kashiwabara K., Yagyu H., Matsuoka T. Increased secretion of urokinase-type plasminogen activator by human lung microvascular endothelial cells. Am. J. Physiol. 1998;275:L47–L54. doi: 10.1152/ajplung.1998.275.1.L47.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajplung.1998.275.1.L47</ArticleId><ArticleId IdType="pubmed">9688934</ArticleId></ArticleIdList></Reference><Reference><Citation>Schleef R.R., Bevilacqua M.P., Sawdey M., Gimbrone M.A., Jr., Loskutoff D.J. Cytokine activation of vascular endothelium. Effects on tissue-type plasminogen activator and type 1 plasminogen activator inhibitor. J. Biol. Chem. 1988;263:5797–5803. doi: 10.1016/S0021-9258(18)60636-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)60636-2</ArticleId><ArticleId IdType="pubmed">3128548</ArticleId></ArticleIdList></Reference><Reference><Citation>Gallicchio M., Hufnagl P., Wojta J., Tipping P. Ifn-gamma inhibits thrombin- and endotoxin-induced plasminogen activator inhibitor type 1 in human endothelial cells. J. Immunol. 1996;157:2610–2617. doi: 10.4049/jimmunol.157.6.2610.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.157.6.2610</ArticleId><ArticleId IdType="pubmed">8805664</ArticleId></ArticleIdList></Reference><Reference><Citation>Arnman V., Stemme S., Rymo L., Risberg B. Interferon-gamma modulates the fibrinolytic response in cultured human endothelial cells. Thromb. Res. 1995;77:431–440. doi: 10.1016/0049-3848(95)93879-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0049-3848(95)93879-5</ArticleId><ArticleId IdType="pubmed">7778058</ArticleId></ArticleIdList></Reference><Reference><Citation>Niedbala M.J., Picarella M.S. Tumor necrosis factor induction of endothelial cell urokinase-type plasminogen activator mediated proteolysis of extracellular matrix and its antagonism by gamma-interferon. Blood. 1992;79:678–687. doi: 10.1182/blood.V79.3.678.678.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V79.3.678.678</ArticleId><ArticleId IdType="pubmed">1732009</ArticleId></ArticleIdList></Reference><Reference><Citation>Wojta J., Gallicchio M., Zoellner H., Filonzi E.L., Hamilton J.A., McGrath K. Interleukin-4 stimulates expression of urokinase-type-plasminogen activator in cultured human foreskin microvascular endothelial cells. Blood. 1993;81:3285–3292. doi: 10.1182/blood.V81.12.3285.3285.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V81.12.3285.3285</ArticleId><ArticleId IdType="pubmed">8507866</ArticleId></ArticleIdList></Reference><Reference><Citation>Monsinjon T., Gasque P., Chan P., Ischenko A., Brady J.J., Fontaine M.C. Regulation by complement c3a and c5a anaphylatoxins of cytokine production in human umbilical vein endothelial cells. FASEB J. 2003;17:1003–1014. doi: 10.1096/fj.02-0737com.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.02-0737com</ArticleId><ArticleId IdType="pubmed">12773483</ArticleId></ArticleIdList></Reference><Reference><Citation>Propson N.E., Roy E.R., Litvinchuk A., Kohl J., Zheng H. Endothelial c3a receptor mediates vascular inflammation and blood-brain barrier permeability during aging. J. Clin. Investig. 2021;131:e140966. doi: 10.1172/JCI140966.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI140966</ArticleId><ArticleId IdType="pmc">PMC7773352</ArticleId><ArticleId IdType="pubmed">32990682</ArticleId></ArticleIdList></Reference><Reference><Citation>Shivshankar P., Li Y.D., Mueller-Ortiz S.L., Wetsel R.A. In response to complement anaphylatoxin peptides c3a and c5a, human vascular endothelial cells migrate and mediate the activation of b-cells and polarization of t-cells. FASEB J. 2020;34:7540–7560. doi: 10.1096/fj.201902397R.</Citation><ArticleIdList><ArticleId IdType="doi">10.1096/fj.201902397R</ArticleId><ArticleId IdType="pubmed">32301538</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeda K., Nagasawa K., Horiuchi T., Tsuru T., Nishizaka H., Niho Y. C5a induces tissue factor activity on endothelial cells. Thromb. Haemost. 1997;77:394–398. doi: 10.1055/s-0038-1655974.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1655974</ArticleId><ArticleId IdType="pubmed">9157602</ArticleId></ArticleIdList></Reference><Reference><Citation>Hattori R., Hamilton K.K., McEver R.P., Sims P.J. Complement proteins c5b-9 induce secretion of high molecular weight multimers of endothelial von willebrand factor and translocation of granule membrane protein gmp-140 to the cell surface. J. Biol. Chem. 1989;264:9053–9060. doi: 10.1016/S0021-9258(18)81901-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(18)81901-9</ArticleId><ArticleId IdType="pubmed">2470750</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamilton K.K., Hattori R., Esmon C.T., Sims P.J. Complement proteins c5b-9 induce vesiculation of the endothelial plasma membrane and expose catalytic surface for assembly of the prothrombinase enzyme complex. J. Biol. Chem. 1990;265:3809–3814. doi: 10.1016/S0021-9258(19)39666-8.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(19)39666-8</ArticleId><ArticleId IdType="pubmed">2105954</ArticleId></ArticleIdList></Reference><Reference><Citation>Wang H., Ricklin D., Lambris J.D. Complement-activation fragment c4a mediates effector functions by binding as untethered agonist to protease-activated receptors 1 and 4. Proc. Natl. Acad. Sci. USA. 2017;114:10948–10953. doi: 10.1073/pnas.1707364114.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1707364114</ArticleId><ArticleId IdType="pmc">PMC5642699</ArticleId><ArticleId IdType="pubmed">28973891</ArticleId></ArticleIdList></Reference><Reference><Citation>Megyeri M., Mako V., Beinrohr L., Doleschall Z., Prohaszka Z., Cervenak L., Zavodszky P., Gal P. Complement protease masp-1 activates human endothelial cells: Par4 activation is a link between complement and endothelial function. J. Immunol. 2009;183:3409–3416. doi: 10.4049/jimmunol.0900879.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0900879</ArticleId><ArticleId IdType="pubmed">19667088</ArticleId></ArticleIdList></Reference><Reference><Citation>Pryzdial E.L.G., Leatherdale A., Conway E.M. Coagulation and complement: Key innate defense participants in a seamless web. Front. Immunol. 2022;13:918775. doi: 10.3389/fimmu.2022.918775.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.918775</ArticleId><ArticleId IdType="pmc">PMC9398469</ArticleId><ArticleId IdType="pubmed">36016942</ArticleId></ArticleIdList></Reference><Reference><Citation>Vorobjeva N.V., Chernyak B.V. Netosis: Molecular mechanisms, role in physiology and pathology. Biochem. Biokhimiia. 2020;85:1178–1190. doi: 10.1134/S0006297920100065.</Citation><ArticleIdList><ArticleId IdType="doi">10.1134/S0006297920100065</ArticleId><ArticleId IdType="pmc">PMC7590568</ArticleId><ArticleId IdType="pubmed">33202203</ArticleId></ArticleIdList></Reference><Reference><Citation>Yipp B.G., Petri B., Salina D., Jenne C.N., Scott B.N., Zbytnuik L.D., Pittman K., Asaduzzaman M., Wu K., Meijndert H.C., et al. Infection-induced netosis is a dynamic process involving neutrophil multitasking in vivo. Nat. Med. 2012;18:1386–1393. doi: 10.1038/nm.2847.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.2847</ArticleId><ArticleId IdType="pmc">PMC4529131</ArticleId><ArticleId IdType="pubmed">22922410</ArticleId></ArticleIdList></Reference><Reference><Citation>Guglietta S., Chiavelli A., Zagato E., Krieg C., Gandini S., Ravenda P.S., Bazolli B., Lu B., Penna G., Rescigno M. Coagulation induced by c3ar-dependent netosis drives protumorigenic neutrophils during small intestinal tumorigenesis. Nat. Commun. 2016;7:11037. doi: 10.1038/ncomms11037.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms11037</ArticleId><ArticleId IdType="pmc">PMC4802169</ArticleId><ArticleId IdType="pubmed">26996437</ArticleId></ArticleIdList></Reference><Reference><Citation>de Bont C.M., Boelens W.C., Pruijn G.J.M. Netosis, complement, and coagulation: A triangular relationship. Cell. Mol. Immunol. 2019;16:19–27. doi: 10.1038/s41423-018-0024-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-018-0024-0</ArticleId><ArticleId IdType="pmc">PMC6318284</ArticleId><ArticleId IdType="pubmed">29572545</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinelli S., Urosevic M., Daryadel A., Oberholzer P.A., Baumann C., Fey M.F., Dummer R., Simon H.U., Yousefi S. Induction of genes mediating interferon-dependent extracellular trap formation during neutrophil differentiation. J. Biol. Chem. 2004;279:44123–44132. doi: 10.1074/jbc.M405883200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M405883200</ArticleId><ArticleId IdType="pubmed">15302890</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu X., Wang Y., Bauer A.T., Kirschfink M., Ding P., Gebhardt C., Borsig L., Tuting T., Renne T., Haffner K., et al. Neutrophils activated by membrane attack complexes increase the permeability of melanoma blood vessels. Proc. Natl. Acad. Sci. USA. 2022;119:e2122716119. doi: 10.1073/pnas.2122716119.</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.2122716119</ArticleId><ArticleId IdType="pmc">PMC9388087</ArticleId><ArticleId IdType="pubmed">35960843</ArticleId></ArticleIdList></Reference><Reference><Citation>Folco E.J., Mawson T.L., Vromman A., Bernardes-Souza B., Franck G., Persson O., Nakamura M., Newton G., Luscinskas F.W., Libby P. Neutrophil extracellular traps induce endothelial cell activation and tissue factor production through interleukin-1alpha and cathepsing. Arterioscler. Thromb. Vasc. Biol. 2018;38:1901–1912. doi: 10.1161/ATVBAHA.118.311150.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.118.311150</ArticleId><ArticleId IdType="pmc">PMC6202190</ArticleId><ArticleId IdType="pubmed">29976772</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhu Y., Chen X., Liu X. Netosis and neutrophil extracellular traps in COVID-19: Immunothrombosis and beyond. Front. Immunol. 2022;13:838011. doi: 10.3389/fimmu.2022.838011.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2022.838011</ArticleId><ArticleId IdType="pmc">PMC8924116</ArticleId><ArticleId IdType="pubmed">35309344</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghanbari E.P., Jakobs K., Puccini M., Reinshagen L., Friebel J., Haghikia A., Krankel N., Landmesser U., Rauch-Krohnert U. The role of netosis and complement activation in COVID-19-associated coagulopathies. Biomedicines. 2023;11:1371. doi: 10.3390/biomedicines11051371.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/biomedicines11051371</ArticleId><ArticleId IdType="pmc">PMC10216097</ArticleId><ArticleId IdType="pubmed">37239041</ArticleId></ArticleIdList></Reference><Reference><Citation>Huckriede J., Anderberg S.B., Morales A., de Vries F., Hultstrom M., Bergqvist A., Ortiz-Perez J.T., Sels J.W., Wichapong K., Lipcsey M., et al. Evolution of netosis markers and damps have prognostic value in critically ill COVID-19 patients. Sci. Rep. 2021;11:15701. doi: 10.1038/s41598-021-95209-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-95209-x</ArticleId><ArticleId IdType="pmc">PMC8333321</ArticleId><ArticleId IdType="pubmed">34344929</ArticleId></ArticleIdList></Reference><Reference><Citation>Middeldorp S., Coppens M., van Haaps T.F., Foppen M., Vlaar A.P., Muller M.C.A., Bouman C.C.S., Beenen L.F.M., Kootte R.S., Heijmans J., et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. J. Thromb. Haemost. JTH. 2020;18:1995–2002. doi: 10.1111/jth.14888.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14888</ArticleId><ArticleId IdType="pmc">PMC7497052</ArticleId><ArticleId IdType="pubmed">32369666</ArticleId></ArticleIdList></Reference><Reference><Citation>Lodigiani C., Iapichino G., Carenzo L., Cecconi M., Ferrazzi P., Sebastian T., Kucher N., Studt J.D., Sacco C., Bertuzzi A., et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. Thromb. Res. 2020;191:9–14. doi: 10.1016/j.thromres.2020.04.024.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.04.024</ArticleId><ArticleId IdType="pmc">PMC7177070</ArticleId><ArticleId IdType="pubmed">32353746</ArticleId></ArticleIdList></Reference><Reference><Citation>Klok F.A., Kruip M., van der Meer N.J.M., Arbous M.S., Gommers D., Kant K.M., Kaptein F.H.J., van Paassen J., Stals M.A.M., Huisman M.V., et al. Incidence of thrombotic complications in critically ill icu patients with COVID-19. Thromb. Res. 2020;191:145–147. doi: 10.1016/j.thromres.2020.04.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.04.013</ArticleId><ArticleId IdType="pmc">PMC7146714</ArticleId><ArticleId IdType="pubmed">32291094</ArticleId></ArticleIdList></Reference><Reference><Citation>Poli D., Antonucci E., Ageno W., Prandoni P., Barillari G., Bitti G., Imbalzano E., Bucherini E., Chistolini A., Fregoni V., et al. Thromboembolic complications in covid-19 patients hospitalized in italian ordinary wards: Data from the multicenter observational start-covid register. TH Open Companion J. Thromb. Haemost. 2022;6:e251–e256. doi: 10.1055/a-1878-6806.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/a-1878-6806</ArticleId><ArticleId IdType="pmc">PMC9467691</ArticleId><ArticleId IdType="pubmed">36299804</ArticleId></ArticleIdList></Reference><Reference><Citation>Duca S.T., Costache A.D., Miftode R.S., Mitu O., Petri S.A., Costache Hypercoagulability in COVID-19: From an unknown beginning to future therapies. Med. Pharm. Rep. 2022;95:236–242. doi: 10.15386/mpr-2195.</Citation><ArticleIdList><ArticleId IdType="doi">10.15386/mpr-2195</ArticleId><ArticleId IdType="pmc">PMC9387574</ArticleId><ArticleId IdType="pubmed">36060499</ArticleId></ArticleIdList></Reference><Reference><Citation>Thachil J., Tang N., Gando S., Falanga A., Cattaneo M., Levi M., Clark C., Iba T. Isth interim guidance on recognition and management of coagulopathy in COVID-19. J. Thromb. Haemost. JTH. 2020;18:1023–1026. doi: 10.1111/jth.14810.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14810</ArticleId><ArticleId IdType="pmc">PMC9906133</ArticleId><ArticleId IdType="pubmed">32338827</ArticleId></ArticleIdList></Reference><Reference><Citation>Hanff T.C., Mohareb A.M., Giri J., Cohen J.B., Chirinos J.A. Thrombosis in COVID-19. Am. J. Hematol. 2020;95:1578–1589. doi: 10.1002/ajh.25982.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.25982</ArticleId><ArticleId IdType="pmc">PMC7674272</ArticleId><ArticleId IdType="pubmed">32857878</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi G., Lee J.J., Jamil A., Gunnam V., Najafi H., Memar Montazerin S., Shojaei F., Marszalek J. Venous thromboembolism among hospitalized patients with COVID-19 undergoing thromboprophylaxis: A systematic review and meta-analysis. J. Clin. Med. 2020;9:2489. doi: 10.3390/jcm9082489.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9082489</ArticleId><ArticleId IdType="pmc">PMC7463975</ArticleId><ArticleId IdType="pubmed">32756383</ArticleId></ArticleIdList></Reference><Reference><Citation>Porfidia A., Valeriani E., Pola R., Porreca E., Rutjes A.W.S., Di Nisio M. Venous thromboembolism in patients with COVID-19: Systematic review and meta-analysis. Thromb. Res. 2020;196:67–74. doi: 10.1016/j.thromres.2020.08.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2020.08.020</ArticleId><ArticleId IdType="pmc">PMC7420982</ArticleId><ArticleId IdType="pubmed">32853978</ArticleId></ArticleIdList></Reference><Reference><Citation>Mansory E.M., Srigunapalan S., Lazo-Langner A. Venous thromboembolism in hospitalized critical and noncritical COVID-19 patients: A systematic review and meta-analysis. TH Open Companion J. Thromb. Haemost. 2021;5:e286–e294. doi: 10.1055/s-0041-1730967.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0041-1730967</ArticleId><ArticleId IdType="pmc">PMC8260281</ArticleId><ArticleId IdType="pubmed">34240001</ArticleId></ArticleIdList></Reference><Reference><Citation>Llitjos J.F., Leclerc M., Chochois C., Monsallier J.M., Ramakers M., Auvray M., Merouani K. High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J. Thromb. Haemost. JTH. 2020;18:1743–1746. doi: 10.1111/jth.14869.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14869</ArticleId><ArticleId IdType="pmc">PMC7264774</ArticleId><ArticleId IdType="pubmed">32320517</ArticleId></ArticleIdList></Reference><Reference><Citation>Poissy J., Goutay J., Caplan M., Parmentier E., Duburcq T., Lassalle F., Jeanpierre E., Rauch A., Labreuche J., Susen S., et al. Pulmonary embolism in patients with COVID-19: Awareness of an increased prevalence. Circulation. 2020;142:184–186. doi: 10.1161/CIRCULATIONAHA.120.047430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.047430</ArticleId><ArticleId IdType="pubmed">32330083</ArticleId></ArticleIdList></Reference><Reference><Citation>Ren B., Yan F., Deng Z., Zhang S., Xiao L., Wu M., Cai L. Extremely high incidence of lower extremity deep venous thrombosis in 48 patients with severe COVID-19 in Wuhan. Circulation. 2020;142:181–183. doi: 10.1161/CIRCULATIONAHA.120.047407.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.047407</ArticleId><ArticleId IdType="pubmed">32412320</ArticleId></ArticleIdList></Reference><Reference><Citation>Jimenez D., Garcia-Sanchez A., Rali P., Muriel A., Bikdeli B., Ruiz-Artacho P., Le Mao R., Rodriguez C., Hunt B.J., Monreal M. Incidence of vte and bleeding among hospitalized patients with coronavirus disease 2019: A systematic review and meta-analysis. Chest. 2021;159:1182–1196. doi: 10.1016/j.chest.2020.11.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.chest.2020.11.005</ArticleId><ArticleId IdType="pmc">PMC7670889</ArticleId><ArticleId IdType="pubmed">33217420</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi S., Qin M., Shen B., Cai Y., Liu T., Yang F., Gong W., Liu X., Liang J., Zhao Q., et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China. JAMA Cardiol. 2020;5:802–810. doi: 10.1001/jamacardio.2020.0950.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamacardio.2020.0950</ArticleId><ArticleId IdType="pmc">PMC7097841</ArticleId><ArticleId IdType="pubmed">32211816</ArticleId></ArticleIdList></Reference><Reference><Citation>Zuin M., Barco S., Giannakoulas G., Engelen M.M., Hobohm L., Valerio L., Vandenbriele C., Verhamme P., Vanassche T., Konstantinides S.V. Risk of venous thromboembolic events after COVID-19 infection: A systematic review and meta-analysis. J. Thromb. Thrombolysis. 2023;55:490–498. doi: 10.1007/s11239-022-02766-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-022-02766-7</ArticleId><ArticleId IdType="pmc">PMC9845812</ArticleId><ArticleId IdType="pubmed">36652137</ArticleId></ArticleIdList></Reference><Reference><Citation>Iba T., Levy J.H., Connors J.M., Warkentin T.E., Thachil J., Levi M. The unique characteristics of COVID-19 coagulopathy. Crit. Care. 2020;24:360. doi: 10.1186/s13054-020-03077-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s13054-020-03077-0</ArticleId><ArticleId IdType="pmc">PMC7301352</ArticleId><ArticleId IdType="pubmed">32552865</ArticleId></ArticleIdList></Reference><Reference><Citation>Levi M., Thachil J., Iba T., Levy J.H. Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol. 2020;7:e438–e440. doi: 10.1016/S2352-3026(20)30145-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2352-3026(20)30145-9</ArticleId><ArticleId IdType="pmc">PMC7213964</ArticleId><ArticleId IdType="pubmed">32407672</ArticleId></ArticleIdList></Reference><Reference><Citation>Lippi G., Plebani M., Henry B.M. Thrombocytopenia is associated with severe coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin. Chim. Acta Int. J. Clin. Chem. 2020;506:145–148. doi: 10.1016/j.cca.2020.03.022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cca.2020.03.022</ArticleId><ArticleId IdType="pmc">PMC7102663</ArticleId><ArticleId IdType="pubmed">32178975</ArticleId></ArticleIdList></Reference><Reference><Citation>Thachil J. What do monitoring platelet counts in COVID-19 teach us? J. Thromb. Haemost. JTH. 2020;18:2071–2072. doi: 10.1111/jth.14879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14879</ArticleId><ArticleId IdType="pmc">PMC7267313</ArticleId><ArticleId IdType="pubmed">32344467</ArticleId></ArticleIdList></Reference><Reference><Citation>Welder D., Jeon-Slaughter H., Ashraf B., Choi S.H., Chen W., Ibrahim I., Bat T. Immature platelets as a biomarker for disease severity and mortality in COVID-19 patients. Br. J. Haematol. 2021;194:530–536. doi: 10.1111/bjh.17656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17656</ArticleId><ArticleId IdType="pmc">PMC8444912</ArticleId><ArticleId IdType="pubmed">34132393</ArticleId></ArticleIdList></Reference><Reference><Citation>Cohen A., Harari E., Yahud E., Cipok M., Bryk G., Lador N.K., Mann T., Mayo A., Lev E.I. Immature platelets in patients with COVID-19: Association with disease severity. J. Thromb. Thrombolysis. 2021;52:708–714. doi: 10.1007/s11239-021-02560-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-021-02560-x</ArticleId><ArticleId IdType="pmc">PMC8437739</ArticleId><ArticleId IdType="pubmed">34519015</ArticleId></ArticleIdList></Reference><Reference><Citation>Campo G., Contoli M., Fogagnolo A., Vieceli Dalla Sega F., Zucchetti O., Ronzoni L., Verri M., Fortini F., Pavasini R., Morandi L., et al. Over time relationship between platelet reactivity, myocardial injury and mortality in patients with SARS-CoV-2-associated respiratory failure. Platelets. 2021;32:560–567. doi: 10.1080/09537104.2020.1852543.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09537104.2020.1852543</ArticleId><ArticleId IdType="pmc">PMC7754923</ArticleId><ArticleId IdType="pubmed">33270471</ArticleId></ArticleIdList></Reference><Reference><Citation>Zaid Y., Puhm F., Allaeys I., Naya A., Oudghiri M., Khalki L., Limami Y., Zaid N., Sadki K., Ben El Haj R., et al. Platelets can associate with SARS-CoV-2 rna and are hyperactivated in COVID-19. Circ. Res. 2020;127:1404–1418. doi: 10.1161/CIRCRESAHA.120.317703.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.120.317703</ArticleId><ArticleId IdType="pmc">PMC7641188</ArticleId><ArticleId IdType="pubmed">32938299</ArticleId></ArticleIdList></Reference><Reference><Citation>Canzano P., Brambilla M., Porro B., Cosentino N., Tortorici E., Vicini S., Poggio P., Cascella A., Pengo M.F., Veglia F., et al. Platelet and endothelial activation as potential mechanisms behind the thrombotic complications of COVID-19 patients. JACC Basic. Transl. Sci. 2021;6:202–218. doi: 10.1016/j.jacbts.2020.12.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacbts.2020.12.009</ArticleId><ArticleId IdType="pmc">PMC7904280</ArticleId><ArticleId IdType="pubmed">33649738</ArticleId></ArticleIdList></Reference><Reference><Citation>Petito E., Falcinelli E., Paliani U., Cesari E., Vaudo G., Sebastiano M., Cerotto V., Guglielmini G., Gori F., Malvestiti M., et al. Association of neutrophil activation, more than platelet activation, with thrombotic complications in coronavirus disease 2019. J. Infect. Dis. 2021;223:933–944. doi: 10.1093/infdis/jiaa756.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/infdis/jiaa756</ArticleId><ArticleId IdType="pmc">PMC7798977</ArticleId><ArticleId IdType="pubmed">33280009</ArticleId></ArticleIdList></Reference><Reference><Citation>Hottz E.D., Azevedo-Quintanilha I.G., Palhinha L., Teixeira L., Barreto E.A., Pao C.R.R., Righy C., Franco S., Souza T.M.L., Kurtz P., et al. Platelet activation and platelet-monocyte aggregate formation trigger tissue factor expression in patients with severe COVID-19. Blood. 2020;136:1330–1341. doi: 10.1182/blood.2020007252.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020007252</ArticleId><ArticleId IdType="pmc">PMC7483437</ArticleId><ArticleId IdType="pubmed">32678428</ArticleId></ArticleIdList></Reference><Reference><Citation>Manne B.K., Denorme F., Middleton E.A., Portier I., Rowley J.W., Stubben C., Petrey A.C., Tolley N.D., Guo L., Cody M., et al. Platelet gene expression and function in patients with COVID-19. Blood. 2020;136:1317–1329. doi: 10.1182/blood.2020007214.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.2020007214</ArticleId><ArticleId IdType="pmc">PMC7483430</ArticleId><ArticleId IdType="pubmed">32573711</ArticleId></ArticleIdList></Reference><Reference><Citation>Gurbel P.A., Bliden K.P., Rout A., Rapista N., Walia N., Chaudhary R., Ens G., Traianova M., Barnes J.S., Tantry U.S. Bedside thromboelastography to rapidly assess the pharmacodynamic response of anticoagulants and aspirin in COVID-19: Evidence of inadequate therapy in a predominantly minority population. J. Thromb. Thrombolysis. 2021;51:902–904. doi: 10.1007/s11239-021-02435-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-021-02435-1</ArticleId><ArticleId IdType="pmc">PMC8024672</ArticleId><ArticleId IdType="pubmed">33826054</ArticleId></ArticleIdList></Reference><Reference><Citation>Tantry U.S., Bliden K.P., Cho A., Walia N., Dahlen J.R., Ens G., Traianova M., Jerjian C., Usman A., Gurbel P.A. First experience addressing the prognostic utility of novel urinary biomarkers in patients with COVID-19. Open Forum Infect. Dis. 2021;8:ofab274. doi: 10.1093/ofid/ofab274.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ofid/ofab274</ArticleId><ArticleId IdType="pmc">PMC8194603</ArticleId><ArticleId IdType="pubmed">34250193</ArticleId></ArticleIdList></Reference><Reference><Citation>Taus F., Salvagno G., Cane S., Fava C., Mazzaferri F., Carrara E., Petrova V., Barouni R.M., Dima F., Dalbeni A., et al. Platelets promote thromboinflammation in SARS-CoV-2 pneumonia. Arterioscler. Thromb. Vasc. Biol. 2020;40:2975–2989. doi: 10.1161/ATVBAHA.120.315175.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.120.315175</ArticleId><ArticleId IdType="pmc">PMC7682791</ArticleId><ArticleId IdType="pubmed">33052054</ArticleId></ArticleIdList></Reference><Reference><Citation>McCafferty C., Van Den Helm S., Letunica N., Attard C., Karlaftis V., Cai T., Praporski S., Swaney E., Burgner D., Neeland M., et al. Increased platelet activation in SARS-CoV-2 infected non-hospitalised children and adults, and their household contacts. Br. J. Haematol. 2021;195:90–94. doi: 10.1111/bjh.17629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.17629</ArticleId><ArticleId IdType="pmc">PMC8239564</ArticleId><ArticleId IdType="pubmed">34101171</ArticleId></ArticleIdList></Reference><Reference><Citation>Fogarty H., Townsend L., Ni Cheallaigh C., Bergin C., Martin-Loeches I., Browne P., Bacon C.L., Gaule R., Gillett A., Byrne M., et al. COVID19 coagulopathy in caucasian patients. Br. J. Haematol. 2020;189:1044–1049. doi: 10.1111/bjh.16749.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.16749</ArticleId><ArticleId IdType="pmc">PMC7264579</ArticleId><ArticleId IdType="pubmed">32330308</ArticleId></ArticleIdList></Reference><Reference><Citation>Ranucci M., Sitzia C., Baryshnikova E., Di Dedda U., Cardani R., Martelli F., Corsi Romanelli M. COVID-19-associated coagulopathy: Biomarkers of thrombin generation and fibrinolysis leading the outcome. J. Clin. Med. 2020;9:3487. doi: 10.3390/jcm9113487.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/jcm9113487</ArticleId><ArticleId IdType="pmc">PMC7692774</ArticleId><ArticleId IdType="pubmed">33126772</ArticleId></ArticleIdList></Reference><Reference><Citation>de la Morena-Barrio M.E., Bravo-Perez C., Minano A., de la Morena-Barrio B., Fernandez-Perez M.P., Bernal E., Gomez-Verdu J.M., Herranz M.T., Vicente V., Corral J., et al. Prognostic value of thrombin generation parameters in hospitalized COVID-19 patients. Sci. Rep. 2021;11:7792. doi: 10.1038/s41598-021-85906-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-85906-y</ArticleId><ArticleId IdType="pmc">PMC8032761</ArticleId><ArticleId IdType="pubmed">33833254</ArticleId></ArticleIdList></Reference><Reference><Citation>Campello E., Bulato C., Spiezia L., Boscolo A., Poletto F., Cola M., Gavasso S., Simion C., Radu C.M., Cattelan A., et al. Thrombin generation in patients with COVID-19 with and without thromboprophylaxis. Clin. Chem. Lab. Med. 2021;59:1323–1330. doi: 10.1515/cclm-2021-0108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/cclm-2021-0108</ArticleId><ArticleId IdType="pubmed">33544518</ArticleId></ArticleIdList></Reference><Reference><Citation>Al-Samkari H., Song F., Van Cott E.M., Kuter D.J., Rosovsky R. Evaluation of the prothrombin fragment 1.2 in patients with coronavirus disease 2019 (COVID-19) Am. J. Hematol. 2020;95:1479–1485. doi: 10.1002/ajh.25962.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/ajh.25962</ArticleId><ArticleId IdType="pmc">PMC7436379</ArticleId><ArticleId IdType="pubmed">32780525</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger J.S., Kunichoff D., Adhikari S., Ahuja T., Amoroso N., Aphinyanaphongs Y., Cao M., Goldenberg R., Hindenburg A., Horowitz J., et al. Prevalence and outcomes of d-dimer elevation in hospitalized patients with COVID-19. Arterioscler. Thromb. Vasc. Biol. 2020;40:2539–2547. doi: 10.1161/ATVBAHA.120.314872.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.120.314872</ArticleId><ArticleId IdType="pmc">PMC7505147</ArticleId><ArticleId IdType="pubmed">32840379</ArticleId></ArticleIdList></Reference><Reference><Citation>Wright F.L., Vogler T.O., Moore E.E., Moore H.B., Wohlauer M.V., Urban S., Nydam T.L., Moore P.K., McIntyre R.C., Jr. Fibrinolysis shutdown correlation with thromboembolic events in severe COVID-19 infection. J. Am. Coll. Surg. 2020;231:193–203 e191. doi: 10.1016/j.jamcollsurg.2020.05.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jamcollsurg.2020.05.007</ArticleId><ArticleId IdType="pmc">PMC7227511</ArticleId><ArticleId IdType="pubmed">32422349</ArticleId></ArticleIdList></Reference><Reference><Citation>Ibanez C., Perdomo J., Calvo A., Ferrando C., Reverter J.C., Tassies D., Blasi A. High d dimers and low global fibrinolysis coexist in COVID19 patients: What is going on in there? J. Thromb. Thrombolysis. 2021;51:308–312. doi: 10.1007/s11239-020-02226-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-020-02226-0</ArticleId><ArticleId IdType="pmc">PMC7363162</ArticleId><ArticleId IdType="pubmed">32671609</ArticleId></ArticleIdList></Reference><Reference><Citation>Bachler M., Bosch J., Sturzel D.P., Hell T., Giebl A., Strohle M., Klein S.J., Schafer V., Lehner G.F., Joannidis M., et al. Impaired fibrinolysis in critically ill COVID-19 patients. Br. J. Anaesth. 2021;126:590–598. doi: 10.1016/j.bja.2020.12.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bja.2020.12.010</ArticleId><ArticleId IdType="pmc">PMC7833514</ArticleId><ArticleId IdType="pubmed">33422287</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiss E., Roux O., Moyer J.D., Paugam-Burtz C., Boudaoud L., Ajzenberg N., Faille D., de Raucourt E. Fibrinolysis resistance: A potential mechanism underlying COVID-19 coagulopathy. Thromb. Haemost. 2020;120:1343–1345. doi: 10.1055/s-0040-1713637.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0040-1713637</ArticleId><ArticleId IdType="pubmed">32645725</ArticleId></ArticleIdList></Reference><Reference><Citation>Heinz C., Miesbach W., Herrmann E., Sonntagbauer M., Raimann F.J., Zacharowski K., Weber C.F., Adam E.H. Greater fibrinolysis resistance but no greater platelet aggregation in critically ill COVID-19 patients. Anesthesiology. 2021;134:457–467. doi: 10.1097/ALN.0000000000003685.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/ALN.0000000000003685</ArticleId><ArticleId IdType="pmc">PMC7864605</ArticleId><ArticleId IdType="pubmed">33417674</ArticleId></ArticleIdList></Reference><Reference><Citation>Nougier C., Benoit R., Simon M., Desmurs-Clavel H., Marcotte G., Argaud L., David J.S., Bonnet A., Negrier C., Dargaud Y. Hypofibrinolytic state and high thrombin generation may play a major role in SARS-CoV2 associated thrombosis. J. Thromb. Haemost. JTH. 2020;18:2215–2219. doi: 10.1111/jth.15016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15016</ArticleId><ArticleId IdType="pmc">PMC7405476</ArticleId><ArticleId IdType="pubmed">32668058</ArticleId></ArticleIdList></Reference><Reference><Citation>Baycan O.F., Barman H.A., Bolen F., Atici A., Erman H., Korkmaz R., Calim M., Atalay B., Aciksari G., Cekmen M.B., et al. Plasminogen activator inhibitor-1 levels as an indicator of severity and mortality for COVID-19. North. Clin. Istanb. 2023;10:1–9. doi: 10.14744/nci.2022.09076.</Citation><ArticleIdList><ArticleId IdType="doi">10.14744/nci.2022.09076</ArticleId><ArticleId IdType="pmc">PMC9996651</ArticleId><ArticleId IdType="pubmed">36910430</ArticleId></ArticleIdList></Reference><Reference><Citation>Aksakal A., Kilic A.F., Afsin D.E., Baygutalp N.K., Kerget B. Evaluation of the relationship between tafi level and prognosis in COVID-19 patients. Eur. Rev. Med. Pharmacol. Sci. 2023;27:4764–4771. doi: 10.26355/eurrev_202305_32487.</Citation><ArticleIdList><ArticleId IdType="doi">10.26355/eurrev_202305_32487</ArticleId><ArticleId IdType="pubmed">37259759</ArticleId></ArticleIdList></Reference><Reference><Citation>Correa T.D., Cordioli R.L., Campos Guerra J.C., Caldin da Silva B., Dos Reis Rodrigues R., de Souza G.M., Midega T.D., Campos N.S., Carneiro B.V., Campos F.N.D., et al. Coagulation profile of COVID-19 patients admitted to the icu: An exploratory study. PLoS ONE. 2020;15:e0243604. doi: 10.1371/journal.pone.0243604.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0243604</ArticleId><ArticleId IdType="pmc">PMC7737963</ArticleId><ArticleId IdType="pubmed">33320874</ArticleId></ArticleIdList></Reference><Reference><Citation>Nielsen N.D., Rollins-Raval M.A., Raval J.S., Thachil J. Is it hyperfibrinolysis or fibrinolytic shutdown in severe COVID-19? Thromb. Res. 2022;210:1–3. doi: 10.1016/j.thromres.2021.12.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2021.12.012</ArticleId><ArticleId IdType="pmc">PMC8686202</ArticleId><ArticleId IdType="pubmed">34953317</ArticleId></ArticleIdList></Reference><Reference><Citation>Medcalf R.L., Keragala C.B., Myles P.S. Fibrinolysis and COVID-19: A plasmin paradox. J. Thromb. Haemost. JTH. 2020;18:2118–2122. doi: 10.1111/jth.14960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14960</ArticleId><ArticleId IdType="pmc">PMC7323332</ArticleId><ArticleId IdType="pubmed">32543119</ArticleId></ArticleIdList></Reference><Reference><Citation>Nossent E.J., Schuurman A.R., Reijnders T.D.Y., Saris A., Jongerius I., Blok S.G., de Vries H., Duitman J., Vonk Noordegraaf A., Meijboom L.J., et al. Pulmonary procoagulant and innate immune responses in critically ill COVID-19 patients. Front. Immunol. 2021;12:664209. doi: 10.3389/fimmu.2021.664209.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.664209</ArticleId><ArticleId IdType="pmc">PMC8160522</ArticleId><ArticleId IdType="pubmed">34054832</ArticleId></ArticleIdList></Reference><Reference><Citation>Yun S.H., Sim E.H., Goh R.Y., Park J.I., Han J.Y. Platelet activation: The mechanisms and potential biomarkers. BioMed Res. Int. 2016;2016:9060143. doi: 10.1155/2016/9060143.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2016/9060143</ArticleId><ArticleId IdType="pmc">PMC4925965</ArticleId><ArticleId IdType="pubmed">27403440</ArticleId></ArticleIdList></Reference><Reference><Citation>Marco A., Marco P. Von willebrand factor and adamts13 activity as clinical severity markers in patients with COVID-19. J. Thromb. Thrombolysis. 2021;52:497–503. doi: 10.1007/s11239-021-02457-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s11239-021-02457-9</ArticleId><ArticleId IdType="pmc">PMC8053027</ArticleId><ArticleId IdType="pubmed">33866481</ArticleId></ArticleIdList></Reference><Reference><Citation>Rodriguez Rodriguez M., Castro Quismondo N., Zafra Torres D., Gil Alos D., Ayala R., Martinez-Lopez J. Increased von willebrand factor antigen and low adamts13 activity are related to poor prognosis in COVID-19 patients. Int. J. Lab. Hematol. 2021;43:O152–O155. doi: 10.1111/ijlh.13476.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/ijlh.13476</ArticleId><ArticleId IdType="pmc">PMC8014254</ArticleId><ArticleId IdType="pubmed">33502080</ArticleId></ArticleIdList></Reference><Reference><Citation>Karabag Yilmaz E., Cebi M.N., Karahan I., Saygili S., Gulmez R., Demirgan E.B., Durak C., Aygun F., Ozaltin F., Caliskan S., et al. COVID-19 associated thrombotic microangiopathy. Nephrology. 2023;28:557–560. doi: 10.1111/nep.14225.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/nep.14225</ArticleId><ArticleId IdType="pubmed">37485596</ArticleId></ArticleIdList></Reference><Reference><Citation>Malgaj Vrecko M., Veceric-Haler Z. Coronavirus disease 2019-associated thrombotic microangiopathy. J. Hematol. 2022;11:148–153. doi: 10.14740/jh1019.</Citation><ArticleIdList><ArticleId IdType="doi">10.14740/jh1019</ArticleId><ArticleId IdType="pmc">PMC9451549</ArticleId><ArticleId IdType="pubmed">36118551</ArticleId></ArticleIdList></Reference><Reference><Citation>Schmid E.F., Binder K., Grell M., Scheurich P., Pfizenmaier K. Both tumor necrosis factor receptors, tnfr60 and tnfr80, are involved in signaling endothelial tissue factor expression by juxtacrine tumor necrosis factor alpha. Blood. 1995;86:1836–1841. doi: 10.1182/blood.V86.5.1836.bloodjournal8651836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V86.5.1836.bloodjournal8651836</ArticleId><ArticleId IdType="pubmed">7544644</ArticleId></ArticleIdList></Reference><Reference><Citation>Pradier O., Gerard C., Delvaux A., Lybin M., Abramowicz D., Capel P., Velu T., Goldman M. Interleukin-10 inhibits the induction of monocyte procoagulant activity by bacterial lipopolysaccharide. Eur. J. Immunol. 1993;23:2700–2703. doi: 10.1002/eji.1830231048.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.1830231048</ArticleId><ArticleId IdType="pubmed">8405069</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramani M., Khechai F., Ollivier V., Ternisien C., Bridey F., Hakim J., de Prost D. Interleukin-10 and pentoxifylline inhibit c-reactive protein-induced tissue factor gene expression in peripheral human blood monocytes. FEBS Lett. 1994;356:86–88. doi: 10.1016/0014-5793(94)01236-9.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0014-5793(94)01236-9</ArticleId><ArticleId IdType="pubmed">7988727</ArticleId></ArticleIdList></Reference><Reference><Citation>Pajkrt D., van der Poll T., Levi M., Cutler D.L., Affrime M.B., van den Ende A., ten Cate J.W., van Deventer S.J. Interleukin-10 inhibits activation of coagulation and fibrinolysis during human endotoxemia. Blood. 1997;89:2701–2705. doi: 10.1182/blood.V89.8.2701.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V89.8.2701</ArticleId><ArticleId IdType="pubmed">9108387</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Poll T., Jansen P.M., Montegut W.J., Braxton C.C., Calvano S.E., Stackpole S.A., Smith S.R., Swanson S.W., Hack C.E., Lowry S.F., et al. Effects of il-10 on systemic inflammatory responses during sublethal primate endotoxemia. J. Immunol. 1997;158:1971–1975. doi: 10.4049/jimmunol.158.4.1971.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.158.4.1971</ArticleId><ArticleId IdType="pubmed">9029140</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamamoto K., Shimokawa T., Kojima T., Loskutoff D.J., Saito H. Regulation of murine protein c gene expression in vivo: Effects of tumor necrosis factor-alpha, interleukin-1, and transforming growth factor-beta. Thromb. Haemost. 1999;82:1297–1301.</Citation><ArticleIdList><ArticleId IdType="pubmed">10544917</ArticleId></ArticleIdList></Reference><Reference><Citation>Healy A.M., Gelehrter T.D. Induction of plasminogen activator inhibitor-1 in hepg2 human hepatoma cells by mediators of the acute phase response. J. Biol. Chem. 1994;269:19095–19100. doi: 10.1016/S0021-9258(17)32279-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(17)32279-2</ArticleId><ArticleId IdType="pubmed">8034668</ArticleId></ArticleIdList></Reference><Reference><Citation>de Boer J.P., Abbink J.J., Brouwer M.C., Meijer C., Roem D., Voorn G.P., Lambers J.W., van Mourik J.A., Hack C.E. Pai-1 synthesis in the human hepatoma cell line hepg2 is increased by cytokines--evidence that the liver contributes to acute phase behaviour of pai-1. Thromb. Haemost. 1991;65:181–185.</Citation><ArticleIdList><ArticleId IdType="pubmed">1711245</ArticleId></ArticleIdList></Reference><Reference><Citation>Busso N., Nicodeme E., Chesne C., Guillouzo A., Belin D., Hyafil F. Urokinase and type i plasminogen activator inhibitor production by normal human hepatocytes: Modulation by inflammatory agents. Hepatology. 1994;20:186–190. doi: 10.1016/0270-9139(94)90152-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0270-9139(94)90152-x</ArticleId><ArticleId IdType="pubmed">8020888</ArticleId></ArticleIdList></Reference><Reference><Citation>Seki T., Gelehrter T.D. Interleukin-1 induction of type-1 plasminogen activator inhibitor (pai-1) gene expression in the mouse hepatocyte line, aml 12. J. Cell. Physiol. 1996;168:648–656. doi: 10.1002/(SICI)1097-4652(199609)168:3&lt;648::AID-JCP17&gt;3.0.CO;2-V.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/(SICI)1097-4652(199609)168:3&lt;648::AID-JCP17&gt;3.0.CO;2-V</ArticleId><ArticleId IdType="pubmed">8816919</ArticleId></ArticleIdList></Reference><Reference><Citation>van der Poll T., Levi M., van Deventer S.J., ten Cate H., Haagmans B.L., Biemond B.J., Buller H.R., Hack C.E., ten Cate J.W. Differential effects of anti-tumor necrosis factor monoclonal antibodies on systemic inflammatory responses in experimental endotoxemia in chimpanzees. Blood. 1994;83:446–451. doi: 10.1182/blood.V83.2.446.446.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V83.2.446.446</ArticleId><ArticleId IdType="pubmed">8286742</ArticleId></ArticleIdList></Reference><Reference><Citation>DeLa Cadena R.A., Majluf-Cruz A., Stadnicki A., Tropea M., Reda D., Agosti J.M., Colman R.W., Suffredini A.F. Recombinant tumor necrosis factor receptor p75 fusion protein (tnfr:Fc) alters endotoxin-induced activation of the kinin, fibrinolytic, and coagulation systems in normal humans. Thromb. Haemost. 1998;80:114–118.</Citation><ArticleIdList><ArticleId IdType="pubmed">9684796</ArticleId></ArticleIdList></Reference><Reference><Citation>Jansen P.M., Boermeester M.A., Fischer E., de Jong I.W., van der Poll T., Moldawer L.L., Hack C.E., Lowry S.F. Contribution of interleukin-1 to activation of coagulation and fibrinolysis, neutrophil degranulation, and the release of secretory-type phospholipase a2 in sepsis: Studies in nonhuman primates after interleukin-1 alpha administration and during lethal bacteremia. Blood. 1995;86:1027–1034.</Citation><ArticleIdList><ArticleId IdType="pubmed">7620156</ArticleId></ArticleIdList></Reference><Reference><Citation>Baars J.W., de Boer J.P., Wagstaff J., Roem D., Eerenberg-Belmer A.J., Nauta J., Pinedo H.M., Hack C.E. Interleukin-2 induces activation of coagulation and fibrinolysis: Resemblance to the changes seen during experimental endotoxaemia. Br. J. Haematol. 1992;82:295–301. doi: 10.1111/j.1365-2141.1992.tb06421.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2141.1992.tb06421.x</ArticleId><ArticleId IdType="pubmed">1419810</ArticleId></ArticleIdList></Reference><Reference><Citation>Lauw F.N., Dekkers P.E., te Velde A.A., Speelman P., Levi M., Kurimoto M., Hack C.E., van Deventer S.J., van der Poll T. Interleukin-12 induces sustained activation of multiple host inflammatory mediator systems in chimpanzees. J. Infect. Dis. 1999;179:646–652. doi: 10.1086/314636.</Citation><ArticleIdList><ArticleId IdType="doi">10.1086/314636</ArticleId><ArticleId IdType="pubmed">9952371</ArticleId></ArticleIdList></Reference><Reference><Citation>Stouthard J.M., Levi M., Hack C.E., Veenhof C.H., Romijn H.A., Sauerwein H.P., van der Poll T. Interleukin-6 stimulates coagulation, not fibrinolysis, in humans. Thromb. Haemost. 1996;76:738–742. doi: 10.1055/s-0038-1650653.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1650653</ArticleId><ArticleId IdType="pubmed">8950783</ArticleId></ArticleIdList></Reference><Reference><Citation>Jones A., Geczy C.L. Thrombin and factor xa enhance the production of interleukin-1. Immunology. 1990;71:236–241.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1384310</ArticleId><ArticleId IdType="pubmed">2228024</ArticleId></ArticleIdList></Reference><Reference><Citation>Sower L.E., Froelich C.J., Carney D.H., Fenton J.W., 2nd, Klimpel G.R. Thrombin induces il-6 production in fibroblasts and epithelial cells. Evidence for the involvement of the seven-transmembrane domain (std) receptor for alpha-thrombin. J. Immunol. 1995;155:895–901. doi: 10.4049/jimmunol.155.2.895.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.155.2.895</ArticleId><ArticleId IdType="pubmed">7608566</ArticleId></ArticleIdList></Reference><Reference><Citation>Qi J., Goralnick S., Kreutzer D.L. Fibrin regulation of interleukin-8 gene expression in human vascular endothelial cells. Blood. 1997;90:3595–3602. doi: 10.1182/blood.V90.9.3595.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V90.9.3595</ArticleId><ArticleId IdType="pubmed">9345043</ArticleId></ArticleIdList></Reference><Reference><Citation>Senden N.H., Jeunhomme T.M., Heemskerk J.W., Wagenvoord R., van’t Veer C., Hemker H.C., Buurman W.A. Factor xa induces cytokine production and expression of adhesion molecules by human umbilical vein endothelial cells. J. Immunol. 1998;161:4318–4324. doi: 10.4049/jimmunol.161.8.4318.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.161.8.4318</ArticleId><ArticleId IdType="pubmed">9780208</ArticleId></ArticleIdList></Reference><Reference><Citation>Ueno A., Murakami K., Yamanouchi K., Watanabe M., Kondo T. Thrombin stimulates production of interleukin-8 in human umbilical vein endothelial cells. Immunology. 1996;88:76–81. doi: 10.1046/j.1365-2567.1996.d01-635.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1046/j.1365-2567.1996.d01-635.x</ArticleId><ArticleId IdType="pmc">PMC1456474</ArticleId><ArticleId IdType="pubmed">8707354</ArticleId></ArticleIdList></Reference><Reference><Citation>Anrather D., Millan M.T., Palmetshofer A., Robson S.C., Geczy C., Ritchie A.J., Bach F.H., Ewenstein B.M. Thrombin activates nuclear factor-kappab and potentiates endothelial cell activation by tnf. J. Immunol. 1997;159:5620–5628. doi: 10.4049/jimmunol.159.11.5620.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.159.11.5620</ArticleId><ArticleId IdType="pubmed">9548505</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson K., Aarden L., Choi Y., De Groot E., Creasey A. The proinflammatory cytokine response to coagulation and endotoxin in whole blood. Blood. 1996;87:5051–5060. doi: 10.1182/blood.V87.12.5051.bloodjournal87125051.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V87.12.5051.bloodjournal87125051</ArticleId><ArticleId IdType="pubmed">8652818</ArticleId></ArticleIdList></Reference><Reference><Citation>Johnson K., Choi Y., DeGroot E., Samuels I., Creasey A., Aarden L. Potential mechanisms for a proinflammatory vascular cytokine response to coagulation activation. J. Immunol. 1998;160:5130–5135. doi: 10.4049/jimmunol.160.10.5130.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.160.10.5130</ArticleId><ArticleId IdType="pubmed">9590265</ArticleId></ArticleIdList></Reference><Reference><Citation>Hancock W.W., Tsuchida A., Hau H., Thomson N.M., Salem H.H. The anticoagulants protein c and protein s display potent antiinflammatory and immunosuppressive effects relevant to transplant biology and therapy. Transplant. Proc. 1992;24:2302–2303.</Citation><ArticleIdList><ArticleId IdType="pubmed">1413069</ArticleId></ArticleIdList></Reference><Reference><Citation>Grey S.T., Tsuchida A., Hau H., Orthner C.L., Salem H.H., Hancock W.W. Selective inhibitory effects of the anticoagulant activated protein c on the responses of human mononuclear phagocytes to lps, ifn-gamma, or phorbol ester. J. Immunol. 1994;153:3664–3672. doi: 10.4049/jimmunol.153.8.3664.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.153.8.3664</ArticleId><ArticleId IdType="pubmed">7523500</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami K., Okajima K., Uchiba M., Johno M., Nakagaki T., Okabe H., Takatsuki K. Activated protein c attenuates endotoxin-induced pulmonary vascular injury by inhibiting activated leukocytes in rats. Blood. 1996;87:642–647. doi: 10.1182/blood.V87.2.642.bloodjournal872642.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V87.2.642.bloodjournal872642</ArticleId><ArticleId IdType="pubmed">8555486</ArticleId></ArticleIdList></Reference><Reference><Citation>Hancock W.W., Bach F.H. Immunobiology and therapeutic applications of protein c/protein s/thrombomodulin in human and experimental allotransplantation and xenotransplantation. Trends Cardiovasc. Med. 1997;7:174–183. doi: 10.1016/S1050-1738(97)00032-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1050-1738(97)00032-7</ArticleId><ArticleId IdType="pubmed">21235882</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor F.B., Jr., Stearns-Kurosawa D.J., Kurosawa S., Ferrell G., Chang A.C., Laszik Z., Kosanke S., Peer G., Esmon C.T. The endothelial cell protein c receptor aids in host defense against Escherichia coli sepsis. Blood. 2000;95:1680–1686. doi: 10.1182/blood.V95.5.1680.005k33_1680_1686.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V95.5.1680.005k33_1680_1686</ArticleId><ArticleId IdType="pubmed">10688824</ArticleId></ArticleIdList></Reference><Reference><Citation>Robson S.C., Saunders R., Kirsch R.E. Monocyte-macrophage release of il-1 is inhibited by type-1 plasminogen activator inhibitors. J. Clin. Lab. Immunol. 1990;33:83–90.</Citation><ArticleIdList><ArticleId IdType="pubmed">1967070</ArticleId></ArticleIdList></Reference><Reference><Citation>Sitrin R.G., Shollenberger S.B., Strieter R.M., Gyetko M.R. Endogenously produced urokinase amplifies tumor necrosis factor-alpha secretion by thp-1 mononuclear phagocytes. J. Leukoc. Biol. 1996;59:302–311. doi: 10.1002/jlb.59.2.302.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jlb.59.2.302</ArticleId><ArticleId IdType="pubmed">8604004</ArticleId></ArticleIdList></Reference><Reference><Citation>Parmely M.J., Sterner K.E., Gale A., Zhou W.W. U937 cells can utilize plasminogen activator to regulate human interferon-gamma. J. Interferon Res. 1993;13:397–406. doi: 10.1089/jir.1993.13.397.</Citation><ArticleIdList><ArticleId IdType="doi">10.1089/jir.1993.13.397</ArticleId><ArticleId IdType="pubmed">8151133</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor F.B., Chang A.C., Peer G., Li A., Ezban M., Hedner U. Active site inhibited factor viia (degr viia) attenuates the coagulant and interleukin-6 and -8, but not tumor necrosis factor, responses of the baboon to ld100 Escherichia coli. Blood. 1998;91:1609–1615. doi: 10.1182/blood.V91.5.1609.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V91.5.1609</ArticleId><ArticleId IdType="pubmed">9473226</ArticleId></ArticleIdList></Reference><Reference><Citation>Carr C., Bild G.S., Chang A.C., Peer G.T., Palmier M.O., Frazier R.B., Gustafson M.E., Wun T.C., Creasey A.A., Hinshaw L.B., et al. Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Circ. Shock. 1994;44:126–137.</Citation><ArticleIdList><ArticleId IdType="pubmed">7600636</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor F.B., Jr., Chang A., Esmon C.T., D’Angelo A., Vigano-D’Angelo S., Blick K.E. Protein c prevents the coagulopathic and lethal effects of Escherichia coli infusion in the baboon. J. Clin. Investig. 1987;79:918–925. doi: 10.1172/JCI112902.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI112902</ArticleId><ArticleId IdType="pmc">PMC424237</ArticleId><ArticleId IdType="pubmed">3102560</ArticleId></ArticleIdList></Reference><Reference><Citation>Taylor F., Chang A., Ferrell G., Mather T., Catlett R., Blick K., Esmon C.T. C4b-binding protein exacerbates the host response to Escherichia coli. Blood. 1991;78:357–363. doi: 10.1182/blood.V78.2.357.357.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V78.2.357.357</ArticleId><ArticleId IdType="pubmed">1829967</ArticleId></ArticleIdList></Reference><Reference><Citation>Creasey A.A., Chang A.C., Feigen L., Wun T.C., Taylor F.B., Jr., Hinshaw L.B. Tissue factor pathway inhibitor reduces mortality from Escherichia coli septic shock. J. Clin. Investig. 1993;91:2850–2860. doi: 10.1172/JCI116529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI116529</ArticleId><ArticleId IdType="pmc">PMC443354</ArticleId><ArticleId IdType="pubmed">8514893</ArticleId></ArticleIdList></Reference><Reference><Citation>Conway E.M. Complement-coagulation connections. Blood Coagul. Fibrinolysis Int. J. Haemost. Thromb. 2018;29:243–251. doi: 10.1097/MBC.0000000000000720.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/MBC.0000000000000720</ArticleId><ArticleId IdType="pubmed">29517503</ArticleId></ArticleIdList></Reference><Reference><Citation>Lim M.S., McRae S. COVID-19 and immunothrombosis: Pathophysiology and therapeutic implications. Crit. Rev. Oncol./Hematol. 2021;168:103529. doi: 10.1016/j.critrevonc.2021.103529.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.critrevonc.2021.103529</ArticleId><ArticleId IdType="pmc">PMC8596655</ArticleId><ArticleId IdType="pubmed">34800652</ArticleId></ArticleIdList></Reference><Reference><Citation>Chauhan A.J., Wiffen L.J., Brown T.P. COVID-19: A collision of complement, coagulation and inflammatory pathways. J. Thromb. Haemost. JTH. 2020;18:2110–2117. doi: 10.1111/jth.14981.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14981</ArticleId><ArticleId IdType="pmc">PMC7361520</ArticleId><ArticleId IdType="pubmed">32608159</ArticleId></ArticleIdList></Reference><Reference><Citation>Peerschke E.I., Valentino A., So R.J., Shulman S., Ravinder Thromboinflammation supports complement activation in cancer patients with COVID-19. Front. Immunol. 2021;12:716361. doi: 10.3389/fimmu.2021.716361.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.716361</ArticleId><ArticleId IdType="pmc">PMC8416543</ArticleId><ArticleId IdType="pubmed">34491250</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramlall V., Thangaraj P.M., Meydan C., Foox J., Butler D., Kim J., May B., De Freitas J.K., Glicksberg B.S., Mason C.E., et al. Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection. Nat. Med. 2020;26:1609–1615. doi: 10.1038/s41591-020-1021-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-020-1021-2</ArticleId><ArticleId IdType="pmc">PMC7809634</ArticleId><ArticleId IdType="pubmed">32747830</ArticleId></ArticleIdList></Reference><Reference><Citation>Montaño A., Marco A., López-Jaime F.J., Fernandez-Bello I., García-Candel F., Blanquer Blanquer M., Muñoz-Pérez M.I., Marco-Vera P. Thrombomodulin resistance may be involved in the prothrombotic state of COVID-19. Blood. 2022;140:2778–2779. doi: 10.1182/blood-2022-166296.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2022-166296</ArticleId></ArticleIdList></Reference><Reference><Citation>Yamazaki A., Nukui Y., Kameda T., Saito R., Koda Y., Ichimura N., Tohda S., Ohkawa R. Variation in presepsin and thrombomodulin levels for predicting COVID-19 mortality. Sci. Rep. 2023;13:21493. doi: 10.1038/s41598-023-48633-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-023-48633-0</ArticleId><ArticleId IdType="pmc">PMC10700539</ArticleId><ArticleId IdType="pubmed">38057335</ArticleId></ArticleIdList></Reference><Reference><Citation>Della-Morte D., Pacifici F., Ricordi C., Massoud R., Rovella V., Proietti S., Iozzo M., Lauro D., Bernardini S., Bonassi S., et al. Low level of plasminogen increases risk for mortality in COVID-19 patients. Cell Death Dis. 2021;12:773. doi: 10.1038/s41419-021-04070-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41419-021-04070-3</ArticleId><ArticleId IdType="pmc">PMC8340078</ArticleId><ArticleId IdType="pubmed">34354045</ArticleId></ArticleIdList></Reference><Reference><Citation>Busch M.H., Timmermans S., Nagy M., Visser M., Huckriede J., Aendekerk J.P., de Vries F., Potjewijd J., Jallah B., Ysermans R., et al. Neutrophils and contact activation of coagulation as potential drivers of COVID-19. Circulation. 2020;142:1787–1790. doi: 10.1161/CIRCULATIONAHA.120.050656.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.050656</ArticleId><ArticleId IdType="pmc">PMC7594534</ArticleId><ArticleId IdType="pubmed">32946302</ArticleId></ArticleIdList></Reference><Reference><Citation>Savitt A.G., Manimala S., White T., Fandaros M., Yin W., Duan H., Xu X., Geisbrecht B.V., Rubenstein D.A., Kaplan A.P., et al. SARS-CoV-2 exacerbates COVID-19 pathology through activation of the complement and kinin systems. Front. Immunol. 2021;12:767347. doi: 10.3389/fimmu.2021.767347.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.767347</ArticleId><ArticleId IdType="pmc">PMC8602850</ArticleId><ArticleId IdType="pubmed">34804054</ArticleId></ArticleIdList></Reference><Reference><Citation>Farndale R.W. Collagen-induced platelet activation. Blood Cells Mol. Dis. 2006;36:162–165. doi: 10.1016/j.bcmd.2005.12.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bcmd.2005.12.016</ArticleId><ArticleId IdType="pubmed">16464621</ArticleId></ArticleIdList></Reference><Reference><Citation>Bennett J.S., Berger B.W., Billings P.C. The structure and function of platelet integrins. J. Thromb. Haemost. JTH. 2009;7((Suppl. S1)):200–205. doi: 10.1111/j.1538-7836.2009.03378.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2009.03378.x</ArticleId><ArticleId IdType="pubmed">19630800</ArticleId></ArticleIdList></Reference><Reference><Citation>Jennings L.K. Role of platelets in atherothrombosis. Am. J. Cardiol. 2009;103:4A–10A. doi: 10.1016/j.amjcard.2008.11.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.amjcard.2008.11.017</ArticleId><ArticleId IdType="pubmed">19166707</ArticleId></ArticleIdList></Reference><Reference><Citation>Puri R.N., Colman R.W. Adp-induced platelet activation. Crit. Rev. Biochem. Mol. Biol. 1997;32:437–502. doi: 10.3109/10409239709082000.</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/10409239709082000</ArticleId><ArticleId IdType="pubmed">9444477</ArticleId></ArticleIdList></Reference><Reference><Citation>Martel C., Cointe S., Maurice P., Matar S., Ghitescu M., Theroux P., Bonnefoy A. Requirements for membrane attack complex formation and anaphylatoxins binding to collagen-activated platelets. PLoS ONE. 2011;6:e18812. doi: 10.1371/journal.pone.0018812.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0018812</ArticleId><ArticleId IdType="pmc">PMC3078139</ArticleId><ArticleId IdType="pubmed">21526204</ArticleId></ArticleIdList></Reference><Reference><Citation>Meuer S., Hugli T.E., Andreatta R.H., Hadding U., Bitter-Suermann D. Comparative study on biological activities of various anaphylatoxins (c4a, c3a, c5a). Investigations on their ability to induce platelet secretion. Inflammation. 1981;5:263–273. doi: 10.1007/BF00911092.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/BF00911092</ArticleId><ArticleId IdType="pubmed">6976935</ArticleId></ArticleIdList></Reference><Reference><Citation>Polley M.J., Nachman R.L. Human platelet activation by c3a and c3a des-arg. J. Exp. Med. 1983;158:603–615. doi: 10.1084/jem.158.2.603.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.158.2.603</ArticleId><ArticleId IdType="pmc">PMC2187348</ArticleId><ArticleId IdType="pubmed">6604123</ArticleId></ArticleIdList></Reference><Reference><Citation>Aiello S., Gastoldi S., Galbusera M., Ruggenenti P., Portalupi V., Rota S., Rubis N., Liguori L., Conti S., Tironi M., et al. C5a and c5ar1 are key drivers of microvascular platelet aggregation in clinical entities spanning from ahus to COVID-19. Blood Adv. 2022;6:866–881. doi: 10.1182/bloodadvances.2021005246.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/bloodadvances.2021005246</ArticleId><ArticleId IdType="pmc">PMC8945302</ArticleId><ArticleId IdType="pubmed">34852172</ArticleId></ArticleIdList></Reference><Reference><Citation>Sharda A., Flaumenhaft R. The life cycle of platelet granules. F1000Research. 2018;7:236. doi: 10.12688/f1000research.13283.1.</Citation><ArticleIdList><ArticleId IdType="doi">10.12688/f1000research.13283.1</ArticleId><ArticleId IdType="pmc">PMC5832915</ArticleId><ArticleId IdType="pubmed">29560259</ArticleId></ArticleIdList></Reference><Reference><Citation>Eriksson O., Mohlin C., Nilsson B., Ekdahl K.N. The human platelet as an innate immune cell: Interactions between activated platelets and the complement system. Front. Immunol. 2019;10:1590. doi: 10.3389/fimmu.2019.01590.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01590</ArticleId><ArticleId IdType="pmc">PMC6635567</ArticleId><ArticleId IdType="pubmed">31354729</ArticleId></ArticleIdList></Reference><Reference><Citation>Golebiewska E.M., Poole A.W. Platelet secretion: From haemostasis to wound healing and beyond. Blood Rev. 2015;29:153–162. doi: 10.1016/j.blre.2014.10.003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.blre.2014.10.003</ArticleId><ArticleId IdType="pmc">PMC4452143</ArticleId><ArticleId IdType="pubmed">25468720</ArticleId></ArticleIdList></Reference><Reference><Citation>Wu H., Denna T.H., Storkersen J.N., Gerriets V.A. Beyond a neurotransmitter: The role of serotonin in inflammation and immunity. Pharmacol. Res. 2019;140:100–114. doi: 10.1016/j.phrs.2018.06.015.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.phrs.2018.06.015</ArticleId><ArticleId IdType="pubmed">29953943</ArticleId></ArticleIdList></Reference><Reference><Citation>Branco A., Yoshikawa F.S.Y., Pietrobon A.J., Sato M.N. Role of histamine in modulating the immune response and inflammation. Mediat. Inflamm. 2018;2018:9524075. doi: 10.1155/2018/9524075.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2018/9524075</ArticleId><ArticleId IdType="pmc">PMC6129797</ArticleId><ArticleId IdType="pubmed">30224900</ArticleId></ArticleIdList></Reference><Reference><Citation>Speth C., Rambach G., Wurzner R., Lass-Florl C., Kozarcanin H., Hamad O.A., Nilsson B., Ekdahl K.N. Complement and platelets: Mutual interference in the immune network. Mol. Immunol. 2015;67:108–118. doi: 10.1016/j.molimm.2015.03.244.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2015.03.244</ArticleId><ArticleId IdType="pubmed">25886718</ArticleId></ArticleIdList></Reference><Reference><Citation>Del Conde I., Cruz M.A., Zhang H., Lopez J.A., Afshar-Kharghan V. Platelet activation leads to activation and propagation of the complement system. J. Exp. Med. 2005;201:871–879. doi: 10.1084/jem.20041497.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20041497</ArticleId><ArticleId IdType="pmc">PMC2213112</ArticleId><ArticleId IdType="pubmed">15781579</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin W., Ghebrehiwet B., Weksler B., Peerschke E.I. Classical pathway complement activation on human endothelial cells. Mol. Immunol. 2007;44:2228–2234. doi: 10.1016/j.molimm.2006.11.012.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2006.11.012</ArticleId><ArticleId IdType="pmc">PMC1865514</ArticleId><ArticleId IdType="pubmed">17173972</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamad O.A., Ekdahl K.N., Nilsson P.H., Andersson J., Magotti P., Lambris J.D., Nilsson B. Complement activation triggered by chondroitin sulfate released by thrombin receptor-activated platelets. J. Thromb. Haemost. JTH. 2008;6:1413–1421. doi: 10.1111/j.1538-7836.2008.03034.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1538-7836.2008.03034.x</ArticleId><ArticleId IdType="pmc">PMC2673520</ArticleId><ArticleId IdType="pubmed">18503629</ArticleId></ArticleIdList></Reference><Reference><Citation>Skoglund C., Wettero J., Tengvall P., Bengtsson T. C1q induces a rapid up-regulation of p-selectin and modulates collagen- and collagen-related peptide-triggered activation in human platelets. Immunobiology. 2010;215:987–995. doi: 10.1016/j.imbio.2009.11.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2009.11.004</ArticleId><ArticleId IdType="pubmed">20163886</ArticleId></ArticleIdList></Reference><Reference><Citation>Hamad O.A., Nilsson P.H., Wouters D., Lambris J.D., Ekdahl K.N., Nilsson B. Complement component c3 binds to activated normal platelets without preceding proteolytic activation and promotes binding to complement receptor 1. J. Immunol. 2010;184:2686–2692. doi: 10.4049/jimmunol.0902810.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0902810</ArticleId><ArticleId IdType="pmc">PMC2953618</ArticleId><ArticleId IdType="pubmed">20139276</ArticleId></ArticleIdList></Reference><Reference><Citation>Saggu G., Cortes C., Emch H.N., Ramirez G., Worth R.G., Ferreira V.P. Identification of a novel mode of complement activation on stimulated platelets mediated by properdin and C3(H2O) J. Immunol. 2013;190:6457–6467. doi: 10.4049/jimmunol.1300610.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1300610</ArticleId><ArticleId IdType="pmc">PMC3784323</ArticleId><ArticleId IdType="pubmed">23677468</ArticleId></ArticleIdList></Reference><Reference><Citation>Carter A.M. Complement activation: An emerging player in the pathogenesis of cardiovascular disease. Scientifica. 2012;2012:402783. doi: 10.6064/2012/402783.</Citation><ArticleIdList><ArticleId IdType="doi">10.6064/2012/402783</ArticleId><ArticleId IdType="pmc">PMC3820556</ArticleId><ArticleId IdType="pubmed">24278688</ArticleId></ArticleIdList></Reference><Reference><Citation>Wiedmer T., Esmon C.T., Sims P.J. Complement proteins c5b-9 stimulate procoagulant activity through platelet prothrombinase. Blood. 1986;68:875–880. doi: 10.1182/blood.V68.4.875.875.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V68.4.875.875</ArticleId><ArticleId IdType="pubmed">3092889</ArticleId></ArticleIdList></Reference><Reference><Citation>Sims P.J., Faioni E.M., Wiedmer T., Shattil S.J. Complement proteins c5b-9 cause release of membrane vesicles from the platelet surface that are enriched in the membrane receptor for coagulation factor va and express prothrombinase activity. J. Biol. Chem. 1988;263:18205–18212. doi: 10.1016/S0021-9258(19)81346-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0021-9258(19)81346-7</ArticleId><ArticleId IdType="pubmed">2848029</ArticleId></ArticleIdList></Reference><Reference><Citation>Yin W., Ghebrehiwet B., Peerschke E.I. Expression of complement components and inhibitors on platelet microparticles. Platelets. 2008;19:225–233. doi: 10.1080/09537100701777311.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/09537100701777311</ArticleId><ArticleId IdType="pmc">PMC2659880</ArticleId><ArticleId IdType="pubmed">18432523</ArticleId></ArticleIdList></Reference><Reference><Citation>DiScipio R.G., Schraufstatter I.U. The role of the complement anaphylatoxins in the recruitment of eosinophils. Int. Immunopharmacol. 2007;7:1909–1923. doi: 10.1016/j.intimp.2007.07.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2007.07.006</ArticleId><ArticleId IdType="pubmed">18039528</ArticleId></ArticleIdList></Reference><Reference><Citation>Yadav M.K., Maharana J., Yadav R., Saha S., Sarma P., Soni C., Singh V., Saha S., Ganguly M., Li X.X., et al. Molecular basis of anaphylatoxin binding, activation, and signaling bias at complement receptors. Cell. 2023;186:4956–4973 e4921. doi: 10.1016/j.cell.2023.09.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cell.2023.09.020</ArticleId><ArticleId IdType="pmc">PMC7615941</ArticleId><ArticleId IdType="pubmed">37852260</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhou W. The new face of anaphylatoxins in immune regulation. Immunobiology. 2012;217:225–234. doi: 10.1016/j.imbio.2011.07.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2011.07.016</ArticleId><ArticleId IdType="pubmed">21856033</ArticleId></ArticleIdList></Reference><Reference><Citation>Ritis K., Doumas M., Mastellos D., Micheli A., Giaglis S., Magotti P., Rafail S., Kartalis G., Sideras P., Lambris J.D. A novel c5a receptor-tissue factor cross-talk in neutrophils links innate immunity to coagulation pathways. J. Immunol. 2006;177:4794–4802. doi: 10.4049/jimmunol.177.7.4794.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.177.7.4794</ArticleId><ArticleId IdType="pubmed">16982920</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y., Gauer J.S., Baker S.R., Philippou H., Connell S.D., Ariens R.A.S. Neutrophils can promote clotting via fxi and impact clot structure via neutrophil extracellular traps in a distinctive manner in vitro. Sci. Rep. 2021;11:1718. doi: 10.1038/s41598-021-81268-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-021-81268-7</ArticleId><ArticleId IdType="pmc">PMC7814028</ArticleId><ArticleId IdType="pubmed">33462294</ArticleId></ArticleIdList></Reference><Reference><Citation>Martinod K., Wagner D.D. Thrombosis: Tangled up in nets. Blood. 2014;123:2768–2776. doi: 10.1182/blood-2013-10-463646.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2013-10-463646</ArticleId><ArticleId IdType="pmc">PMC4007606</ArticleId><ArticleId IdType="pubmed">24366358</ArticleId></ArticleIdList></Reference><Reference><Citation>von Bruhl M.L., Stark K., Steinhart A., Chandraratne S., Konrad I., Lorenz M., Khandoga A., Tirniceriu A., Coletti R., Kollnberger M., et al. Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo. J. Exp. Med. 2012;209:819–835. doi: 10.1084/jem.20112322.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.20112322</ArticleId><ArticleId IdType="pmc">PMC3328366</ArticleId><ArticleId IdType="pubmed">22451716</ArticleId></ArticleIdList></Reference><Reference><Citation>Yuen J., Pluthero F.G., Douda D.N., Riedl M., Cherry A., Ulanova M., Kahr W.H., Palaniyar N., Licht C. Netosing neutrophils activate complement both on their own nets and bacteria via alternative and non-alternative pathways. Front. Immunol. 2016;7:137. doi: 10.3389/fimmu.2016.00137.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2016.00137</ArticleId><ArticleId IdType="pmc">PMC4831636</ArticleId><ArticleId IdType="pubmed">27148258</ArticleId></ArticleIdList></Reference><Reference><Citation>Goel M.S., Diamond S.L. Neutrophil cathepsin g promotes prothrombinase and fibrin formation under flow conditions by activating fibrinogen-adherent platelets. J. Biol. Chem. 2003;278:9458–9463. doi: 10.1074/jbc.M211956200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M211956200</ArticleId><ArticleId IdType="pubmed">12524437</ArticleId></ArticleIdList></Reference><Reference><Citation>LaRosa C.A., Rohrer M.J., Benoit S.E., Rodino L.J., Barnard M.R., Michelson A.D. Human neutrophil cathepsin g is a potent platelet activator. J. Vasc. Surg. 1994;19:306–318; discussion 318–309. doi: 10.1016/S0741-5214(94)70106-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0741-5214(94)70106-7</ArticleId><ArticleId IdType="pubmed">7509416</ArticleId></ArticleIdList></Reference><Reference><Citation>Renesto P., Chignard M. Enhancement of cathepsin g-induced platelet activation by leukocyte elastase: Consequence for the neutrophil-mediated platelet activation. Blood. 1993;82:139–144. doi: 10.1182/blood.V82.1.139.bloodjournal821139.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V82.1.139.bloodjournal821139</ArticleId><ArticleId IdType="pubmed">8324217</ArticleId></ArticleIdList></Reference><Reference><Citation>Allen D.H., Tracy P.B. Human coagulation factor v is activated to the functional cofactor by elastase and cathepsin g expressed at the monocyte surface. J. Biol. Chem. 1995;270:1408–1415. doi: 10.1074/jbc.270.3.1408.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.270.3.1408</ArticleId><ArticleId IdType="pubmed">7836408</ArticleId></ArticleIdList></Reference><Reference><Citation>Gale A.J., Rozenshteyn D. Cathepsin g, a leukocyte protease, activates coagulation factor viii. Thromb. Haemost. 2008;99:44–51. doi: 10.1160/TH07-08-0495.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH07-08-0495</ArticleId><ArticleId IdType="pubmed">18217133</ArticleId></ArticleIdList></Reference><Reference><Citation>Plescia J., Altieri D.C. Activation of mac-1 (cd11b/cd18)-bound factor x by released cathepsin g defines an alternative pathway of leucocyte initiation of coagulation. Pt 3Biochem. J. 1996;319:873–879. doi: 10.1042/bj3190873.</Citation><ArticleIdList><ArticleId IdType="doi">10.1042/bj3190873</ArticleId><ArticleId IdType="pmc">PMC1217869</ArticleId><ArticleId IdType="pubmed">8920993</ArticleId></ArticleIdList></Reference><Reference><Citation>Petersen L.C., Bjorn S.E., Nordfang O. Effect of leukocyte proteinases on tissue factor pathway inhibitor. Thromb. Haemost. 1992;67:537–541. doi: 10.1055/s-0038-1648489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1648489</ArticleId><ArticleId IdType="pubmed">1519213</ArticleId></ArticleIdList></Reference><Reference><Citation>Jochum M., Lander S., Heimburger N., Fritz H. Effect of human granulocytic elastase on isolated human antithrombin iii. Hoppe-Seyler’s Z. Fur Physiol. Chem. 1981;362:103–112. doi: 10.1515/bchm2.1981.362.1.103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1515/bchm2.1981.362.1.103</ArticleId><ArticleId IdType="pubmed">6783500</ArticleId></ArticleIdList></Reference><Reference><Citation>Mastellos D.C., Pires da Silva B.G.P., Fonseca B.A.L., Fonseca N.P., Auxiliadora-Martins M., Mastaglio S., Ruggeri A., Sironi M., Radermacher P., Chrysanthopoulou A., et al. Complement c3 vs c5 inhibition in severe COVID-19: Early clinical findings reveal differential biological efficacy. Clin. Immunol. 2020;220:108598. doi: 10.1016/j.clim.2020.108598.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.clim.2020.108598</ArticleId><ArticleId IdType="pmc">PMC7501834</ArticleId><ArticleId IdType="pubmed">32961333</ArticleId></ArticleIdList></Reference><Reference><Citation>Wojta J., Kaun C., Zorn G., Ghannadan M., Hauswirth A.W., Sperr W.R., Fritsch G., Printz D., Binder B.R., Schatzl G., et al. C5a stimulates production of plasminogen activator inhibitor-1 in human mast cells and basophils. Blood. 2002;100:517–523. doi: 10.1182/blood.V100.2.517.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V100.2.517</ArticleId><ArticleId IdType="pubmed">12091343</ArticleId></ArticleIdList></Reference><Reference><Citation>Wojta J., Huber K., Valent P. New aspects in thrombotic research: Complement induced switch in mast cells from a profibrinolytic to a prothrombotic phenotype. Pathophysiol. Haemost. Thromb. 2003;33:438–441. doi: 10.1159/000083842.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000083842</ArticleId><ArticleId IdType="pubmed">15692257</ArticleId></ArticleIdList></Reference><Reference><Citation>Samstad E.O., Niyonzima N., Nymo S., Aune M.H., Ryan L., Bakke S.S., Lappegard K.T., Brekke O.L., Lambris J.D., Damas J.K., et al. Cholesterol crystals induce complement-dependent inflammasome activation and cytokine release. J. Immunol. 2014;192:2837–2845. doi: 10.4049/jimmunol.1302484.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1302484</ArticleId><ArticleId IdType="pmc">PMC3985066</ArticleId><ArticleId IdType="pubmed">24554772</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi J., Tang Y., Liang F., Liu L., Liang N., Yang X., Zhang N., Yi Z., Zhong Y., Wang W., et al. Nlrp3 inflammasome contributes to endotoxin-induced coagulation. Thromb. Res. 2022;214:8–15. doi: 10.1016/j.thromres.2022.04.001.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2022.04.001</ArticleId><ArticleId IdType="pubmed">35421682</ArticleId></ArticleIdList></Reference><Reference><Citation>Gulla K.C., Gupta K., Krarup A., Gal P., Schwaeble W.J., Sim R.B., O’Connor C.D., Hajela K. Activation of mannan-binding lectin-associated serine proteases leads to generation of a fibrin clot. Immunology. 2010;129:482–495. doi: 10.1111/j.1365-2567.2009.03200.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1365-2567.2009.03200.x</ArticleId><ArticleId IdType="pmc">PMC2842495</ArticleId><ArticleId IdType="pubmed">20002787</ArticleId></ArticleIdList></Reference><Reference><Citation>Jenny L., Dobo J., Gal P., Schroeder V. Masp-1 of the complement system promotes clotting via prothrombin activation. Mol. Immunol. 2015;65:398–405. doi: 10.1016/j.molimm.2015.02.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2015.02.014</ArticleId><ArticleId IdType="pubmed">25745807</ArticleId></ArticleIdList></Reference><Reference><Citation>Krarup A., Gulla K.C., Gal P., Hajela K., Sim R.B. The action of mbl-associated serine protease 1 (masp1) on factor xiii and fibrinogen. Biochim. Biophys. Acta. 2008;1784:1294–1300. doi: 10.1016/j.bbapap.2008.03.020.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbapap.2008.03.020</ArticleId><ArticleId IdType="pubmed">18456010</ArticleId></ArticleIdList></Reference><Reference><Citation>Howes J.M., Richardson V.R., Smith K.A., Schroeder V., Somani R., Shore A., Hess K., Ajjan R., Pease R.J., Keen J.N., et al. Complement c3 is a novel plasma clot component with anti-fibrinolytic properties. Diabetes Vasc. Dis. Res. 2012;9:216–225. doi: 10.1177/1479164111432788.</Citation><ArticleIdList><ArticleId IdType="doi">10.1177/1479164111432788</ArticleId><ArticleId IdType="pubmed">22253322</ArticleId></ArticleIdList></Reference><Reference><Citation>Distelmaier K., Adlbrecht C., Jakowitsch J., Winkler S., Dunkler D., Gerner C., Wagner O., Lang I.M., Kubicek M. Local complement activation triggers neutrophil recruitment to the site of thrombus formation in acute myocardial infarction. Thromb. Haemost. 2009;102:564–572. doi: 10.1160/TH09-02-0103.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH09-02-0103</ArticleId><ArticleId IdType="pubmed">19718478</ArticleId></ArticleIdList></Reference><Reference><Citation>Richardson V.R., Schroeder V., Grant P.J., Standeven K.F., Carter A.M. Complement c3 is a substrate for activated factor xiii that is cross-linked to fibrin during clot formation. Br. J. Haematol. 2013;160:116–119. doi: 10.1111/bjh.12096.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bjh.12096</ArticleId><ArticleId IdType="pubmed">23078103</ArticleId></ArticleIdList></Reference><Reference><Citation>Heurich M., McCluskey G. Complement and coagulation crosstalk—Factor h in the spotlight. Immunobiology. 2023;228:152707. doi: 10.1016/j.imbio.2023.152707.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2023.152707</ArticleId><ArticleId IdType="pubmed">37633063</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi V., Cseh S., Bally I., Thielens N.M., Jensenius J.C., Arlaud G.J. Substrate specificities of recombinant mannan-binding lectin-associated serine proteases-1 and -2. J. Biol. Chem. 2001;276:40880–40887. doi: 10.1074/jbc.M105934200.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M105934200</ArticleId><ArticleId IdType="pubmed">11527969</ArticleId></ArticleIdList></Reference><Reference><Citation>Ravindran S., Grys T.E., Welch R.A., Schapira M., Patston P.A. Inhibition of plasma kallikrein by c1-inhibitor: Role of endothelial cells and the amino-terminal domain of c1-inhibitor. Thromb. Haemost. 2004;92:1277–1283. doi: 10.1160/TH04-01-0008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1160/TH04-01-0008</ArticleId><ArticleId IdType="pubmed">15583734</ArticleId></ArticleIdList></Reference><Reference><Citation>Amara U., Flierl M.A., Rittirsch D., Klos A., Chen H., Acker B., Bruckner U.B., Nilsson B., Gebhard F., Lambris J.D., et al. Molecular intercommunication between the complement and coagulation systems. J. Immunol. 2010;185:5628–5636. doi: 10.4049/jimmunol.0903678.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.0903678</ArticleId><ArticleId IdType="pmc">PMC3123139</ArticleId><ArticleId IdType="pubmed">20870944</ArticleId></ArticleIdList></Reference><Reference><Citation>Kerr F.K., Thomas A.R., Wijeyewickrema L.C., Whisstock J.C., Boyd S.E., Kaiserman D., Matthews A.Y., Bird P.I., Thielens N.M., Rossi V., et al. Elucidation of the substrate specificity of the masp-2 protease of the lectin complement pathway and identification of the enzyme as a major physiological target of the serpin, c1-inhibitor. Mol. Immunol. 2008;45:670–677. doi: 10.1016/j.molimm.2007.07.008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2007.07.008</ArticleId><ArticleId IdType="pubmed">17709141</ArticleId></ArticleIdList></Reference><Reference><Citation>Ratnoff O.D. Some relationships among hemostasis, fibrinolytic phenomena, immunity, and the inflammatory response. Adv. Immunol. 1969;10:145–227. doi: 10.1016/s0065-2776(08)60417-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/s0065-2776(08)60417-4</ArticleId><ArticleId IdType="pubmed">4242699</ArticleId></ArticleIdList></Reference><Reference><Citation>Hiemstra P.S., Daha M.R., Bouma B.N. Activation of factor b of the complement system by kallikrein and its light chain. Thromb. Res. 1985;38:491–503. doi: 10.1016/0049-3848(85)90182-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0049-3848(85)90182-3</ArticleId><ArticleId IdType="pubmed">3848216</ArticleId></ArticleIdList></Reference><Reference><Citation>Irmscher S., Doring N., Halder L.D., Jo E.A.H., Kopka I., Dunker C., Jacobsen I.D., Luo S., Slevogt H., Lorkowski S., et al. Kallikrein cleaves c3 and activates complement. J. Innate Immun. 2018;10:94–105. doi: 10.1159/000484257.</Citation><ArticleIdList><ArticleId IdType="doi">10.1159/000484257</ArticleId><ArticleId IdType="pmc">PMC6757171</ArticleId><ArticleId IdType="pubmed">29237166</ArticleId></ArticleIdList></Reference><Reference><Citation>Ghebrehiwet B., Randazzo B.P., Dunn J.T., Silverberg M., Kaplan A.P. Mechanisms of activation of the classical pathway of complement by hageman factor fragment. J. Clin. Investig. 1983;71:1450–1456. doi: 10.1172/JCI110898.</Citation><ArticleIdList><ArticleId IdType="doi">10.1172/JCI110898</ArticleId><ArticleId IdType="pmc">PMC437009</ArticleId><ArticleId IdType="pubmed">6304147</ArticleId></ArticleIdList></Reference><Reference><Citation>Foley J.H., Walton B.L., Aleman M.M., O’Byrne A.M., Lei V., Harrasser M., Foley K.A., Wolberg A.S., Conway E.M. Complement activation in arterial and venous thrombosis is mediated by plasmin. EBioMedicine. 2016;5:175–182. doi: 10.1016/j.ebiom.2016.02.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ebiom.2016.02.011</ArticleId><ArticleId IdType="pmc">PMC4816834</ArticleId><ArticleId IdType="pubmed">27077125</ArticleId></ArticleIdList></Reference><Reference><Citation>Polley M.J., Nachman R. The human complement system in thrombin-mediated platelet function. J. Exp. Med. 1978;147:1713–1726. doi: 10.1084/jem.147.6.1713.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.147.6.1713</ArticleId><ArticleId IdType="pmc">PMC2184322</ArticleId><ArticleId IdType="pubmed">681879</ArticleId></ArticleIdList></Reference><Reference><Citation>Polley M.J., Nachman R.L. Human complement in thrombin-mediated platelet function: Uptake of the c5b-9 complex. J. Exp. Med. 1979;150:633–645. doi: 10.1084/jem.150.3.633.</Citation><ArticleIdList><ArticleId IdType="doi">10.1084/jem.150.3.633</ArticleId><ArticleId IdType="pmc">PMC2185636</ArticleId><ArticleId IdType="pubmed">479764</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobo J., Szakacs D., Oroszlan G., Kortvely E., Kiss B., Boros E., Szasz R., Zavodszky P., Gal P., Pal G. Masp-3 is the exclusive pro-factor d activator in resting blood: The lectin and the alternative complement pathways are fundamentally linked. Sci. Rep. 2016;6:31877. doi: 10.1038/srep31877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/srep31877</ArticleId><ArticleId IdType="pmc">PMC4989169</ArticleId><ArticleId IdType="pubmed">27535802</ArticleId></ArticleIdList></Reference><Reference><Citation>Oroszlan G., Kortvely E., Szakacs D., Kocsis A., Dammeier S., Zeck A., Ueffing M., Zavodszky P., Pal G., Gal P., et al. Masp-1 and masp-2 do not activate pro-factor d in resting human blood, whereas masp-3 is a potential activator: Kinetic analysis involving specific masp-1 and masp-2 inhibitors. J. Immunol. 2016;196:857–865. doi: 10.4049/jimmunol.1501717.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1501717</ArticleId><ArticleId IdType="pubmed">26673137</ArticleId></ArticleIdList></Reference><Reference><Citation>Krisinger M.J., Goebeler V., Lu Z., Meixner S.C., Myles T., Pryzdial E.L., Conway E.M. Thrombin generates previously unidentified c5 products that support the terminal complement activation pathway. Blood. 2012;120:1717–1725. doi: 10.1182/blood-2012-02-412080.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2012-02-412080</ArticleId><ArticleId IdType="pubmed">22802338</ArticleId></ArticleIdList></Reference><Reference><Citation>Tateishi K., Imaoka M., Matsushita M. Dual modulating functions of thrombomodulin in the alternative complement pathway. Biosci. Trends. 2016;10:231–234. doi: 10.5582/bst.2016.01052.</Citation><ArticleIdList><ArticleId IdType="doi">10.5582/bst.2016.01052</ArticleId><ArticleId IdType="pubmed">27210597</ArticleId></ArticleIdList></Reference><Reference><Citation>Barthel D., Schindler S., Zipfel P.F. Plasminogen is a complement inhibitor. J. Biol. Chem. 2012;287:18831–18842. doi: 10.1074/jbc.M111.323287.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M111.323287</ArticleId><ArticleId IdType="pmc">PMC3365705</ArticleId><ArticleId IdType="pubmed">22451663</ArticleId></ArticleIdList></Reference><Reference><Citation>Lidington E.A., Haskard D.O., Mason J.C. Induction of decay-accelerating factor by thrombin through a protease-activated receptor 1 and protein kinase c-dependent pathway protects vascular endothelial cells from complement-mediated injury. Blood. 2000;96:2784–2792. doi: 10.1182/blood.V96.8.2784.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood.V96.8.2784</ArticleId><ArticleId IdType="pubmed">11023512</ArticleId></ArticleIdList></Reference><Reference><Citation>Ellis V., Scully M., MacGregor I., Kakkar V. Inhibition of human factor xa by various plasma protease inhibitors. Biochim. Biophys. Acta. 1982;701:24–31. doi: 10.1016/0167-4838(82)90307-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/0167-4838(82)90307-7</ArticleId><ArticleId IdType="pubmed">6173074</ArticleId></ArticleIdList></Reference><Reference><Citation>Osterud B., Miller-Andersson M., Abildgaard U., Prydz H. The effect of antithrombin iii on the activity of the coagulation factors vii, ix and x. Thromb. Haemost. 1976;35:295–304. doi: 10.1055/s-0038-1647922.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0038-1647922</ArticleId><ArticleId IdType="pubmed">61631</ArticleId></ArticleIdList></Reference><Reference><Citation>Parej K., Dobo J., Zavodszky P., Gal P. The control of the complement lectin pathway activation revisited: Both c1-inhibitor and antithrombin are likely physiological inhibitors, while alpha2-macroglobulin is not. Mol. Immunol. 2013;54:415–422. doi: 10.1016/j.molimm.2013.01.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2013.01.009</ArticleId><ArticleId IdType="pubmed">23399388</ArticleId></ArticleIdList></Reference><Reference><Citation>Mast A.E., Ruf W. Regulation of coagulation by tissue factor pathway inhibitor: Implications for hemophilia therapy. J. Thromb. Haemost. JTH. 2022;20:1290–1300. doi: 10.1111/jth.15697.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.15697</ArticleId><ArticleId IdType="pmc">PMC9314982</ArticleId><ArticleId IdType="pubmed">35279938</ArticleId></ArticleIdList></Reference><Reference><Citation>Maroney S.A., Ellery P.E., Mast A.E. Alternatively spliced isoforms of tissue factor pathway inhibitor. Thromb. Res. 2010;125((Suppl. S1)):52–56. doi: 10.1016/j.thromres.2010.01.038.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2010.01.038</ArticleId><ArticleId IdType="pmc">PMC2839007</ArticleId><ArticleId IdType="pubmed">20176395</ArticleId></ArticleIdList></Reference><Reference><Citation>Mast A.E. Tissue factor pathway inhibitor: Multiple anticoagulant activities for a single protein. Arterioscler. Thromb. Vasc. Biol. 2016;36:9–14. doi: 10.1161/ATVBAHA.115.305996.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.115.305996</ArticleId><ArticleId IdType="pmc">PMC4690769</ArticleId><ArticleId IdType="pubmed">26603155</ArticleId></ArticleIdList></Reference><Reference><Citation>Keizer M.P., Pouw R.B., Kamp A.M., Patiwael S., Marsman G., Hart M.H., Zeerleder S., Kuijpers T.W., Wouters D. Tfpi inhibits lectin pathway of complement activation by direct interaction with masp-2. Eur. J. Immunol. 2015;45:544–550. doi: 10.1002/eji.201445070.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201445070</ArticleId><ArticleId IdType="pubmed">25359215</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell W.D., Lazoura E., Okada N., Okada H. Inactivation of c3a and c5a octapeptides by carboxypeptidase r and carboxypeptidasen. Microbiol. Immunol. 2002;46:131–134. doi: 10.1111/j.1348-0421.2002.tb02669.x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/j.1348-0421.2002.tb02669.x</ArticleId><ArticleId IdType="pubmed">11939578</ArticleId></ArticleIdList></Reference><Reference><Citation>Leung L.L., Myles T., Nishimura T., Song J.J., Robinson W.H. Regulation of tissue inflammation by thrombin-activatable carboxypeptidase b (or tafi) Mol. Immunol. 2008;45:4080–4083. doi: 10.1016/j.molimm.2008.07.010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2008.07.010</ArticleId><ArticleId IdType="pmc">PMC3771643</ArticleId><ArticleId IdType="pubmed">18706698</ArticleId></ArticleIdList></Reference><Reference><Citation>Delvaeye M., Noris M., De Vriese A., Esmon C.T., Esmon N.L., Ferrell G., Del-Favero J., Plaisance S., Claes B., Lambrechts D., et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2009;361:345–357. doi: 10.1056/NEJMoa0810739.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa0810739</ArticleId><ArticleId IdType="pmc">PMC3530919</ArticleId><ArticleId IdType="pubmed">19625716</ArticleId></ArticleIdList></Reference><Reference><Citation>Heurich M., Preston R.J., O’Donnell V.B., Morgan B.P., Collins P.W. Thrombomodulin enhances complement regulation through strong affinity interactions with factor h and c3b-factor h complex. Thromb. Res. 2016;145:84–92. doi: 10.1016/j.thromres.2016.07.017.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.thromres.2016.07.017</ArticleId><ArticleId IdType="pubmed">27513882</ArticleId></ArticleIdList></Reference><Reference><Citation>Puy C., Pang J., Reitsma S.E., Lorentz C.U., Tucker E.I., Gailani D., Gruber A., Lupu F., McCarty O.J.T. Cross-talk between the complement pathway and the contact activation system of coagulation: Activated factor xi neutralizes complement factor h. J. Immunol. 2021;206:1784–1792. doi: 10.4049/jimmunol.2000398.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.2000398</ArticleId><ArticleId IdType="pmc">PMC8030746</ArticleId><ArticleId IdType="pubmed">33811105</ArticleId></ArticleIdList></Reference><Reference><Citation>Chen L.J., Liu D.T., Tam P.O., Chan W.M., Liu K., Chong K.K., Lam D.S., Pang C.P. Association of complement factor h polymorphisms with exudative age-related macular degeneration. Mol. Vis. 2006;12:1536–1542. doi: 10.1016/j.ajo.2006.12.019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ajo.2006.12.019</ArticleId><ArticleId IdType="pubmed">17167412</ArticleId></ArticleIdList></Reference><Reference><Citation>Thangaraj S.S., Christiansen S.H., Graversen J.H., Sidelmann J.J., Hansen S.W.K., Bygum A., Gram J.B., Palarasah Y. Contact activation-induced complex formation between complement factor h and coagulation factor xiia. J. Thromb. Haemost. JTH. 2020;18:876–884. doi: 10.1111/jth.14742.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/jth.14742</ArticleId><ArticleId IdType="pubmed">31984663</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng S., Liang X., Cruz M.A., Vu H., Zhou Z., Pemmaraju N., Dong J.F., Kroll M.H., Afshar-Kharghan V. The interaction between factor h and von willebrand factor. PLoS ONE. 2013;8:e73715. doi: 10.1371/journal.pone.0073715.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0073715</ArticleId><ArticleId IdType="pmc">PMC3753316</ArticleId><ArticleId IdType="pubmed">23991205</ArticleId></ArticleIdList></Reference><Reference><Citation>Nolasco L., Nolasco J., Feng S., Afshar-Kharghan V., Moake J. Human complement factor h is a reductase for large soluble von willebrand factor multimers--brief report. Arterioscler. Thromb. Vasc. Biol. 2013;33:2524–2528. doi: 10.1161/ATVBAHA.113.302280.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/ATVBAHA.113.302280</ArticleId><ArticleId IdType="pubmed">24008159</ArticleId></ArticleIdList></Reference><Reference><Citation>Rayes J., Roumenina L.T., Dimitrov J.D., Repesse Y., Ing M., Christophe O., Jokiranta T.S., Halbwachs-Mecarelli L., Borel-Derlon A., Kaveri S.V., et al. The interaction between factor h and vwf increases factor h cofactor activity and regulates vwf prothrombotic status. Blood. 2014;123:121–125. doi: 10.1182/blood-2013-04-495853.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2013-04-495853</ArticleId><ArticleId IdType="pubmed">24014239</ArticleId></ArticleIdList></Reference><Reference><Citation>Turner N., Nolasco L., Nolasco J., Sartain S., Moake J. Thrombotic microangiopathies and the linkage between von willebrand factor and the alternative complement pathway. Semin. Thromb. Hemost. 2014;40:544–550. doi: 10.1055/s-0034-1383547.</Citation><ArticleIdList><ArticleId IdType="doi">10.1055/s-0034-1383547</ArticleId><ArticleId IdType="pubmed">24967890</ArticleId></ArticleIdList></Reference><Reference><Citation>Feng S., Liang X., Kroll M.H., Chung D.W., Afshar-Kharghan V. Von willebrand factor is a cofactor in complement regulation. Blood. 2015;125:1034–1037. doi: 10.1182/blood-2014-06-585430.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2014-06-585430</ArticleId><ArticleId IdType="pmc">PMC4319234</ArticleId><ArticleId IdType="pubmed">25395424</ArticleId></ArticleIdList></Reference><Reference><Citation>Subramaniam S., Jurk K., Hobohm L., Jackel S., Saffarzadeh M., Schwierczek K., Wenzel P., Langer F., Reinhardt C., Ruf W. Distinct contributions of complement factors to platelet activation and fibrin formation in venous thrombus development. Blood. 2017;129:2291–2302. doi: 10.1182/blood-2016-11-749879.</Citation><ArticleIdList><ArticleId IdType="doi">10.1182/blood-2016-11-749879</ArticleId><ArticleId IdType="pmc">PMC5399485</ArticleId><ArticleId IdType="pubmed">28223279</ArticleId></ArticleIdList></Reference><Reference><Citation>Dobo J., Schroeder V., Jenny L., Cervenak L., Zavodszky P., Gal P. Multiple roles of complement masp-1 at the interface of innate immune response and coagulation. Mol. Immunol. 2014;61:69–78. doi: 10.1016/j.molimm.2014.05.013.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2014.05.013</ArticleId><ArticleId IdType="pubmed">24935208</ArticleId></ArticleIdList></Reference><Reference><Citation>Takahashi K., Chang W.C., Takahashi M., Pavlov V., Ishida Y., La Bonte L., Shi L., Fujita T., Stahl G.L., Van Cott E.M. Mannose-binding lectin and its associated proteases (masps) mediate coagulation and its deficiency is a risk factor in developing complications from infection, including disseminated intravascular coagulation. Immunobiology. 2011;216:96–102. doi: 10.1016/j.imbio.2010.02.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.imbio.2010.02.005</ArticleId><ArticleId IdType="pmc">PMC2912947</ArticleId><ArticleId IdType="pubmed">20399528</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi C., Tingting W., Li J.P., Sullivan M.A., Wang C., Wang H., Deng B., Zhang Y. Comprehensive landscape of heparin therapy for COVID-19. Carbohydr. Polym. 2021;254:117232. doi: 10.1016/j.carbpol.2020.117232.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.carbpol.2020.117232</ArticleId><ArticleId IdType="pmc">PMC7581413</ArticleId><ArticleId IdType="pubmed">33357843</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin L., Lu L., Cao W., Li T. Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia. Emerg. Microbes Infect. 2020;9:727–732. doi: 10.1080/22221751.2020.1746199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1080/22221751.2020.1746199</ArticleId><ArticleId IdType="pmc">PMC7170333</ArticleId><ArticleId IdType="pubmed">32196410</ArticleId></ArticleIdList></Reference><Reference><Citation>Fang T., Pan X., Huang J., Chen J., Song S., Zhan Q. Heparin therapy in COVID-19: Call for randomized controlled trials (rcts) Biosci. Trends. 2022;16:307–311. doi: 10.5582/bst.2022.01225.</Citation><ArticleIdList><ArticleId IdType="doi">10.5582/bst.2022.01225</ArticleId><ArticleId IdType="pubmed">35908881</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauch-Krohnert U., Puccini M., Placzek M., Beyer-Westendorf J., Jakobs K., Friebel J., Hein S., Seidel M., Pieske B., Massberg S., et al. Initial therapeutic anticoagulation with rivaroxaban compared to prophylactic therapy with heparins in moderate to severe COVID-19: Results of the COVID-prevent randomized controlled trial. Clin. Res. Cardiol. 2023;112:1620–1638. doi: 10.1007/s00392-023-02240-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00392-023-02240-1</ArticleId><ArticleId IdType="pmc">PMC10584737</ArticleId><ArticleId IdType="pubmed">37407731</ArticleId></ArticleIdList></Reference><Reference><Citation>Spyropoulos A.C., Ageno W., Albers G.W., Elliott C.G., Halperin J.L., Hiatt W.R., Maynard G.A., Steg P.G., Weitz J.I., Suh E., et al. Rivaroxaban for thromboprophylaxis after hospitalization for medical illness. N. Engl. J. Med. 2018;379:1118–1127. doi: 10.1056/NEJMoa1805090.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa1805090</ArticleId><ArticleId IdType="pubmed">30145946</ArticleId></ArticleIdList></Reference><Reference><Citation>Spyropoulos A.C., Ageno W., Albers G.W., Elliott C.G., Halperin J.L., Hiatt W.R., Maynard G.A., Steg P.G., Weitz J.I., Lu W., et al. Post-discharge prophylaxis with rivaroxaban reduces fatal and major thromboembolic events in medically ill patients. J. Am. Coll. Cardiol. 2020;75:3140–3147. doi: 10.1016/j.jacc.2020.04.071.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jacc.2020.04.071</ArticleId><ArticleId IdType="pmc">PMC7308003</ArticleId><ArticleId IdType="pubmed">32586587</ArticleId></ArticleIdList></Reference><Reference><Citation>Sievers B.L., Cheng M.T.K., Csiba K., Meng B., Gupta R.K. SARS-CoV-2 and innate immunity: The good, the bad, and the “goldilocks”. Cell. Mol. Immunol. 2024;21:171–183. doi: 10.1038/s41423-023-01104-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41423-023-01104-y</ArticleId><ArticleId IdType="pmc">PMC10805730</ArticleId><ArticleId IdType="pubmed">37985854</ArticleId></ArticleIdList></Reference><Reference><Citation>Purbey P.K., Roy K., Gupta S., Paul M.K. Mechanistic insight into the protective and pathogenic immune-responses against SARS-CoV-2. Mol. Immunol. 2023;156:111–126. doi: 10.1016/j.molimm.2023.03.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2023.03.009</ArticleId><ArticleId IdType="pmc">PMC10009586</ArticleId><ArticleId IdType="pubmed">36921486</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Sterne J.A.C., Murthy S., Diaz J.V., Slutsky A.S., Villar J., Angus D.C., Annane D., Azevedo L.C.P., Berwanger O., et al. Association between administration of systemic corticosteroids and mortality among critically ill patients with COVID-19: A meta-analysis. JAMA. 2020;324:1330–1341. doi: 10.1001/jama.2020.17023.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2020.17023</ArticleId><ArticleId IdType="pmc">PMC7489434</ArticleId><ArticleId IdType="pubmed">32876694</ArticleId></ArticleIdList></Reference><Reference><Citation>Shirzad M., Nourigorji M., Sajedi A., Ranjbar M., Rasti F., Sourani Z., Moradi M., Mostafa Mir S., Memar M.Y. Targeted therapy in coronavirus disease 2019 (COVID-19): Implication from cell and gene therapy to immunotherapy and vaccine. Int. Immunopharmacol. 2022;111:109161. doi: 10.1016/j.intimp.2022.109161.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.intimp.2022.109161</ArticleId><ArticleId IdType="pmc">PMC9385778</ArticleId><ArticleId IdType="pubmed">35998506</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group. Horby P., Lim W.S., Emberson J.R., Mafham M., Bell J.L., Linsell L., Staplin N., Brightling C., Ustianowski A., et al. Dexamethasone in hospitalized patients with COVID-19. N. Engl. J. Med. 2021;384:693–704. doi: 10.1056/NEJMoa2021436.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2021436</ArticleId><ArticleId IdType="pmc">PMC7383595</ArticleId><ArticleId IdType="pubmed">32678530</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group Baricitinib in patients admitted to hospital with COVID-19 (recovery): A randomised, controlled, open-label, platform trial and updated meta-analysis. Lancet. 2022;400:359–368. doi: 10.1016/S0140-6736(22)01109-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)01109-6</ArticleId><ArticleId IdType="pmc">PMC9333998</ArticleId><ArticleId IdType="pubmed">35908569</ArticleId></ArticleIdList></Reference><Reference><Citation>Ely E.W., Ramanan A.V., Kartman C.E., de Bono S., Liao R., Piruzeli M.L.B., Goldman J.D., Saraiva J.F.K., Chakladar S., Marconi V.C., et al. Efficacy and safety of baricitinib plus standard of care for the treatment of critically ill hospitalised adults with COVID-19 on invasive mechanical ventilation or extracorporeal membrane oxygenation: An exploratory, randomised, placebo-controlled trial. Lancet Respir. Med. 2022;10:327–336. doi: 10.1016/S2213-2600(22)00006-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00006-6</ArticleId><ArticleId IdType="pmc">PMC8813065</ArticleId><ArticleId IdType="pubmed">35123660</ArticleId></ArticleIdList></Reference><Reference><Citation>Marconi V.C., Ramanan A.V., de Bono S., Kartman C.E., Krishnan V., Liao R., Piruzeli M.L.B., Goldman J.D., Alatorre-Alexander J., de Cassia Pellegrini R., et al. Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (cov-barrier): A randomised, double-blind, parallel-group, placebo-controlled phase 3 trial. Lancet Respir. Med. 2021;9:1407–1418. doi: 10.1016/S2213-2600(21)00331-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(21)00331-3</ArticleId><ArticleId IdType="pmc">PMC8409066</ArticleId><ArticleId IdType="pubmed">34480861</ArticleId></ArticleIdList></Reference><Reference><Citation>WHO Rapid Evidence Appraisal for COVID-19 Therapies (REACT) Working Group. Shankar-Hari M., Vale C.L., Godolphin P.J., Fisher D., Higgins J.P.T., Spiga F., Savovic J., Tierney J., Baron G., et al. Association between administration of il-6 antagonists and mortality among patients hospitalized for COVID-19: A meta-analysis. JAMA. 2021;326:499–518. doi: 10.1001/jama.2021.11330.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jama.2021.11330</ArticleId><ArticleId IdType="pmc">PMC8261689</ArticleId><ArticleId IdType="pubmed">34228774</ArticleId></ArticleIdList></Reference><Reference><Citation>Murakami N., Hayden R., Hills T., Al-Samkari H., Casey J., Del Sorbo L., Lawler P.R., Sise M.E., Leaf D.E. Therapeutic advances in COVID-19. Nat. Rev. Nephrol. 2023;19:38–52. doi: 10.1038/s41581-022-00642-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41581-022-00642-4</ArticleId><ArticleId IdType="pmc">PMC9574806</ArticleId><ArticleId IdType="pubmed">36253508</ArticleId></ArticleIdList></Reference><Reference><Citation>Perner A., Venkatesh B. Higher-dose dexamethasone for patients with COVID-19 and hypoxaemia? Lancet. 2023;401:1474–1476. doi: 10.1016/S0140-6736(23)00587-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(23)00587-1</ArticleId><ArticleId IdType="pmc">PMC10097504</ArticleId><ArticleId IdType="pubmed">37060914</ArticleId></ArticleIdList></Reference><Reference><Citation>Boulware D.R., Lindsell C.J., Stewart T.G., Hernandez A.F., Collins S., McCarthy M.W., Jayaweera D., Gentile N., Castro M., Sulkowski M., et al. Inhaled fluticasone furoate for outpatient treatment of COVID-19. N. Engl. J. Med. 2023;389:1085–1095. doi: 10.1056/NEJMoa2209421.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2209421</ArticleId><ArticleId IdType="pmc">PMC10597427</ArticleId><ArticleId IdType="pubmed">37733308</ArticleId></ArticleIdList></Reference><Reference><Citation>Mettananda C., Peiris C., Abeyrathna D., Gunasekara A., Egodage T., Dantanarayana C., Pathmeswaran A., Ranasinha C. Inhaled beclomethasone in the treatment of early COVID-19: A double-blind, placebo-controlled, randomised, hospital-based trial in sri lanka. BMJ Open. 2023;13:e075803. doi: 10.1136/bmjopen-2023-075803.</Citation><ArticleIdList><ArticleId IdType="doi">10.1136/bmjopen-2023-075803</ArticleId><ArticleId IdType="pmc">PMC10729268</ArticleId><ArticleId IdType="pubmed">38101843</ArticleId></ArticleIdList></Reference><Reference><Citation>Cardenas G., Chavez-Canales M., Espinosa A.M., Jordan-Rios A., Malagon D.A., Murillo M.F.M., Araujo L.V.T., Campos R.L.B., Wong-Chew R.M., Gonzalez L.E.R., et al. Intranasal versus intravenous dexamethasone to treat hospitalized COVID-19 patients: A randomized multicenter clinical trial. Arch. Med. Res. 2024;55:102960. doi: 10.1016/j.arcmed.2024.102960.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.arcmed.2024.102960</ArticleId><ArticleId IdType="pubmed">38290199</ArticleId></ArticleIdList></Reference><Reference><Citation>Maayah Z.H., Ferdaoussi M., Takahara S., Soni S., Dyck J.R.B. Empagliflozin suppresses inflammation and protects against acute septic renal injury. Inflammopharmacology. 2021;29:269–279. doi: 10.1007/s10787-020-00732-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s10787-020-00732-4</ArticleId><ArticleId IdType="pubmed">32564182</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonnet F., Scheen A.J. Effects of sglt2 inhibitors on systemic and tissue low-grade inflammation: The potential contribution to diabetes complications and cardiovascular disease. Diabetes Metab. 2018;44:457–464. doi: 10.1016/j.diabet.2018.09.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.diabet.2018.09.005</ArticleId><ArticleId IdType="pubmed">30266577</ArticleId></ArticleIdList></Reference><Reference><Citation>Kim S.R., Lee S.G., Kim S.H., Kim J.H., Choi E., Cho W., Rim J.H., Hwang I., Lee C.J., Lee M., et al. Sglt2 inhibition modulates nlrp3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat. Commun. 2020;11:2127. doi: 10.1038/s41467-020-15983-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-15983-6</ArticleId><ArticleId IdType="pmc">PMC7195385</ArticleId><ArticleId IdType="pubmed">32358544</ArticleId></ArticleIdList></Reference><Reference><Citation>Chang Y.S., Ko B.H., Ju J.C., Chang H.H., Huang S.H., Lin C.W. Sars unique domain (sud) of severe acute respiratory syndrome coronavirus induces nlrp3 inflammasome-dependent cxcl10-mediated pulmonary inflammation. Int. J. Mol. Sci. 2020;21:3179. doi: 10.3390/ijms21093179.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms21093179</ArticleId><ArticleId IdType="pmc">PMC7247444</ArticleId><ArticleId IdType="pubmed">32365944</ArticleId></ArticleIdList></Reference><Reference><Citation>Dalan R., Ang L.W., Tan W.Y.T., Fong S.W., Tay W.C., Chan Y.H., Renia L., Ng L.F.P., Lye D.C., Chew D.E.K., et al. The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: An observational study. Eur. Heart J. Cardiovasc. Pharmacother. 2021;7:e48–e51. doi: 10.1093/ehjcvp/pvaa098.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcvp/pvaa098</ArticleId><ArticleId IdType="pmc">PMC7454507</ArticleId><ArticleId IdType="pubmed">32766831</ArticleId></ArticleIdList></Reference><Reference><Citation>Kosiborod M.N., Esterline R., Furtado R.H.M., Oscarsson J., Gasparyan S.B., Koch G.G., Martinez F., Mukhtar O., Verma S., Chopra V., et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (dare-19): A randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9:586–594. doi: 10.1016/S2213-8587(21)00180-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(21)00180-7</ArticleId><ArticleId IdType="pmc">PMC8294807</ArticleId><ArticleId IdType="pubmed">34302745</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group Empagliflozin in patients admitted to hospital with COVID-19 (recovery): A randomised, controlled, open-label, platform trial. Lancet Diabetes Endocrinol. 2023;11:905–914. doi: 10.1016/S2213-8587(23)00253-X.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-8587(23)00253-X</ArticleId><ArticleId IdType="pmc">PMC10957483</ArticleId><ArticleId IdType="pubmed">37865101</ArticleId></ArticleIdList></Reference><Reference><Citation>Olagnier D., Farahani E., Thyrsted J., Blay-Cadanet J., Herengt A., Idorn M., Hait A., Hernaez B., Knudsen A., Iversen M.B., et al. SARS-CoV2-mediated suppression of nrf2-signaling reveals potent antiviral and anti-inflammatory activity of 4-octyl-itaconate and dimethyl fumarate. Nat. Commun. 2020;11:4938. doi: 10.1038/s41467-020-18764-3.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-020-18764-3</ArticleId><ArticleId IdType="pmc">PMC7532469</ArticleId><ArticleId IdType="pubmed">33009401</ArticleId></ArticleIdList></Reference><Reference><Citation>RECOVERY Collaborative Group. Horby P.W., Peto L., Staplin N., Campbell M., Pessoa-Amorim G., Mafham M., Emberson J.R., Stewart R., Prudon B., et al. Dimethyl fumarate in patients admitted to hospital with COVID-19 (recovery): A randomised, controlled, open-label, platform trial. Nat. Commun. 2024;15:924. doi: 10.1038/s41467-023-43644-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41467-023-43644-x</ArticleId><ArticleId IdType="pmc">PMC10831058</ArticleId><ArticleId IdType="pubmed">38296965</ArticleId></ArticleIdList></Reference><Reference><Citation>McKinnon J.E., Santiaguel J., Murta de Oliveira C., Yu D., Khursheed M., Moreau F., Klopp-Schulze L., Shaw J., Roy S., Kao A.H., et al. Enpatoran in COVID-19 pneumonia: Safety and efficacy results from a phase ii randomized trial. Clin. Transl. Sci. 2023;16:2640–2653. doi: 10.1111/cts.13658.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/cts.13658</ArticleId><ArticleId IdType="pmc">PMC10719456</ArticleId><ArticleId IdType="pubmed">37873555</ArticleId></ArticleIdList></Reference><Reference><Citation>Lin D.Y., Wang J., Anstrom K.J., LaVange L.M., Wen J., Bozzette S.A., Powderly W.G., ACTIV-1 IM Study Group Efficacy of infliximab, abatacept, and cenicriviroc for the treatment of adults hospitalized with COVID-19 pneumonia. Int. J. Infect. Dis. IJID. 2024;146:107168. doi: 10.1016/j.ijid.2024.107168.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2024.107168</ArticleId><ArticleId IdType="pmc">PMC11317211</ArticleId><ArticleId IdType="pubmed">38977241</ArticleId></ArticleIdList></Reference><Reference><Citation>Piscoya A., Parra Del Riego A., Cerna-Viacava R., Rocco J., Roman Y.M., Escobedo A.A., Pasupuleti V., White C.M., Hernandez A.V. Efficacy and harms of tocilizumab for the treatment of COVID-19 patients: A systematic review and meta-analysis. PLoS ONE. 2022;17:e0269368. doi: 10.1371/journal.pone.0269368.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0269368</ArticleId><ArticleId IdType="pmc">PMC9165853</ArticleId><ArticleId IdType="pubmed">35657993</ArticleId></ArticleIdList></Reference><Reference><Citation>Stone J.H., Frigault M.J., Serling-Boyd N.J., Fernandes A.D., Harvey L., Foulkes A.S., Horick N.K., Healy B.C., Shah R., Bensaci A.M., et al. Efficacy of tocilizumab in patients hospitalized with COVID-19. N. Engl. J. Med. 2020;383:2333–2344. doi: 10.1056/NEJMoa2028836.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2028836</ArticleId><ArticleId IdType="pmc">PMC7646626</ArticleId><ArticleId IdType="pubmed">33085857</ArticleId></ArticleIdList></Reference><Reference><Citation>Salvarani C., Dolci G., Massari M., Merlo D.F., Cavuto S., Savoldi L., Bruzzi P., Boni F., Braglia L., Turra C., et al. Effect of tocilizumab vs standard care on clinical worsening in patients hospitalized with COVID-19 pneumonia: A randomized clinical trial. JAMA Intern. Med. 2021;181:24–31. doi: 10.1001/jamainternmed.2020.6615.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamainternmed.2020.6615</ArticleId><ArticleId IdType="pmc">PMC7577199</ArticleId><ArticleId IdType="pubmed">33080005</ArticleId></ArticleIdList></Reference><Reference><Citation>Selvaraj V., Finn A., Lal A., Khan M.S., Dapaah-Afriyie K., Carino G.P. Baricitinib in hospitalised patients with COVID-19: A meta-analysis of randomised controlled trials. EClinicalMedicine. 2022;49:101489. doi: 10.1016/j.eclinm.2022.101489.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2022.101489</ArticleId><ArticleId IdType="pmc">PMC9163705</ArticleId><ArticleId IdType="pubmed">35677732</ArticleId></ArticleIdList></Reference><Reference><Citation>Barkas F., Filippas-Ntekouan S., Kosmidou M., Liberopoulos E., Liontos A., Milionis H. Anakinra in hospitalized non-intubated patients with coronavirus disease 2019: A systematic review and meta-analysis. Rheumatology. 2021;60:5527–5537. doi: 10.1093/rheumatology/keab447.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/rheumatology/keab447</ArticleId><ArticleId IdType="pmc">PMC8194671</ArticleId><ArticleId IdType="pubmed">33999135</ArticleId></ArticleIdList></Reference><Reference><Citation>Geng J., Wang F., Huang Z., Chen X., Wang Y. Perspectives on anti-il-1 inhibitors as potential therapeutic interventions for severe COVID-19. Cytokine. 2021;143:155544. doi: 10.1016/j.cyto.2021.155544.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cyto.2021.155544</ArticleId><ArticleId IdType="pmc">PMC8052468</ArticleId><ArticleId IdType="pubmed">33926774</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyriazopoulou E., Poulakou G., Milionis H., Metallidis S., Adamis G., Tsiakos K., Fragkou A., Rapti A., Damoulari C., Fantoni M., et al. Author correction: Early treatment of COVID-19 with anakinra guided by soluble urokinase plasminogen receptor plasma levels: A double-blind, randomized controlled phase 3 trial. Nat. Med. 2021;27:1850. doi: 10.1038/s41591-021-01569-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41591-021-01569-2</ArticleId><ArticleId IdType="pmc">PMC8500253</ArticleId><ArticleId IdType="pubmed">34625750</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyriazopoulou E., Huet T., Cavalli G., Gori A., Kyprianou M., Pickkers P., Eugen-Olsen J., Clerici M., Veas F., Chatellier G., et al. Effect of anakinra on mortality in patients with COVID-19: A systematic review and patient-level meta-analysis. Lancet Rheumatol. 2021;3:e690–e697. doi: 10.1016/S2665-9913(21)00216-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(21)00216-2</ArticleId><ArticleId IdType="pmc">PMC8352496</ArticleId><ArticleId IdType="pubmed">34396156</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalli G., De Luca G., Campochiaro C., Della-Torre E., Ripa M., Canetti D., Oltolini C., Castiglioni B., Tassan Din C., Boffini N., et al. Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: A retrospective cohort study. Lancet Rheumatol. 2020;2:e325–e331. doi: 10.1016/S2665-9913(20)30127-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2665-9913(20)30127-2</ArticleId><ArticleId IdType="pmc">PMC7252085</ArticleId><ArticleId IdType="pubmed">32501454</ArticleId></ArticleIdList></Reference><Reference><Citation>Balkhair A., Al-Zakwani I., Al Busaidi M., Al-Khirbash A., Al Mubaihsi S., BaTaher H., Al Aghbari J., Al Busaidi I., Al Kindi M., Baawain S., et al. Anakinra in hospitalized patients with severe COVID-19 pneumonia requiring oxygen therapy: Results of a prospective, open-label, interventional study. Int. J. Infect. Dis. IJID. 2021;103:288–296. doi: 10.1016/j.ijid.2020.11.149.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.ijid.2020.11.149</ArticleId><ArticleId IdType="pmc">PMC7670920</ArticleId><ArticleId IdType="pubmed">33217576</ArticleId></ArticleIdList></Reference><Reference><Citation>Kyriazopoulou E., Panagopoulos P., Metallidis S., Dalekos G.N., Poulakou G., Gatselis N., Karakike E., Saridaki M., Loli G., Stefos A., et al. An open label trial of anakinra to prevent respiratory failure in COVID-19. Elife. 2021;10:e66125. doi: 10.7554/eLife.66125.</Citation><ArticleIdList><ArticleId IdType="doi">10.7554/eLife.66125</ArticleId><ArticleId IdType="pmc">PMC8034977</ArticleId><ArticleId IdType="pubmed">33682678</ArticleId></ArticleIdList></Reference><Reference><Citation>Kharazmi A.B., Moradi O., Haghighi M., Kouchek M., Manafi-Rasi A., Raoufi M., Shoaei S.D., Hadavand F., Nabavi M., Miri M.M., et al. A randomized controlled clinical trial on efficacy and safety of anakinra in patients with severe COVID-19. Immun. Inflamm. Dis. 2022;10:201–208. doi: 10.1002/iid3.563.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.563</ArticleId><ArticleId IdType="pmc">PMC8652881</ArticleId><ArticleId IdType="pubmed">34762351</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson L.E., Khullar N., Beukelman T., Chapleau C., Kamath A., Cron R.Q., Chatham W.W. Prediction of survival by il-6 in a randomized placebo-controlled trial of anakinra in COVID-19 cytokine storm. Viruses. 2023;15:2036. doi: 10.3390/v15102036.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v15102036</ArticleId><ArticleId IdType="pmc">PMC10612044</ArticleId><ArticleId IdType="pubmed">37896812</ArticleId></ArticleIdList></Reference><Reference><Citation>The CORIMUNO-19 Collaborative group Effect of anakinra versus usual care in adults in hospital with COVID-19 and mild-to-moderate pneumonia (corimuno-ana-1): A randomised controlled trial. Lancet Respir. Med. 2021;9:295–304. doi: 10.1016/S2213-2600(20)30556-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(20)30556-7</ArticleId><ArticleId IdType="pmc">PMC7825875</ArticleId><ArticleId IdType="pubmed">33493450</ArticleId></ArticleIdList></Reference><Reference><Citation>Hall F.C., Cheriyan J., Cope A.P., Galloway J., Wilkinson I., Bond S., Norton S., Banham-Hall E., Bayes H., Kostapanos M., et al. Efficacy and safety of baricitinib or ravulizumab in adult patients with severe COVID-19 (tactic-r): A randomised, parallel-arm, open-label, phase 4 trial. Lancet Respir. Med. 2023;11:1064–1074. doi: 10.1016/S2213-2600(23)00376-4.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(23)00376-4</ArticleId><ArticleId IdType="pmc">PMC10682367</ArticleId><ArticleId IdType="pubmed">37977159</ArticleId></ArticleIdList></Reference><Reference><Citation>Annane D., Pittock S.J., Kulkarni H.S., Pickering B.W., Khoshnevis M.R., Siegel J.L., Powell C.A., Castro P., Fujii T., Dunn D., et al. Intravenous ravulizumab in mechanically ventilated patients hospitalised with severe COVID-19: A phase 3, multicentre, open-label, randomised controlled trial. Lancet Respir. Med. 2023;11:1051–1063. doi: 10.1016/S2213-2600(23)00082-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(23)00082-6</ArticleId><ArticleId IdType="pmc">PMC10027334</ArticleId><ArticleId IdType="pubmed">36958364</ArticleId></ArticleIdList></Reference><Reference><Citation>Vlaar A.P.J., Witzenrath M., van Paassen P., Heunks L.M.A., Mourvillier B., de Bruin S., Lim E.H.T., Brouwer M.C., Tuinman P.R., Saraiva J.F.K., et al. Anti-c5a antibody (vilobelimab) therapy for critically ill, invasively mechanically ventilated patients with COVID-19 (panamo): A multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Respir. Med. 2022;10:1137–1146. doi: 10.1016/S2213-2600(22)00297-1.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S2213-2600(22)00297-1</ArticleId><ArticleId IdType="pmc">PMC9451499</ArticleId><ArticleId IdType="pubmed">36087611</ArticleId></ArticleIdList></Reference><Reference><Citation>Stankiewicz Karita H.C., Dong T.Q., Johnston C., Neuzil K.M., Paasche-Orlow M.K., Kissinger P.J., Bershteyn A., Thorpe L.E., Deming M., Kottkamp A., et al. Trajectory of viral rna load among persons with incident SARS-CoV-2 g614 infection (wuhan strain) in association with COVID-19 symptom onset and severity. JAMA Netw. Open. 2022;5:e2142796. doi: 10.1001/jamanetworkopen.2021.42796.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamanetworkopen.2021.42796</ArticleId><ArticleId IdType="pmc">PMC8749477</ArticleId><ArticleId IdType="pubmed">35006245</ArticleId></ArticleIdList></Reference><Reference><Citation>Reis G., Moreira Silva E.A.S., Medeiros Silva D.C., Thabane L., Campos V.H.S., Ferreira T.S., Santos C.V.Q., Nogueira A.M.R., Almeida A., Savassi L.C.M., et al. Early treatment with pegylated interferon lambda for COVID-19. N. Engl. J. Med. 2023;388:518–528. doi: 10.1056/NEJMoa2209760.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2209760</ArticleId><ArticleId IdType="pmc">PMC9933926</ArticleId><ArticleId IdType="pubmed">36780676</ArticleId></ArticleIdList></Reference><Reference><Citation>Drysdale M., Tibble H., Patel V., Gibbons D.C., Lloyd E.J., Kerr W., Macdonald C., Birch H.J., Sheikh A. Characteristics and outcomes of patients with COVID-19 at high risk of disease progression receiving sotrovimab, oral antivirals, or no treatment: A retrospective cohort study. BMC Infect. Dis. 2024;24:670. doi: 10.1186/s12879-024-09576-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12879-024-09576-7</ArticleId><ArticleId IdType="pmc">PMC11225175</ArticleId><ArticleId IdType="pubmed">38965495</ArticleId></ArticleIdList></Reference><Reference><Citation>Grundeis F., Ansems K., Dahms K., Thieme V., Metzendorf M.I., Skoetz N., Benstoem C., Mikolajewska A., Griesel M., Fichtner F., et al. Remdesivir for the treatment of COVID-19. Cochrane Database Syst. Rev. 2023;1:CD014962. doi: 10.1002/14651858.CD014962.pub2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/14651858.CD014962.pub2</ArticleId><ArticleId IdType="pmc">PMC9875553</ArticleId><ArticleId IdType="pubmed">36695483</ArticleId></ArticleIdList></Reference><Reference><Citation>Monk P.D., Brookes J.L., Tear V.J., Batten T.N., Mankowski M., Adzic-Vukicevic T., Crooks M.G., Dosanjh D.P.S., Kraft M., Brightling C.E., et al. Nebulised interferon-beta1a (sng001) in hospitalised COVID-19: Sprinter phase iii study. ERJ Open Res. 2023;9:00605–2022. doi: 10.1183/23120541.00605-2022.</Citation><ArticleIdList><ArticleId IdType="doi">10.1183/23120541.00605-2022</ArticleId><ArticleId IdType="pmc">PMC9790107</ArticleId><ArticleId IdType="pubmed">36994453</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryoo S., Koh D.H., Yu S.Y., Choi M., Huh K., Yeom J.S., Heo J.Y. Clinical efficacy and safety of interferon (type i and type iii) therapy in patients with COVID-19: A systematic review and meta-analysis of randomized controlled trials. PLoS ONE. 2023;18:e0272826. doi: 10.1371/journal.pone.0272826.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0272826</ArticleId><ArticleId IdType="pmc">PMC10057835</ArticleId><ArticleId IdType="pubmed">36989209</ArticleId></ArticleIdList></Reference><Reference><Citation>Ader F., DisCoVeRy Study G. An open-label randomized, controlled trial of the effect of lopinavir and ritonavir, lopinavir and ritonavir plus interferon-beta-1a, and hydroxychloroquine in hospitalized patients with COVID-19: Final results. Clin. Microbiol. Infect. 2022;28:1293–1296. doi: 10.1016/j.cmi.2022.04.016.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cmi.2022.04.016</ArticleId><ArticleId IdType="pmc">PMC9076583</ArticleId><ArticleId IdType="pubmed">35533972</ArticleId></ArticleIdList></Reference><Reference><Citation>Consortium W.H.O.S.T. Remdesivir and three other drugs for hospitalised patients with COVID-19: Final results of the who solidarity randomised trial and updated meta-analyses. Lancet. 2022;399:1941–1953. doi: 10.1016/S0140-6736(22)00519-0.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0140-6736(22)00519-0</ArticleId><ArticleId IdType="pmc">PMC9060606</ArticleId><ArticleId IdType="pubmed">35512728</ArticleId></ArticleIdList></Reference><Reference><Citation>Brzoska J., von Eick H., Hundgen M. Interferons in COVID-19: Missed opportunities to prove efficacy in clinical phase iii trials? Front. Med. 2023;10:1198576. doi: 10.3389/fmed.2023.1198576.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fmed.2023.1198576</ArticleId><ArticleId IdType="pmc">PMC10263057</ArticleId><ArticleId IdType="pubmed">37324124</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>